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Introduction 
Renal Cancer 
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 80-
90% of all kidney cancers. In 2012 approximately 338.000 new cases were diagnosed with 
RCC worldwide and 143.000 patients died from metastasized RCC (mRCC) [1,2]. The 
incidence of RCC is increasing by approximately 2% per year, probably due to incidentally 
discovered renal masses by non-invasive imaging performed for other reasons [3,4]. It is 
possible that because such imaging is becoming more common, more RCC is being 
diagnosed, and at an earlier stage. In contrast, mortality is stable. The male: female 
incidence ratio is approximately 1.7:1. 
There are three major histological subtypes of RCC, of which clear cell renal cell 
carcinoma (ccRCC) is the most prominent subtype (Table 1) [5]. 
Table 1 Renal cell carcinoma classification 
(Adapted from Lopez-Beltran et al. European urology 2006;49:798–805) 
Despite advances in detection, about 30% of patients present with synchronous 
metastases and 20-30% of patients will develop metastatic disease after nephrectomy with 
curative intent [6]. The five year overall survival (OS) of patients with RCC decreases from 
85-90% for localized disease to approximately 15% for metastasized disease [7]. 
In the majority of ccRCC patients, the tumor suppressor gene VHL is inactivated or 
mutated in the tumor cells (Fig. 1). Consequently the VHL protein is unable to interact, bind 
and degrade the transcription factors hypoxia-inducible factor α (HIFα), leading to HIFα 
accumulation and nuclear translocation where it activates a large number of target genes, 
amongst others Vascular Endothelial Growth Factor (VEGF) and Platelet Derived Growth 
Factor (PDGF). This increased production of VEGF and PDGF in ccRCC results in very well 
vascularized tumors [8].  
RCC subtype Incidence (%) 
Clear cell 75 
Papillary 10 
Chromophobe 5 
Collecting ducts of Bellini 1 
Medullary Rare 
Xp11 translocation Rare 
After Neuroblastoma Rare 
Mucinous tubular and spindle cell Rare 
Unclassified 4-6 
11
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Chapter 1 
Figure 1. Biological pathway in Renal Cell Carcinoma 
In conditions of normoxia and normal von Hippel Lindau (VHL) gene function, VHL protein is the 
substrate for hypoxia-inducible factor alpha (HIFα) leading to ubiquitination and degradation. In 
hypoxia or when the VHL gene is mutated (in RCC), the VHL protein is unable to bind to HIFα, leading 
to accumulation of HIF transcription factors. HIF accumulation can also result from activation of 
mammalian target of rapamycin (mTOR) downstream of the PI3-K/Akt pathway. Activated mTOR also 
promotes an increase in the translation of mRNAs that encode cell cycle regulators such as c-Myc and 
cyclin D1 leading to cell growth and survival. Activated HIF translocates into the nucleus and leads to 
transcription of a large number of target genes including vascular endothelial growth factor (VEGF) 
and platelet derived growth factor (PDGF). These ligands bind to their related receptors present on the 
surface of endothelial cells, leading to cell migration and proliferation. Sites of action of targeted 
therapies are illustrated. Temsirolimus and everolimus inhibit the kinase activity of the mTOR complex 
1 (mTORC1). Bevacizumab is a VEGF ligand-binding antibody. Sunitinib, sorafenib, axitinib and 
pazopanib are small molecule inhibitors of multiple tyrosine kinase receptors including VEGFR and 
PDGFR. 
Reprinted from The Lancet, Vol.10 number 10, Brian I. Rini, Michael B. Atkins, Resistance to targeted therapy in renal-cell 
carcinoma, Pages 992-1000, Copyright (2009), with permission from Elsevier.
Treatment of patients with advanced RCC 
Targeted therapy 
Up to 2006, IFNα monotherapy was the standard of treatment for patients with advanced 
RCC. Since the unraveling of genetic events in ccRCC, therapies targeting pathways 
involved in tumor angiogenesis have been developed. 
Sunitinib, an oral tyrosine kinase inhibitor (TKI) of VEGFR2, PDGFR-α,β, Fms-like 
tyrosine kinase 3 (FLT-3) and stem cell factor receptor (SCFR/c-KIT), was the first TKI that 
was approved by the FDA in 2006 as first-line treatment for patients with advanced ccRCC. 
In the first pivotal trials, sunitinib demonstrated activity in patients with cytokine-refractory 
12
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mRCC [9,10]. In a large multicenter, randomized phase 3 trial sunitinib was superior 
compared to Interferon-α (IFNα) [11] with improved progression free survival (PFS, 11 vs. 5 
months) and OS (26 vs. 21 months). Since then numerous agents targeting the VEGF 
pathway have been clinically implemented: TKIs such as sorafenib, pazopanib and axitinib, 
monoclonal antibody (mAb) bevacizumab in combination with IFNα and mTOR inhibitors 
everolimus and temsirolimus. Clinical benefit was proven for all of these agents either as 
first- or second-line treatment (Table 2) [12]. The median PFS with first-line sunitinib, 
pazopanib or bevacizumab plus IFNα is 8 to 11 months, while second-line axitinib or 
everolimus yields a median PFS of 4-5 months [13-16]. However, not all patients benefit from 
this treatment as responses are usually transient with tumor resistance occurring in patients 
when treated for an extended period. Moreover, patients may experience significant toxicities 
leading to dose reduction or cessation of treatment. Finally, complete responses are rare and 
improvement of survival is measured in months. To further improve therapeutic outcome TKI 
combinations and combinations of TKI with cytokines [17-19], bevacizumab [20,21] or mTOR 
inhibitors [22,23] were attempted but these efforts were unsuccessful due to enhanced 
toxicity, the need to reduce drug doses, and the lack of evidence of clinical benefit.  
Because TKI combination treatments were intolerable, sequential treatments were 
investigated. Sequential treatment of sunitinib followed by sorafenib (So-Su) or vice versa 
(Su-So) did not significantly improve mean PFS (12.5 months for So-Su vs. 14.9 months for 
Su-So) and OS (31.5 months for So-Su vs. 30.2 months for Su-So)  [24]. Moreover, the 
results demonstrated that sorafenib followed by sunitinib and vice versa have similar clinical 
benefit in mRCC. 
Standard treatment now often involves treatment with an mTOR inhibitor after disease 
progression on a TKI, supported by studies addressing the sequence in which anti-VEGF 
therapies and mTOR agents were administered. In the RECORD-3 study, 471 patients with 
untreated mRCC were randomized to receive either 1st-line sunitinib or everolimus until 
disease progression, at which point they crossed over to the alternate drug [25]. The median 
combined PFS was 21.1 months for sequential everolimus-sunitinib and 25.8 months for 
sequential sunitinib-everolimus; the median OS was 22.4 months for sequential everolimus-
sunitinib and 32.0 months for sequential sunitinib-everolimus trending towards worse OS in 
the everolimus group.  
Fortunately, additional targeted agents and novel approaches are emerging. In April 2016 
the FDA approved Cabozantinib for the treatment of patients with mRCC who have received 
previous antiangiogenic therapy. Cabozantinib is distinct from other approved targeted 
agents, as it targets multiple tyrosine kinases involved in the development of RCC, including 
VEGFR2, MET proto-oncogene receptor tyrosine kinase and AXL receptor tyrosine kinase. 
The approval was granted on the basis of results from the phase III METEOR trial, which 
compared cabozantinib with everolimus for second-line RCC [26] . Median PFS, the trial's 
primary outcome, was significantly better with cabozantinib than with everolimus (7.4 vs. 3.8 
months; P < .0001). Notably, median OS was also better with cabozantinib than with 
13
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everolimus (21.4 vs. 16.5 months; P = .0003). However as with other TKI, substantial toxicity 
was observed. Dose reduction rates were 60% for cabozantinib and 24% for everolimus and 
treatment was discontinued in 10% of patients of both treatment arms because of adverse 
reactions. 
In conclusion, although there has been substantial progress in the treatment of mRCC, 
targeted therapy has been primarily palliative in nature and further improvement is 
necessary.  
Table 2. Systemic therapy for patients with clear cell mRCC 
MSKCC 
risk group 
First-line Second-line 
Favorable 
Sunitinib 
Pazopanib 
Bevacizumab & IFN 
Axitinib 
Sorafenib 
Everolimus 
Cabozantinib 
Intermediate 
Sunitinib 
Pazopanib 
Bevacizumab & IFN 
Axitinib  
Sorafenib 
Everolimus 
Cabozantinib 
Poor Temsirolimus Any targeted agent 
MSKCC: Memorial Sloan-Kettering Cancer Center; mRCC: metastatic renal cell carcinoma 
Adapted from evidence-based recommendations for systemic therapy of patients with clear cell mRCC [12] 
Immuno-oncology: Checkpoint inhibitors 
The last 30 years of immuno-oncology research have provided solid evidence that tumors 
are recognized by the immune system and that their development can be stopped or 
controlled long term through a process known as immune surveillance. Nevertheless, if the 
immune response fails to completely eliminate the tumor, cancer cells that can resist, avoid, 
or suppress the antitumor immune response are selected, leading to tumor escape and a 
progressively growing tumor. With a tumor microenvironment that prevents the expansion of 
helper and cytotoxic T cells and instead promotes the production of proinflammatory 
cytokines and other factors, suppressive cell populations that inhibit instead of promote 
immunity, accumulate.  
The understanding of the molecular mechanisms of T cell activation and inhibition have 
led to the rapid development of therapeutic mAbs targeting inhibitory immune checkpoints 
14
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such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death 1 or 
its ligand programmed death ligand 1 (PD-1/PD-L1). By blocking the inhibitory checkpoints, T 
cell responses will be sustained and tumor immunity enhanced (Fig. 2). CTLA-4 is 
upregulated on activated T-cells and outcompetes costimulatory molecule CD28 for binding 
to B7 on antigen presenting cells (APC) to dampen T-cell activation in response to tumor 
cells (early inhibitory signal). PD-1 is expressed on the surface of activated T cells, B cells, 
and macrophages. T-cell activation is inhibited by PD-1 binding to its ligand PD-L1 present 
on tumor cells thereby contributing to the tumor’s ability to evade the immune system (late 
inhibitory signal) (Fig. 2). 
Clinical trials with mAbs blocking CTLA4, PD-1 and PD-L1 have resulted in clinical 
benefits in several so called immunogenic tumortypes, i.e. melanoma, Non-small-cell lung 
carcinoma and RCC [28]. In contrast to the mostly transient clinical responses with targeted 
therapies, durable responses were induced with checkpoint inhibitors in subsets of patients. 
Nivolumab, a fully human IgG4 mAb targeting PD-1 and blocking interactions with PD-L1 and 
PD-L2 is now approved for the treatment of advanced RCC based on the checkmate 025 
study that demonstrated superiority of nivolumab in  safety profile and OS (25 mo vs. 9.6 mo) 
over everolimus after 1 or 2 antiangiogenic therapies [29].  
Small studies with the anti-CTLA-4 antibody ipilimumab (human IgG1) in mRCC as 
monotherapy showed some clinical activity but major toxicities were observed, with 33% of 
patients experiencing grade 3 or 4 immune-mediated adverse events [30]. Additional 
investigation of ipilimumab as monotherapy in patients with advanced RCC has not been 
pursued. Promising results were gathered in a phase 1a study with a humanized PD-L1 
antibody, Atezolizumab [31]. Atezolizumab demonstrated a manageable safety profile and 
promising antitumor activity in 63 patients with mRCC with median OS and PFS of 28.9 
months and 5.6 months respectively. Currently, studies combining atezolizumab with 
bevacizumab are ongoing (NCT02420821, NCT01984242). 
Although responses with immune-oncology drugs are durable, they are effective in a 
subset of patients and these drugs can induce high grade tissue-specific inflammatory side 
effects which cause injury to non-cancer tissue, particularly with CTLA-4 blockade. Most 
toxicities are related to immune activation and can be challenging to manage. 
To improve response rates, different combinations are being explored including those with 
other immuno-oncology agents, targeted agents, hormonal therapies, chemotherapies and 
radiation therapies. The most successful of combinations involve ipilimumab with nivolumab 
which was tested in a phase II trial, in two different regimen. Acceptable safety and durable 
antitumor responses were observed with the regimen nivolumab 3 mg/kg + ipilimumab 1 
mg/kg (N3I1) in pre-treated patients with mRCC [32]. Confirmed objective response rates of 
43% (N3I1) and 48% (N1I3) appeared higher than those reported for nivolumab 
monotherapy. Because of higher toxicity rates and treatment discontinuation in the N1I3 
group, the dosing schedule N3I1 was selected for further studies. A phase III trial comparing 
first-line sunitinib vs. N3I1 is currently ongoing and should demonstrate superiority.  
15
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Figure 2. Blockade of PD-1 or CTLA-4 signaling in Tumor Immunotherapy  
T cells recognize antigens presented by the major histocompatibility complex (MHC) on the surface 
of cancer cells through their T-cell receptor (TCR). This first signal is not enough to turn on a T-cell 
response, and a second signal delivered by the B7 costimulatory molecules B7-1 (or CD80) and 
B7-2 (or CD86) is required. Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is up-regulated 
shortly after T-cell activation and initiates negative regulation signaling on T cells during ligation 
with the B7 costimulatory molecules expressed by antigen-presenting cells. When these molecules 
bind to CD28, they provide activation signals; when they bind to CTLA-4, they provide inhibitory 
signals. The interaction between CTLA-4 and the costimulatory molecules happens primarily in the 
priming phase of a T-cell response within lymph nodes. Programmed death 1 (PD-1) inhibitory 
receptor is expressed by T cells during long-term antigen exposure and results in negative 
regulation on T cells during ligation with PD-L1 and PD-L2, which are primarily expressed within 
inflamed tissues and the tumor microenvironment. The PD-1 interaction happens in the effector 
phase of a T-cell response in peripheral tissues. Its blockade with antibodies to PD-1 or PD-L1 
results in the preferential activation of T cells with specificity for the cancer.  
Reproduced with permission from N Engl J Med 2012; 366:2517-2519, Antoni Ribas, Tumor Immunotherapy Directed at PD-
1, Copyright Massachusetts Medical Society [27] 
The combined treatment with sunitinib and the anti-CTLA-4 antibody tremelimumab 
(human IgG2), was not successful in RCC patients; treated patients experienced dose 
limiting toxicity, mainly due to renal failure and 1 patient suffered sudden death. Further 
investigations were not recommended [33]. Multiple clinical studies combining targeted 
therapies with checkpoint therapies are either planned or ongoing [34]. 
Despite the promising results with CTLA-4 and PD-1 inhibitors, there is an urgent need for 
even more agents and combinations to enter clinical use to improve treatment of renal cell 
cancer. The most challenging issue will be the clinical management of these new class of 
agents with their adverse events and toxicities when targeted therapies and 
immunotherapies are combined. 
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Monoclonal antibody G250 targeting CAIX 
Monoclonal antibody G250 (mAbG250) recognizes a conformational determinant on 
carbonic anhydrase IX (CAIX) [35]. This protein is expressed by almost all ccRCC, but 
expression in normal tissues is restricted to the (upper) gastrointestinal mucosa (stomach, 
ileum, proximal and middle colon) and gastrointestinal related structures (intra- and extra-
hepatic biliary system, pancreas) [36,37]. The G250-producing hybridoma was isolated after 
fusion of splenocytes of a mouse immunized with fresh human RCC with a mouse myeloma 
line [38]. Immunohistochemical analysis of mAbG250 on RCC specimen showed 
homogeneous expression in most (>85%) primary RCC and 70% of metastatic lesions. 
Originally, no association with a particular histological RCC subtype was noted, but it is now 
clear that the antigen recognized by mAbG250 is almost ubiquitously expressed (>95%) in 
ccRCC [35,39,40]. Molecular studies showed that CAIX gene expression was exclusively 
HIF1-α dependent, providing a direct link between the presence of an aberrant VHL gene 
product and CAIX expression [41]. These studies provided a straightforward explanation for 
the almost ubiquitous CAIX expression in ccRCC. The homogeneous CAIX expression in 
ccRCC and the excellent targeting capability of mAbG250 in animal models has led to the 
initiation of multiple clinical trials: both murine G250 (mG250) and chimeric G250 
(cG250/Girentuximab), produced after grafting the G250-specificity on a human IgG1 Fc 
region [42], have been studied in patients with ccRCC, both diagnostically as therapeutically 
[35].  
Diagnostic studies 
In several clinical studies the outstanding targeting and imaging ability of mAbG250 has 
been confirmed [37,42-44] and cG250-based immunoPET imaging holds great promise as 
diagnostic modality, both in detecting localized and advanced disease [45-48]. However, the 
current data are inconclusive as to which tracer is superior in the diagnostic performance; the 
performance of 111In-cG250 and 124I-cG250 has not been directly compared yet. Moreover 
89Zirconium, another PET-imageable tracer may permit even better delineation of lesions. 
Recently, a clinical trial with 89Zr-cG250 has been initiated in our center, which will provide 
additional information about the use of cG250-based immunoPET in ccRCC. 
Therapeutic studies 
Clinical trials with unmodified cG250 suggested that treatment with cG250 can influence 
the disease course of mRCC patients [49-53]. Based on this information an adjuvant trial has 
been performed (ARISER), aimed at reducing the recurrence of disease in nephrectomized 
RCC patients who have a high risk of relapse. Although this trial did not meet its primary 
endpoint (reduced recurrence in treated patients, [54]), preliminary results of a retrospective 
subanalysis appear to indicate a positive correlation between CAIX expression and treatment 
response [55]. Therefore, treatment with unmodified cG250 for ccRCC in the adjuvant setting 
might still be an option in a highly defined subpopulation. However, to validate whether 
cG250 treatment is of value, large randomized trials are needed.  
17
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Girentuximab-based radio immunotherapy (RIT) holds promise for the treatment of 
advanced RCC patients with small-volume disease. In a phase 1 dose escalating study with 
177Lu-cG250, disease stabilization was observed in 17/23 (74%) previously progressive 
mRCC patients [56]. In the ongoing phase 2 trial 8 patients have been treated until now. After 
the first RIT cycle, disease stabilization was observed in 5/8 (62.5 %) patients. Three of 
these responding patients received a second cycle of RIT leading to prolongation of disease 
stabilization in two patients. Inclusion of more patients will shed light on the therapeutic 
efficacy of this treatment modality in patients with advanced RCC.  
Finally, there are still several hurdles that prevent implementation of cG250-based RIT as 
a new treatment for patients with mRCC. Besides better patient selection in the future, 
advances in dosimetric analysis will presumably contribute to the improvement of RIT, as the 
trade-off between efficacy and toxicity can be better tailored to the individual patient. Lastly, 
an important deficit in our current knowledge is how to optimally combine cG250-based RIT 
with the current standard of care of metastatic ccRCC patients.  
Thesis outline 
The aim of this thesis was to investigate new treatment strategies for patients with advanced 
RCC using monoclonal antibody G250 in preclinical models. 
Chapter 2 reviews the diagnostic and therapeutic preclinical and clinical studies of murine 
and chimeric monoclonal antibody G250. Also, the development and characterization of the 
antibody is described. 
In Chapter 3, a genetically engineered G250-TNF fusion protein was studied. In-vitro 
characterization of cG250-TNF comprised biochemical analysis and bioactivity assays, alone 
and in combination with Interferon-γ (IFNγ). Results of biodistribution studies on radiolabeled 
125I-G250-TNF and antitumor activity of cG250-TNF, alone and in combination with IFNγ, 
performed in mice with human RCC xenografts, are discussed. 
Chapter 4 describes the effect of several TKI (sunitinib, sorafenib and vandetanib) on the 
biodistribution of monoclonal antibody cG250. Mice with human RCC xenografts were 
treated with sunitinib, vandetanib or sorafenib and injected with 125I-labeled cG250. Results 
of antibody distribution and immunohistochemical analysis for the presence of endothelial 
cells, laminin, smooth muscle actin, CAIX expression and uptake of mAb cG250 performed 
to investigate whether TKI can be combined with mAb G250, are described. 
In Chapter 5, we explored the importance of timing as well as sequence of administration of 
sunitinib and 111In- cG250 in mice with human RCC xenografts. In two different tumors (SK-
18
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RC-52 and NU12) biodistribution of cG250 was studied. Immunohistochemical analyses 
were performed to study the tumor vasculature and CAIX expression and to confirm cG250 
uptake. 
In Chapter 6, the therapeutic efficacy of sunitinib in combination with low dose 177Lu-cG250 
RIT was evaluated in mice with human RCC xenografts (SK-RC-52 and NU12) and 
compared to single treatments. Tumor growth was monitored for 21 to 23 weeks in mice 
treated with 1 or 2 cycles of sunitinib and 177Lu-cG250 RIT. 
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Abstract 
Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase 
IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear cell type 
(ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX expression 
in ccRCC and excellent targeting capability of mAbG250 in animal models led to the initiation 
of the clinical evaluation of mAbG250 in (metastatic) RCC (mRCC) patients. Clinical studies 
confirmed the outstanding targeting ability of mAbG250 and cG250 PET imaging, as 
diagnostic modality holds great promise for the future, both in detecting localized and 
advanced disease. Confirmation of the results obtained in the non-randomized clinical trials 
with unmodified cG250 is needed to substantiate the value of cG250 treatment in mRCC. 
cG250-Based radio immuno-therapy (RIT) holds promise for treatment of patients with small-
volume disease, and adjuvant treatment with unmodified cG250 may be of value in selected 
cases. In the upcoming years, ongoing clinical trials should provide evidence for these 
assumptions. Lastly, whether cG250-based RIT can be combined with tyrosine kinase 
inhibitors, which constitutes the current standard treatment for mRCC, needs to be 
established. 
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1. Introduction
Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers and was 
estimated to be diagnosed in over 60,000 individuals in the United States in 2011 [1]. The 
most prominent subtype of RCC (~70%) is clear cell (ccRCC). In approximately 70% of 
patients, the tumor is confined to the kidney at presentation. In 30% of cases, patients 
present with or develop metastases at a later time point. Patients with advanced disease 
have a poor prognosis with an overall five-year survival of <10%. Based on the molecular 
insight that ccRCC is characterized by molecular aberrations that leads to high expression 
levels of amongst others VEGF, various anti-angiogenic therapies have been developed. For 
patients with metastatic RCC (mRCC), several anti-angiogenic therapies are available [2–7]. 
Implementation of these new treatment modalities has led to a significant increase in 
progression-free survival [8]. However, complete responses (CR) are rare, and long-lasting 
stable disease (SD) is often seen, but eventually all patients progress. Moreover, frequently 
significant toxicity can occur, which may lead to drug cessation or dose reduction.  
Monoclonal antibody G250 (mAbG250) was isolated more than 25 years ago from a 
hybridoma produced from a splenocyte of a mouse immunized with a fresh human RCC [9]. 
Immunohistochemical analysis of renal tumors showed homogeneous expression in the vast 
majority (>80%) of primary RCC and about 70% of mRCC lesions. Analyses of non-RCC 
tumors revealed variable, non-homogeneous staining. Initial specificity analysis on normal 
human tissues revealed cross-reactivity with gastric mucosal cells and large bile ducts. 
Subsequent in-depth fine-specificity analysis revealed reactivity with epithelial cells of the 
upper gastrointestinal tract and pancreatic cells. Originally, no association with a particular 
histological RCC subtype was noted, but it is now clear that the antigen recognized by 
mAbG250 is almost ubiquitously expressed in ccRCC [10,11]. Based on this fine-specificity 
analysis, mAbG250 target antigen was readily suggested as a potential diagnostic and 
therapeutic target. 
2. Cloning of G250 Antigen and Relation to ccRCC
The general occurrence of the antigen recognized by mAbG250 in RCC and absence 
from normal kidney suggested that the aberrant expression was inherently related to tumor 
development, possibly due to a common initiating event [9].  
Cloning of the antigen recognized by mAbG250 showed that mAbG250 recognized a 
conformational determinant of carbonic anhydrase IX (CAIX), a gene originally identified in 
HeLa cells [12,13]. CAIX is a member of the carbonic anhydrase group of enzymes, has a 
transmembrane, as well as a cytosolic domain, and catalyzes the reaction: CO2 + H2O ↔ 
HCO3− + H+. Extensive molecular studies of the CAIX promoter region demonstrated that
HIF-1α binding was an absolute requirement for CAIX expression in ccRCC [14]. This finding 
uncovered a direct molecular link between the observed ccRCC-specificity of mAbG250 and 
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the molecular events leading to ccRCC. Elegant molecular studies in families suffering from 
Von Hippel-Lindau (VHL) syndrome, an autosomal dominant disease, showed that defects in 
the VHL gene were responsible for tumor development. These patients develop multiple 
tumors, including ccRCC. Studies in sporadic ccRCC demonstrated that also in these cases, 
VHL was mutated [15]. Subsequent studies showed that VHL is involved in the hypoxic 
response: under normoxic conditions, hypoxia-inducible factor-1α (HIF-1α) is hydroxylated by 
prolyl hydroxylase domain proteins and bound by pVHL, catalyzing the polyubiquitylation of 
prolyl hydroxylated HIF-1α for subsequent degradation via the 26S proteasome [16,17]. If 
pVHL is mutated, as in ccRCC, binding of HIF-1α by pVHL does not occur; the unbound HIF-
1α is not degraded, but associates with the constitutively stable partner HIF-1β to form an 
active heterodimeric HIF-1 transcription factor, which binds to hypoxia-responsive elements 
located in the promoter/enhancer regions of numerous hypoxia-inducible genes. In view of 
the HIF-1α dependency of CAIX expression, the ubiquitous expression of the G250/CAIX 
antigen could be explained straightforwardly by nonfunctional VHL gene product in ccRCC 
(Figure 1).  
Elucidation of the molecular pathway of CAIX gene expression also readily explained the 
heterogeneous staining pattern in non-RCC tumors: this is the consequence of local hypoxia, 
Figure 1. Schematic representation of regulation of carbonic anhydrase IX expression (CAIX) in 
kidney. In normal kidney tissue, hypoxia inducible factor-1α (HIF-1α) is hydroxylated by prolyl 
hydroxylase domain proteins (PHD) and bound by Von Hippel-Lindau protein (pVHL). 
Subsequently, the complex is ubiquitinated, which causes degradation of HIF-1α. In clear cell renal 
cell carcinoma (ccRCC), pVHL is mutated and binding with HIF-1α is prohibited. Subsequently HIF-
1α forms a heterodimeric complex with HIF-1β, translocates to the nucleus, where it activates 
hypoxia inducible genes, such as vascular endothelial growth factor and CAIX, which is expressed 
on the tumor cell membrane. Reproduced with permission from Stillebroer et al., European 
Urology, published by Elsevier, July, 2010; 58(1):75–83 [20]. 
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leading to HIF-1α stabilization and subsequent G250/CAIX expression. In fact, G250/CAIX is 
now regarded as an appropriate substitute hypoxia marker in various tumor types [18,19]. 
3. Clinical Studies with mAbG250
3.1. Imaging Studies 
The incidental detection of renal lesions has increased up to 50% by improved radiologic 
imaging, such as contrast enhanced CT and positron emission tomography (PET) with 
fluorine-18 fluorodeoxyglucose (18F-FDG) [21,22]. With increased possibilities for nephron-
sparing surgery and the realization that around 20% of these masses are benign tumors, 
25% are indolent tumors with limited metastatic potential and 54% represent the more 
potentially malignant ccRCC, it has become important to differentiate between these entities. 
However, conventional techniques have difficulties in differentiating between benign and 
malignant renal lesions. Therefore, surgical interventions are performed that could have been 
prevented. Consequently, new imaging techniques are needed to improve the differentiation 
between benign and malignant renal lesions. In view of the ccRCC specificity of mAbG250, 
multiple studies have addressed its ccRCC targeting capabilities.  
Since its discovery, numerous preclinical targeting studies were performed in various 
mouse models [23–26] with various radionuclides, as well as in ex vivo perfusion experiments in 
tumor-bearing kidneys [27] with mAbG250. Selective and extraordinary high uptake of murine 
mAbG250 (mG250) in antigen-positive tumor xenografts was observed (e.g., up to more than 
100% of the injected dose per gram tumor tissue at the lowest protein doses (up to 1 µg)). 
The combination of the restricted G250/CAIX expression in normal tissues, homogeneous 
G250/CAIX expression in RCC and excellent targeting capability in animal models provided a 
solid basis for the initiation of the clinical evaluation of mG250 in patients to investigate the 
possibility to use CAIX imaging as a new diagnostic tool. 
The first clinical study with mouse mAbG250 (mG250) concerned a phase I presurgical 
protein dose-escalating study of 131I-mG250 conducted to determine tumor uptake and 
mG250 distribution in patients suspect for RCC [28]. Apart from clear visualization of primary 
and metastatic (known and occult) RCC at protein doses >2 mg, occult metastases were 
imaged, immediately demonstrating the diagnostic potential. Levels of mG250 in tumor tissue 
samples reached levels of up to 0.1% of the injected dose per gram of tumor (%ID/g), these 
levels being among the highest reported in studies of solid tumors. Additionally, normal tissue 
uptake, actually limited to the liver, was saturable, encouraging future development of 
mG250 in RCC. Because histological confirmed CAIX-negative tumors did not image, it was 
concluded that mAbG250 accumulation was CAIX-specific. Since administration of murine 
G250 led to the formation of human-anti-mouse-antibodies (HAMA) in all patients, preventing 
multiple administrations [29], a chimeric variant of G250 (cG250) was constructed (see Table 
1). 
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R
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O
osterw
ijk et al. [28] 
1993 
131I-m
G
250 
15 
Prim
ary R
C
C
 
12/12 pts 
Phase I, dose escalation 
Steffens et al. [30] 
1997 
131I-cG
250 
16 
Prim
ary R
C
C
 
13/13 pts 
Phase I, dose escalation 
Steffens et al. [31] 
1999 
131I-cG
250 &
 
111In-cG
250 
10 
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ary R
C
C
 
10/10 pts 
D
ual label study 
Brouw
ers et al. [32] 
2002 
131I-cG
250 vs. 
18F-FD
G
 
20 
M
 + R
C
C
 
131I-cG
250: 34/112 
lesions  
18F-FD
G
: 77/112 lesions 
C
om
parative intrapatient study 
Brouw
ers et al. [33] 
2003 
131I-cG
250 &
 
111In-cG
250 
5 
M
 + R
C
C
 
111In-cG
250: 47 lesions 
131I-cG
250: 30 lesions 
C
om
parative intrapatient study 
D
ivgi et al. [34] 
2007 
124I-cG
250 
26 
Prim
ary R
C
C
 
15/16 ccR
C
C
 im
aged 
Prospective cG
250-im
m
unoPET 
D
ivgi et al. [35] 
2013 
124I-cG
250 
226 
Prim
ary R
C
C
 
124/143 ccR
C
C
 im
aged 
(sens. & spec. 86%
) 
Phase III, R
ED
EC
T trial 
M
uselaers et al. [36] 
2013 
111In-cG
250 
29 
Prim
ary R
C
C
 
15/16 ccR
C
C
 im
aged 
111In-cG
250 im
m
unoSPEC
T 
# outcom
e refers to diagnostic accuracy, i.e., num
ber of positive im
ages over total num
ber of im
ages m
G
250: m
ouse m
onoclonal antibody G
250; cG
250: 
chim
eric m
onoclonal antibody G
250; ccR
C
C
: clear-cell renal cell carcinom
a; 
18F-FD
G
: fluorine-18 fluorodeoxyglucose; M
 + R
C
C
: m
etastatic renal cell 
carcinom
a;  
PET = positron em
ission tom
ography; S
P
EC
T: single-photon em
ission C
T; sens.: sensitivity; spec.: specificity. 
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Because chimerization might lead to altered pharmacokinetic and pharmacodynamic 
behavior, a phase I protein dose-escalation trial of 131I-cG250 identical to the phase I mG250 
protein dose-escalation trial was necessary [30]. All patients with an antigen-positive tumor (n 
= 13) showed excellent targeting of radioactivity to all known tumor sites. Similar to mG250, 
previously undetected metastatic lesions (brain, bone and soft tissue) were detected. An 
example of the excellent cG250 uptake is shown in Figure 2. The performance of the 
chimerized G250 mAb was almost identical to the mouse mAbG250, including the optimal 
protein dose (5–10 mg) and very high focal uptake (up to 0.52% ID/g). The half-life (t½ β) of 
cG250 was comparable to mG250 (68.5 h vs. 47 h). 131I-cG250 uptake in non-tumor tissues 
remained low. Most importantly, chimerization greatly diminished the immunogenicity of the 
antibody: in only two of 15 patients, low levels of human anti-chimeric antibody (HACA) were 
observed [30]. Thus, multiple administrations became feasible.  
 
. 
    
 
 
Although very high uptake levels were observed, locally, cG250 tumor uptake was 
heterogeneous; this heterogeneity could not be explained by antigen expression alone. No 
consistent association with necrosis or vasculature was noted [37]. Since highly dynamic 
vascularization and intratumoral blood flow may contribute to this heterogeneous tumor 
Figure 2. Whole body scan of a patient with multiple RCC metastases two weeks after infusion of 
4144 MBq 131I-cG250. Ant.: Anterior view; Post.: Posterior view. Note: thyroid uptake is due to 
non-specific accumulation, despite attempts to block thyroid uptake with intake of saturated 
potassium iodide. 
Ant. Post. 
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uptake, the impact of time on tumor uptake of cG250 was studied in a clinical setting. In this 
dual-label study, ten patients with a clinical diagnosis of primary RCC received two 
independent consecutive administrations of cG250, separated by four days. Post-surgery, 
the distribution of both administrations was mapped and analyzed. The study demonstrated 
that cG250 distribution did not differ between different administrations, indicating that intrinsic 
tumor factors, such as internalization and local differences in interstitial fluid pressure, played 
a prominent role in intra-tumoral heterogeneity of antibody distribution [31]. Initially, this 
explanation was felt to be improbable, because 131I-cG250 tumor retention in patients was in 
the order of weeks, suggesting very low internalization rates [29].  
To compare 131I-cG250 radioimmunoscintigraphy (RIS) with 18F-FDG PET, 20 mRCC 
patients were scanned using both techniques. Routine imaging modalities, performed before 
the experimental imaging techniques, revealed 79 metastases in these 20 patients. 18F-FDG 
PET and 131I-cG250 scintigraphy revealed 33 previously unknown lesions, of which 32 were 
PET positive and seven cG250-positive. Remarkably, 131I-cG250 RIS detected only 30% 
(34/112) of documented metastases, whereas with 18F-FDG PET, 69% (77/112) were 
detected [32]. The low percentage of RCC metastases detected by cG250-RIS in this study 
contrasts with the results of many other studies, where excellent visualization of all known 
metastases occurred and often new lesions were visualized, which were not seen using 
conventional imaging techniques. The inferiority of 131I-cG250 RIS in detecting metastases 
might have been due to internalization of the radiolabeled mAb and subsequent excretion of 
131I by the tumor cells. Internalization and translocation of mAbG250 to the endocytic 
recycling compartment in vitro has been described before [38]. Alternatively, it is possible that 
many lesions were CAIX-negative, albeit that, in general, approximately 75% of ccRCC 
metastases are high in CAIX expression [39]. Unfortunately, we were unable to determine 
the CAIX expression in this trial, since lesions were unavailable. 
The dual label clinical trial suggested that cG250 can be internalized by G250 antigen-
expressing RCC cells. Indeed, follow-up animal experiments demonstrated that 
internalization can occur [40] and that accumulation in tumors of cG250 labeled with 
residualizing radionuclides, such as 111In, might be higher than that of non-residualizing 131I 
[25,41]. To investigate this phenomenon in detail in patients with RCC, a dual-label study 
was performed, with cG250 labeled with the residualizing radionuclide 111In and non-
residualizing radionuclide 131I [33]. Four days post injection, the 111In-cG250 images revealed 
more metastatic lesions (n = 47) than 131I-cG250 (n = 30). Moreover, quantitative analysis of 
25 metastases showed higher activities of 111In-cG250 than of 131I-cG250 in 20 of 25 lesions, 
thus 111In-cG250 outperformed 131I-cG250 for visualization of metastatic RCC lesions. This 
was partly due to the superior gamma camera characteristics of 111In, but mainly because 
higher tumor:blood ratios were obtained.  
ImmunoPET—that is, PET scanning that combines the favorable characteristics of PET 
(higher spatial resolution, three-dimensional imaging and superior quantitative analysis of 
images) with cG250—seems ideal for RCC imaging. However, the most commonly used 
positron emitters (11C and 18F) cannot be combined with the relatively slow pharmacokinetics 
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of intravenously injected radiolabeled mAb (optimal tumor uptake after several days), 
because of their too-short half-lives (2 min to 1.8 h). On the other hand, the positron emitters, 
89Zr and 124I (half-lives 78 and 100 h, respectively), seem to be good candidates to match 
these slow kinetics. In the first cG250 immunoPET study, 124I-cG250 (185 MBq, 10 mg) was 
evaluated in 26 patients with suspect renal masses to study whether ccRCC could be 
recognized unequivocally. In 15/16 patients with histological confirmed ccRCC after surgery, 
positive images were obtained (one patient received nonreactive antibody, due to technical 
problems). In addition, all nine non-clear cell renal masses were negative; hence, the 
sensitivity and specificity of 124I-G250 PET for ccRCC was 94% and 100%, respectively. The 
negative (NPV) and positive predictive value (PPV) were 90% and 100%, respectively [34].  
This proof of principle study suggested that immunoPET might help in clinical decision-
making and might aid in the surgical management of patients with small renal masses 
scheduled for partial nephrectomy. 
To substantiate whether cG250 immunoPET might be helpful in the clinical management 
of patients with suspect renal masses, a large multicenter phase III trial comparing 124I-cG250 
immuno PET/computed tomography (CT) (124I-Girentuximab/REDECTANE®) scanning to 
contrast enhanced CT (CECT) for the detection of ccRCC was performed. In total, 226 
patients scheduled for partial or complete nephrectomy were enrolled in this study [35]. 124I-
girentuximab was well tolerated, and 195 patients were evaluable. The results of this trial 
confirmed the high specificity and sensitivity of 124I-cG250 for ccRCC. Notably, the average 
sensitivity and specificity were higher for G250 PET/CT than for CECT (86.2% vs. 75.5% and 
85.9% vs. 46.8%, respectively). The authors concluded that 124I-girentuximab PET/CT can 
accurately and noninvasively identify ccRCC, with potential utility for designing best 
management approaches for patients with renal masses. One limitation of 124I-based 
immunoPET is the limited availability of 124I worldwide, requiring centralized production. 
Because girentuximab labeled with the gamma-emitting radionuclide indium 111In is easier 
to produce as an off-the-shelf agent, not requiring centralized production nor specialized 
equipment, and because dual labeling studies showed superior imaging of 111In-cG250 in 
mRCC [33], we investigated this agent as a potential imaging modality. Similar to 124I-
girentuximab immunoPET, single-photon emission CT (SPECT) with 111In-labeled 
girentuximab is non-invasive and does not require the use of intravenous contrast agents, 
which makes it suitable for patients with an impaired renal function. In this study, 29 patients 
with an incidentaloma of the kidney or having a history of ccRCC with lesions on follow-up 
imaging suspect for metastases were enrolled [36]. Distinct uptake of 111In-girentuximab was 
seen in 16 of 22 patients presenting with a renal mass (Figure 3). All renal masses proven to 
be ccRCC after resection (n = 15) were detected with 111In-girentuximab. In one of the 16 
patients, a type 2 papillary RCC with histological proven CAIX expression was targeted with 
111In-girentuximab. In addition, no targeting was observed in six patients. Histopathological 
evaluation in 4/6 patients revealed two cases of benign oncocytoma, a chromophobe and a 
mucinous tubular spindle cell carcinoma subtype tumor. For the two remaining patients, 
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biopsy material was unavailable, but close monitoring with repeated CT scans did not reveal 
growth of the suspected mass in the follow-up period (>24 months). In this limited group of 
patients, the PPV of 111In-girentuximab imaging for ccRCC was 94%. In addition, seven 
patients with a history of ccRCC and possible metastatic lesions on follow-up computed 
tomography scans were imaged with 111In-girentuximab. In 4/7 patients, the lesions showed 
preferential uptake of 111In-girentuximab and local or systemic treatment was initiated. In 
three other cases, no targeting was seen. During follow-up of these three patients, 1/3 
showed progression, for which systemic treatment was started. In conclusion, cG250 
immunoSPECT either labeled with 124I or with 111In can be used to detect ccRCC lesions in 
patients with a primary renal mass and to clarify the nature of lesions suspect for metastases 
in patients with a history of ccRCC.  
3.2. Therapy Studies 
3.2. Therapy Studies 
The therapeutic potential of CAIX targeting with mAbG250 has been studied in numerous 
clinical trials (see Table 2). Roughly, these can be divided into trials with “naked” antibody 
alone or in combination with cytokines and radioimmunotherapy trials. 
In the first dose escalating radioimmunotherapy (RIT) trial, 131I-mG250 was administered 
to progressive patients with measurable, histological proven ccRCC [29]. In this trial, hepatic 
toxicity was observed, most likely the result of specific mG250 accumulation in the liver. 
Indeed, with higher doses, the liver uptake was decreased, suggesting saturation of G250 
sites by the antibody. The toxicity was transient and not dose-limiting. As in all RIT studies 
with radiolabeled antibodies, dose-limiting toxicity (DLT) was hematopoietic. After 
determining the maximum tolerated dose (MTD) of 131I-activity (3330 MBq/m2), 15 patients 
were treated at the MTD level to determine efficacy, but no major responses were noted. 
Figure 3. Images of a patient with metastatic RCC. Conventional CT (A) and 
111In-girentuximab immunoSPECT (B) images of a patient with metastatic ccRCC. Clear 
and preferential uptake of the radiolabeled antibody was observed in mediastinal and 
pleural lesions (arrows). The patient was enrolled in the phase II 177Lu-girentuximab RIT
trial. 
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However, overall survival of patients treated with 131I-mG250 seemed to be increased in 
comparison with that of historic control patients: 17/33 SD and two minor responses. As 
mentioned earlier, the development of high HAMA levels in all patients precluded 
retreatment, and all subsequent trials were carried out with cG250. 
Following the protein dose-escalation trial with 131I-cG250, which established the most 
favorable protein dose, a phase I 131I-cG250 activity dose escalation was performed to 
establish DLT similar to the mG250 trial [42]. One major adjustment was the inclusion of an 
imaging dose (222 MBq of 131I- labeled to 5 mg of cG250), before being allowed to advance 
to therapeutic dose (1665–2775 MBq of 131I- labeled to 5 mg of cG250) to prevent infusion of 
high-dose 131I-cG250 in CAIX-negative patients.  
Only those patients showing targeting to tumor (n = 8) received the therapeutic infusion of 
131I-cG250 one week later. Unexpectedly, through the administration of the scout dose, liver 
toxicity was avoided, most likely because the liver compartment was saturated. Alternatively, 
hepatic uptake of chimeric mAbG250 is lower than murine mAbG250. At equal doses, liver 
uptake of mG250 [28] was 2–3-times higher than the liver uptake of cG250 [30]. Dose-
limiting toxicity of 131I-cG250 was at 2775 MBq 131I-cG250/m2, significantly lower than DLT 
observed for the murine version. The MTD was therefore set at 2220 MBq/m2. Almost 
certainly, the extended serum half-life is responsible for the enhanced hematopoietic toxicity, 
since this leads to extended radiation of the bone marrow compartment.  
In one patient, HACA was observed in the serum sample obtained prior to the injection of 
the radiolabeled antibody, as well as in subsequent serum samples. cG250 was rapidly 
cleared. The observed HACA was probably due to previous injections with mAbG250. This 
particular patient had participated four months beforehand in another clinical study and had 
received two injections of mAbG250, four days apart. Targeting of mAbG250 was observed 
in his primary tumor at that time. No HACA responses were detected in all other patients.  
An antitumor response was observed in 2/8 patients; one SD for 3–6 months and one 
partial response (PR) >9 months. Both patients were treated at the 2220 MBq/m2 dose level. 
However, quite disappointingly, all other patients showed progression of disease. 
This first RIT trial with cG250 clearly showed that increased doses of radioactivity to the 
tumors were required to achieve more complete and lasting responses. In an effort to 
increase RIT efficacy, a fractionated dose RIT was performed, based on whole-body 
radiation absorbed dose [43]. 
Fractionated RIT is more effective than a single large amount and is associated with a 
lower toxicity profile in animal models. The primary objective of this trial was to determine the 
maximum tolerated whole-body radiation-absorbed dose of fractionated 131I-cG250, with 
dose escalation referred to here as the escalation of average whole-body absorbed dose. 
Fifteen patients with measurable metastatic renal cancer were included. The majority of 
patients tolerated repeated injections with no change in kinetics, confirming the lack of 
immunogenicity of the antibody construct. Whole-body and serum kinetics varied significantly 
between patients, with estimated biologic clearance half-times ranging from 3.2 to 7.5 days
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Table 2. O
verview
 of Therapy studies w
ith m
AbG
250 in R
C
C
 patients. 
R
ef 
Year 
Agent 
N
um
ber of 
patients 
Patients 
R
esponse 
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o 
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Brouw
ers et al. [44] 
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R
; 17 SD
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o 
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R
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36 
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; 
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k 
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y 
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R
; 7 SD
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k 
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*
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250; cG
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R
: com
plete 
response; PR
: partial response; SD
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D
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eeks. 
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for the whole body and from 1.3 to >5 days for serum β–half-life (t½ β). In two of 15 patients, 
HACA was observed, which lead to a faster serum clearance. Similar to single dose, cG250 RIT, 
DLT was hematopoietic. In this logistically demanding fractionated administration regimen, 
sparing of the hematopoietic system was not observed. Moreover, the total dose that could 
be delivered was low, and efforts along these lines were abandoned.  
In view of the minimal clinical response in single doses cG250 RIT, a study was 
performed with two sequential high-dose (at MTD) 131I-cG250 treatments in patients with 
progressive mRCC [44]. After receiving a scout dose of 185 MBq/m2 of 131I-cG250 to 
demonstrate tumor targeting, 29 patients with adequate cG250 uptake received a therapeutic 
dose of 2220 MBq/m2 131I-cG250. In the absence of grade 4 hematological toxicity, patients 
received a second cycle after three months, consisting of a diagnostic infusion and a second 
high dose injection of 131I-cG250, escalated from 1110 MBq/m2 to 1665 MBq/m2. The MTD of 
the second RIT was 1665 MBq/m2, with myelotoxicity as DLT. Four patients were excluded 
from the study, because they developed HACA after the first RIT dose (n = 2), after the 
second scout dose (n = 1) or after the second RIT dose. Those patients developed high 
HACA titers with enhanced clearance of injected mAbG250 (t½ β: 20–27 h). In an additional 
four patients, detectable HACA titers at low levels developed in the course of the study. In 
these patients, no enhanced clearance was observed (t½ β: 52–74 h). Of the 16 patients 
who completed the protocol at both MTDs, none demonstrated an objective response, but 
five previously progressive patients had stabilization of their disease lasting 3–12 months. 
The low efficacy was partly attributed to the bulky disease in these end-stage patients, as 
sufficiently high radiation doses of 131I could not be delivered to these large tumor masses. An 
inverse correlation between the size of metastases and radiation-absorbed dose was 
observed, and dosimetric analyses showed that therapeutic radiation doses (>50 Gy) were 
only guided to lesions smaller than 5 g. Therefore, it was suggested that future RIT with 
cG250 should aim at treatment of small-volume disease or should be used in an adjuvant 
setting, or other more potent radionuclides should be used [52]. 
Preclinical animal studies performed with cG250 labeled with more potent radionuclides 
(177Lu, 90Y or 186Re) for RIT showed that tumor growth was most effectively inhibited by 177Lu-
cG250, followed by 90Y-, 186Re- and 131I-cG250 [41]. Metabolites labeled with metallic 
radionuclides, such as 111In, 90Y and 177Lu, are trapped in the lysosomes and residualize after 
internalization of the mAb–antigen complex by the target cells. Intracellular 131I-cG250 is 
metabolized, and tyrosine-131I is rapidly excreted by the tumor cell upon internalization. 
These RIT studies clearly showed the superiority of 177Lu- and 90Y-based RIT, in line with 
other studies. The dual-label study discussed before [33] also supported that trapped 
radionuclides are superior to the non-trapped iodine. In view of this evidence, subsequent 
clinical studies have focused on the possibility to use 90Y or 177Lu in RIT [53].  
Recently, the results of a phase I/II trial with 177Lu-cG250 were published [45]. This trial 
was paralleled by a trial with 90Y-cG250 at Memorial Sloan Kettering Cancer Centre, New 
York (clinicaltrials.gov/NCT00199875). In the 177Lu-cG250 trial, 23 patients with progressive 
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mRCC with proven ccRCC received a diagnostic dose of 111In-cG250 (185 MBq), to establish 
adequate tumor accumulation followed by a dose of 177Lu-cG250 one week post 111In-cG250 
injection (start dose 1110 MBq/m2 177Lu, increments of 370 MBq/m2; three patients/dose 
level). In four patients, elevated HACA levels during treatment were observed. In two 
patients, these HACA levels precluded administration of a subsequent treatment cycle. In the 
absence of grade 4 toxicity, patients were eligible to receive a second (13/23) and a third 
cycle (4/23), at 75% of the dose level of the previous injection. Hematopoietic toxicity was 
dose-limiting, and MTD was set at 2405 MBq/m2, 111In-cG250 images were superimposable 
on the 177Lu-cG250 images, illuminating the predictive value of 111In-cG250 for 177Lu-cG250 
accumulation [45]. In one patient, grade IV toxicity was observed at the 1850 MBq/m2 dose 
level. No significant toxicity was observed in the other patients treated at MTD, also not after 
the second or third treatment cycle. The majority of patients responded by stabilization of 
disease. In one patient (1850 MBq/m2 dose level), a PR was documented that lasted for nine 
months. Dosimetric analyses indicated effective uptake after consecutive treatments. 
Observed hematologic toxicity, especially platelet toxicity, correlated significantly with the 
administered activity, whole-body absorbed dose and red marrow dose. The tumor-to-red 
marrow dose ratio was higher for RIT with 177Lu-cG250 than for RIT with 90Y-cG250, 
indicating that 177Lu has a wider therapeutic window for RIT with cG250 than 90Y. The authors 
concluded that in patients with metastasized renal cell carcinoma, higher radiation doses can 
be guided to the tumors with 177Lu-cG250 than with 90Y-cG250 [54]. The authors concluded 
that RIT with 177Lu-cG250, targeting CAIX, may stabilize previously progressive metastatic 
ccRCC. 
3.3. Therapeutic Studies with Unmodified cG250 
Antibodies have the capacity to lyse cells by complement activation or by antibody-
dependent cellular cytotoxicity (ADCC). In vitro studies established that cG250 could initiate 
cell lysis through ADCC of CAIX-positive cells [55,56]. Also, significant tumor growth 
reduction was noted when mice bearing human RCC xenografts were treated with naked 
mAbG250 [49]. Based on these results, a phase 1 study with escalating doses of 5–50 
mg/m2 of cG250 (Girentuximab/RENCAREX®), with weekly infusions for 6 weeks, was 
initiated. Treatment up to the highest dose was safe and well tolerated. Of the 11 mRCC 
patients treated, one patient showed a CR and nine patients had SD after one treatment 
cycle [46]. 
In the subsequent phase 2 study, 36 patients with advanced RCC were included, all 
received 50 mg of cG250 weekly for 12 weeks. Before treatment, 80% of patients were 
progressive. After one treatment cycle, 28% of previously progressive patients had SD for at 
least six months, suggesting a clinical benefit [47]. During follow-up, one CR and one PR 
were noted, which lasted >1 year. The median survival of 15 months with 41% of the 32 
evaluable patients still alive after two years suggested that cG250 might be able to modulate 
the natural course of mRCC. One group of patients received extended treatment (an 
39
Processed on: 28-10-2016
505946-L-bw-Wakka
Chapter 2 
 
additional eight weeks of treatment). These patients showed a median survival of 39 months, 
compared to 10 months in the discontinued group. Patients receiving extended treatment 
with cG250 showed a significantly longer survival rate than the nonresponsive patients (70% 
vs. 26%). The levels of mAbG250-mediated ADCC differed between the patients: 42% of the 
patients showed moderate ADCC (5%–25%), whereas in 33% of patients, no ADCC was 
demonstrated. There was no clear correlation between the in vitro levels of cytotoxicity and 
the clinical responses. In addition, no correlation between the proportion of NK cells and the 
level of mAbG250-mediated ADCC was observed. In this non-randomized setting, it has 
been difficult to evaluate the true effect of cG250 treatment on the disease course of patients, 
as the natural disease course of mRCC is highly variable and periods with SD and/or PR can 
occur, even in the absence of treatment.  
Based on these results, an adjuvant double-blind, placebo controlled phase 3 trial was 
started (ARISER, Adjuvant RENCAREX® Immunotherapy Phase III trial to study efficacy in 
non-metastatic RCC), aiming at reducing the recurrence of disease in nephrectomized RCC 
patients who have a high risk of relapse (http://www.wilex.de/portfolio-english/rencarex/ 
phase-III-ariser/) [48]. The trial recruited 864 patients with prior nephrectomy of primary 
ccRCC; patients received a once-weekly infusion of RENCAREX® or placebo for 24 weeks. 
Those patients receiving the active drug received a loading dose of 50 mg in week 1 and 
weekly doses of 20 mg during weeks 2–24.  
Unfortunately, the trial did not meet its primary endpoint. The analysis showed no 
improvement in median DFS (approximately 72 months) following RENCAREX® treatment 
compared with placebo. However, preliminary results of a retrospective subanalysis appear 
to indicate that with increasing CAIX expression in tumor tissue, as quantified by a CAIX 
score, the treatment was more effective; DFS showed a clinically and statistically significant 
improvement in the patient population with a high CAIX level treated with cG250 compared to 
both placebo and patients with a low CAIX score (press release Wilex, 26 February, 2013). 
No other data are available at present. Therefore, an cG250-based immunotherapy for ccRCC 
in the adjuvant setting might still be an option in a highly defined subpopulation. 
Since interleukin-2 (IL-2) has been known to enhance ADCC of mAbs, the combination of 
this cytokine with cG250 was evaluated. In vitro studies had demonstrated that cG250 ADCC 
was increased when cells from IL-2-treated patients were used, suggesting that the 
combination of cG250 with IL-2 might be superior to cG250 alone [55]. In a phase 2 trial, 35 
patients with progressive mRCC received weekly intravenous infusions of 50 mg of cG250 
and daily subcutaneous low-dose IL-2 for 11 weeks. Treatment was well tolerated with little 
toxicity, attributable to IL-2. Clinical benefit was noted in eight of 35 patients (23%), with one 
long-lasting PR (>95 weeks), six long-lasting SD (>24 weeks) and a mean survival of 24 
months, with 45% of the 30 evaluable patients still alive after two years. The extended 
treatment group (an additional six weeks of treatment) showed a median survival of 41 
months, compared with 13 months in the non-response group. Patients receiving extended 
treatment showed a significantly longer survival rate than the non-response patients (55% vs. 
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25%). The increased survival (as compared to historic controls) was deemed to be cG250-
related and not related to the IL-2, as a six-fold decrease of the normal IL-2 dose was used 
[50]. The favorable outcome might have been due to a synergistic effect of cG250 and IL-2, 
as was observed in the in vitro studies.  
The number of effector cells (CD3−/CD16+/CD56+) increased during treatment, but lytic 
capacity per cell did not increase and ADCC and clinical outcome did not correlate. Similar 
results were observed in the study performed by Davis et al. [49]. Yet again, because 
patients were not randomized, it is difficult to judge the value of this observation. A 
randomized trial is needed to determine the true effect of the IL-2/cG250 treatment. 
Based on in vitro observations that with the addition of Interferons (IFNs), G250/CAIX 
expression was upregulated and that with Interferon gamma (IFN-γ), ADCC of cG250 was 
enhanced, the effect of cG250 combined with IFN-α was studied [56,57].  
In a multicenter, open-label, prospective, single-arm phase I/II trial study, cG250 in 
combination with IFN-α 2a was studied in a total of 32 patients with stage IV progressive 
RCC [51]. Patients received 20 mg cG250 weekly for three months, combined with IFN-α 2a, 
three million international units (MIU), three times per week, subcutaneously. Twenty six of 
31 patients were evaluable for response to treatment. Two patients showed a PR and 14 
patients SD in week 16. One patient experienced a PR for at least eight months, and nine 
patients had long durable disease stabilization (≥24 weeks). Clinical benefit was obtained in 
42% (11/26) of the patients. The overall median survival was 30 months for the 31 patients 
treated with WX-G250 and IFNα, with 57% of patients still alive after two years. The patients 
receiving extended treatment showed a median survival of 45 months compared with 10 
months in the non-extended group. Patients receiving extended treatment with cG250 
showed a significantly longer survival rate than the non-response patients (79% vs. 30%). 
4. Future Prospects
Clinical studies have now firmly established that cG250 adequately targets ccRCC. 
However, to prove that cG250 imaging can be used to guide clinical management, more 
evidence is needed. Thus far, patients for whom surgery was part of their clinical 
management have been studied, but the question whether watchful waiting can be applied in 
patients in whom no cG250 targeting is seen remains to be answered. As suggested by Divgi 
et al. [35], the role of cG250 imaging in influencing outcome would perhaps be best assessed 
in a clinical trial carried out in patients with small renal mass tumors and associated 
comorbidities.  
Another issue that needs further study is choice of radionuclide for imaging purposes. As 
discussed, 111In-cG250 SPECT may provide the same information as 124I-cG250 PET, but 
with the advantage that this can be produced as an off-the-shelf product that can be used on 
site. Alternatively, other radionuclides, such as 89Zr, might provide a useful alternative: it is 
similar with respect to its chemical characteristics, but is PET imageable.  
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Although the adjuvant study in a group of high-risk patients did not reach its primary end-
point, it is noteworthy to mention that in a subgroup analysis, patients with high CAIX 
expression as determined by IHC showed lower recurrence than patients negative or low in 
CAIX expression levels. Biomarker studies have demonstrated that CAIX staining correlates 
with survival, as well as with response to high dose IL-2 [58,59]. A cutoff of 85% CAIX 
staining provided the most accurate prediction of survival. Low CAIX (≤85%) staining was an 
independent poor prognostic factor for survival for patients with mRCC. For patients with 
non-metastatic RCC and at high risk for progression, low CAIX predicted a worse outcome 
similar to patients with metastatic disease. Intriguingly, CAIX expression correlated with 
response to high dose IL-2: survival >5 years was only seen in high CAIX expressers [60,61]. 
It is tempting to speculate that high-dose IL-2 treatment leads to expansion of CAIX-specific 
CTL, but characterization of 18 different TIL cultures suggested that anti-G250 reactivity is 
rare [13]. Patient stratification based on CAIX expression might lead to a (adjuvant) treatment 
strategy similar to, e.g., trastuzumab treatment of patients with breast cancer, where a very 
high correlation exists between HER2 expression and the success of trastuzumab, which 
targets HER2 [62].  
In summary, mAbG250 has shown remarkable targeting ability, and the main value of the 
antibody at present appears to be as diagnostic and, also, as a delivery vehicle for RIT.  
cG250 PET imaging holds great promise for the future, both in detecting localized and 
advanced disease, albeit that the radioisotope to use is still under investigation. In the near 
future, a clinical trial with PET tracer 89Zr-girentuximab will be initiated in our center, which 
will provide additional information about the use of girentuximab-based immunoPET in 
ccRCC. 
Clinical trials with unmodified cG250 suggest that treatment with cG250 can influence the 
disease course in mRCC patients. However, to validate whether cG250 treatment is of value, 
large, randomized trials are needed. 
Besides the usefulness in radioimmunodetection, girentuximab is a potent carrier for RIT 
in ccRCC. However, there are still several hurdles to overcome before girentuximab-based 
RIT can be implemented as a standard treatment. As previously mentioned, it is not clear 
which patients benefit most from RIT. Past results indicate that RIT is mainly suitable for 
treatment of small-volume disease or, possibly, as adjuvant treatment in selected cases, and 
more evidence regarding this topic is expected from the ongoing clinical trials with 90Y and 
177Lu-labeled girentuximab in the upcoming years. Besides better patient selection in the 
future, advances in dosimetric analysis will presumably contribute to the improvement of RIT, 
as the trade-off between efficacy and toxicity can be better tailored to the individual patient. 
Lastly, an important deficit in our current knowledge is how to optimally combine 
girentuximab-based RIT with the current standard of care in metastatic ccRCC.  
CAIX has also been used as a target in gene therapy studies with modified autologous T-
cells [63]. In these studies, patients with advanced RCC were infused with escalating doses 
of T-cells genetically retargeted with a chimeric antibody receptor (CAR) directed towards 
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carbonic anhydrase IX. Thus, the antigen-specific variable regions of mAbG250 (targeting to 
RCC) were linked to T-cell receptor signaling chains, leading to CAIX targeting in an MHC-
independent context. Liver toxicity was observed at the lowest cell dose, illustrating the 
potency of the modified T-cells. The liver toxicity could be prevented by pre-dosing with 
cG250 before administering modified T-cells [64]. Given that similar to mAb studies, the 
observed “on”-target toxicity could be prevented by blocking antigenic sites in off-tumor 
organs, higher T-cell doses might be possible. Although this is a very intriguing approach, 
patient recruitment has been very slow, and the final results are awaited. 
Finally, the clinical management of mRCC has changed significantly over the last few 
years. Implementation of various tyrosine kinase inhibitors (TKI) and mTOR inhibitors has led 
to improved progression-free survival. However, therapy resistance is a major issue, and 
these therapies are directed against the tumor vasculature and not against the tumor cells. 
Combination of TKI and cG250 might be beneficial: they attack different targets, and the 
combination might lead to synergistic effects. In a preclinical study, the biodistribution of 
cG250 was determined in TKI treated mice. TKI are known anti-angiogenic drugs, and thus, 
the accessibility of tumor cells is likely to be altered. In nude mice bearing human RCC 
xenografts treated orally with sunitinib, vandetanib or sorafenib, tumor uptake of cG250 
decreased dramatically, and vascular density decreased considerably, as judged by various 
markers [65]. This is comparable to the TKI effects on tumors in patients: large central 
necrotic areas can develop in tumors when patients are treated with TKI. When treatment 
was stopped, robust neovascularization, mainly at the tumor periphery, became apparent. 
Consequently, cG250 uptake recovered, albeit that cG250 uptake appeared to be restricted 
to the tumor periphery, where vigorous neovascularization was visible. This animal study 
demonstrated that simultaneous administration of TKI and mAb cG250 is unlikely to improve 
therapy outcome. This was also demonstrated in patients; a markedly decreased uptake of 
111In-girentuximab after treatment with TKI sorafenib was observed [66]. Data from this study 
suggest that the effect of girentuximab-based RIT would be severely hampered if given 
during TKI treatment. However, the observation that shortly after discontinuation of TKI 
treatment, mAb accumulation was restored, suggested that sequential treatment strategies 
might be useful [65]. Because cG250 and TKI appear to be feasible in sequence only, 
studies were designed to determine the optimal interval between TKI treatment and cG250 
administration. Biodistribution studies in two different animal models demonstrated that a 3-
day time interval was sufficient to reach optimal antibody accumulation (manuscript in 
preparation). Because TKI are also given in cycles in patients (four week treatment followed 
by two weeks off treatment), it appears that, indeed, combination of Sunitinib with mAb 
cG250 is feasible in mRCC patients, but the optimal treatment schedule needs to be 
determined.  
Anti-CAIX antibodies that combine inhibition of the enzymatic activity of CAIX with ADCC 
and/or CDC might be more potent than mAbG250, which does not inhibit the enzymatic 
activity of CAIX. Recently, a CAIX-specific antibody with an inhibitory effect on the carbonic 
anhydrase activity was described [67]. Up to 76% of CAIX activity was inhibited with the full-
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length IgG antibody MSC8. The authors speculated that combining target specificity with 
enzymatic inhibition in one antibody molecule may have an additive effect on reducing tumor 
growth. This interesting hypothesis will need to be substantiated.  
5. Conclusion
In summary, mAbG250 has shown outstanding targeting ability, and cG250 PET imaging 
holds great promise for the future, both in detecting localized and advanced disease, albeit 
that the most favorable radioisotope still needs to be determined. 
Confirmation of the results obtained in the non-randomized clinical trials with unmodified 
cG250 is needed to substantiate the value of cG250 treatment in mRCC. Girentuximab-
based RIT holds promise for treatment of patients with small-volume disease or, possibly, as 
adjuvant treatment in selected cases, and ongoing clinical trials in the upcoming years should 
provide evidence for this assumption. Lastly, whether combination of girentuximab-based RIT 
with the current TKI is possible needs to be established. 
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Abstract 
Immunotherapeutic targeting of G250/Carbonic anhydrase IX (CA-IX) represents a 
promising strategy for treatment of renal cell carcinoma (RCC). The well characterized 
human-mouse chimeric G250 (cG250) antibody has been shown in human studies to 
speciﬁcally enrich in CA-IX positive tumors and was chosen as a carrier for site speciﬁc 
delivery of TNF in form of our IgG-TNF-fusion protein (cG250-TNF) to RCC xenografts. 
Genetically engineered TNF constructs were designed as CH2/CH3 truncated cG250-TNF 
fusion proteins and eucariotic expression was optimized under serum-free conditions. In-vitro 
characterization of cG250-TNF comprised biochemical analysis and bioactivity assays, alone 
and in combination with Interferon-γ (IFNγ). Biodistribution data on radiolabeled [125-I] 
cG250-TNF and antitumor activity of cG250-TNF, alone and in combination with IFNγ, were 
measured on RCC xenografts in BALB/c nu/nu mice. Combined administration of cG250-
TNF and IFNγ caused synergistic biological effects that represent key mechanisms 
displaying antitumor responses. Biodistribution studies demonstrated speciﬁc accumulation 
and retention of cG250-TNF at CA-IX-positive RCC resulting in growth inhibition of RCC and 
improved progression free survival and overall survival. Antitumor activity induced by 
targeted TNF-based constructs could be enhanced by coadministration of low doses of 
nontargeted IFNγ without signiﬁcant increase in side effects. Administration of cG250-TNF 
and IFNγ resulted in signiﬁcant synergistic tumoricidal activity. Considering the poor outcome 
of renal cancer patients with advanced disease, cG250-TNF-based immunotherapeutic 
approaches warrant clinical evaluation. 
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Introduction 
Renal cell carcinoma (RCC) accounts for 2% of all cancers, leading to 20,000 annual 
deaths in Europe and 12,000 in the United States [1,2]. Although advances in understanding 
the biology of RCC led to novel approaches for the treatment of metastatic disease [3] with 
subsequent increase of progression-free and overall-survival rates, the prognosis for these 
patients is poor with a 5-year survival rate of less than 10% [4]. The predominant histological 
type of RCC is clear-cell carcinoma, comprising more than 85% of metastatic disease. Both, 
sporadic and inherited forms of clear cell RCC are associated with mutations in the von 
Hippel-Lindau (VHL) tumor suppressor gene [5]. Elucidation of its role in up-regulating 
growth factors associated with angiogenesis as well as the hypoxia-induced carbonic 
anhydrase IX (CA-IX) deﬁned a series of potential targets for novel treatment strategies. 
Among them, targeting of a surface expressed epitope of CA-IX (called G250) using chimeric 
G250 monoclonal antibody (cG250) is a promising immunotherapeutic approach [6]. Safe 
administration with excellent tumor targeting properties of the radio-labeled 131I- and 124I- 
cG250 antibody has been demonstrated in phase I clinical trials in patients with metastatic 
clear cell RCC [7–10]. Additional studies showed that multiple doses of cG250 were well 
tolerated and combination with low dose IL-2 resulted in disease stabilization [11,12]. These 
encouraging clinical features prompted us to optimize effector functions of cG250 to further 
improve its antitumor properties. 
We have previously reported on a strategy to promote the therapeutic efﬁcacy of tumor 
speciﬁc antibodies by genetic fusion to tumor necrosis factor (TNF) [13]. The soluble form of 
TNF occurs mainly as a trimer of 3 identical subunits. TNF was ﬁrst identiﬁed as a mediator 
of hemorrhagic tumor necrosis mediating regression of murine [14] and xenotransplanted 
human tumors [15]. Subsequent research revealed that Interferon gamma (IFNγ) plays a 
substantial role in TNF-mediated tumor rejection processes [16,17]. Many IFNγ-mediated 
mechanisms have been proposed to promote antitumor responses including antiproliferative 
and proapoptotic activity on tumor cells [18], inhibition of angiogenesis within tumors [19,20] 
or activation of innate [21,22] and adapted immune responses [23,24]. Thus, both TNF and 
IFNγ exert pleiotropic mechanisms on a variety of cell types and coadministration of both 
cytokines even results in synergistic antitumor activities [25–27]. However, because of its life-
threatening systemic toxicity [28] caused by affection of normal endothelial cells in peripheral 
blood vessels [29,30], the clinical use of TNF in combination with IFNγ as an anticancer drug 
is restricted to loco-regional treatment (e.g. isolated limb perfusion) [31,32]. However, we 
established a 2-step approach to enlarge the therapeutic window of the cytokine: TNF 
molecules were genetically fused to a tumor-speciﬁc antibody to focus TNF at the tumor site. 
In addition, TNF subunits were forced to form a dimer to reduce their activity in peripheral 
blood vessels outside the tumor compartment [13]. Abandoning the natural homotrimeric 
symmetry of TNF resulted in signiﬁcantly reduced toxicity as seen both in immunodeﬁcient 
and immunocompetent mouse strains [33]. The dimeric IgG-TNF molecules displayed 
signiﬁcantly stronger antitumor activity in-vivo than wild type TNF or trimeric TNF-antibody 
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conjugates. Dose escalation increased the therapeutic index of IgG-TNF and repeated 
administration additionally delayed tumor growth with tolerable side effects [33]. 
Here, we describe the construction, expression and puriﬁcation of a cG250-TNF fusion 
protein and its preclinical evaluation in a RCC mouse model. Biodistribution studies in 
G250/CA-IX-positive RCC xenografted BALB/c nu/nu mice showed a signiﬁcant increase of 
tumor-to-blood ratio over time with speciﬁc accumulation and retention of cG250-TNF in the 
tumor resulting in growth control of established RCC. Furthermore, a combination regimen 
with clinically well-tolerated doses of non-targeted IFNγ-induced synergistic activation of 
different tumoricidal pathways and increased signiﬁcantly the antitumor response in vivo. 
Considering the poor outcome of patients with advanced renal cell cancer, cG250-TNF-
based immunotherapeutic approaches could be a valuable therapeutic option. 
Material and methods 
Cell lines and reagents 
RPMI 1640 medium [supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 
penicillin (100 units/ml), streptomycin (0.1 mg/ml) and glutamine (0.3 mg/ml)] (all Gibco, 
Karlsruhe, Germany) was used as standard medium for all cell lines if not indicated 
otherwise. Human renal carcinoma cell lines NU-12, SK-RC-52 (high G250 expression level), 
SK-RC-17 (G250-negative), the cervix carcinoma cell line Me-180, and mouse ﬁbrosarcoma 
cell lines WEHI-164 S (TNF sensitive) and the WEHI-164 R (TNF resistant; a WEHI-164 
variant, cloned under the exposure to TNF) were supplied by Ludwig Institute for Cancer 
Research. HUVEC-c endothelial cell supplemented growth medium was obtained from 
PromoCell (Heidelberg, Germany). For selective cell culture mouse myeloma NSO cells were 
grown in Glutamine- free DMEM supplied by SAFC Biosciences (Lennexa, KS) according to 
Lonza’s manual of operating procedures (Lonza, NH). Human recombinant TNF, human 
recombinant IFNγ, murine recombinant IFNγ and soluble TNF-R1 were purchased from 
Genzyme (Neu-Isenburg, Germany). Anti-FAP-TNF has been described previously [13]. 
Antibodies were obtained from the following sources: rabbit antihuman tissue factor from 
American Diagnostica (Pfungstadt, Germany), rabbit antihuman ICAM-1 from Santa Cruz 
Biotechnology (Heidelberg, Germany), rabbit antihuman actin from Sigma (St. Louis, MO) 
PE-conjugated goat anti- rabbit from Dako (Glostrup, Denmark), murine anti-idiotypic anti- 
G250 and the chimeric G250 mAb were previously described.  
Construction of cG250-TNF fusion protein 
Reverse transcription-PCR on mRNA isolated from peripheral blood mononuclear cells for 
ampliﬁcation of the mature human TNF cDNA sequence was previously described [13]. The 
cDNA sequence coding for the cG250 variable heavy (HC) and light (LC) chain sequence 
was subcloned into pEAK8 mammalian cell expression vector (Edge BioSystems, 
Gaithersburg, MA) with the HC-expression vector containing the previously described human 
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CH2/CH3-truncated IgG1 TNF [13] C-terminally fused to His6 tag. cG250 LC was ampliﬁed 
by PCR with the forward primer (GAACC CGGGG CCGCC ACCAT GGGCA AGATG 
GAGTT TCATA CT) containing Kozak’s sequence and a Sma I restriction side and the 
reverse primers containing the stop codon and a EcoR I restriction enzyme sequence. 
Ampliﬁcation of the cG250 IgG1 CH1 TNF H6 sequence was done by sequential use of two 
reverse primers (CAAAG ATCTC AGGGC AATGA TCCCA AAGTA GAC and CAAGA 
ATTCT CAGTG ATGGT GATGG TGATG CAGGG CAATG ATCCC) and the forward primer 
introducing either the Kozak’s and the Sma I restriction side sequence (GAACC CGGGG 
CCGCC ACCAT GAACT TCGGG CTCAG ATTG). Variable cG250 LC sequence was cloned 
into mammalian expression vector pEE12.4 by Sma I/EcoR I and, respectively, the H6- 
tagged HC-TNF sequence by Sal I/Not I in pEE6.4 (Lonza, Portsmouth, USA). The double-
gene vector encoding the cG250-TNF fusion protein was created by digestion of both vectors 
with Not I and Sal I restriction enzymes and ligation of the pEE6.4 fragment into the larger 
pEE12.4 fragment according to Lonza’s manual of operating procedures. 
Generation of stable transfected cell lines, expression, puriﬁcation and 
characterization of cG250-TNF fusion protein 
Stable transfected NSO cell lines were established by electroporation of Pvu I linearized 
DNA using a GENPULSER (BioRad, Munich, Germany) according to manufacturer’s 
instructions. Transfected cells are selected for their ability to grow in glutamine-free medium. 
Stable cell lines producing high level of antibodies were expanded, weaned off FCS and 
transferred into a Technomouse system (Integra Biosciences, Fernwald, Germany) for large 
scale production. Antibody supernatant from the Technomouse system was dialyzed against 
PBS (phosphate buffered saline, pH 7.2) overnight (4°C). The dialyzed sample was passed 
over Protein A and G sepharose columns (Pharmacia, Freiburg, Germany) in a 2-step 
procedure. Fusion proteins bound to Protein G were stepwise eluted by adding 0.1 M 
glycine/HCl (pH 3.5) and samples were rapidly neutralized by the addition of 1 M Tris buffer 
(pH 8.0). Endotoxin contamination of the ﬁnal product was excluded by Limulus amebocyte 
assay (QCL 1000, BioWhittacker, Walkersville, MD). The size of the fusion protein was 
analyzed in reducing condition on SDS–PAGE and in native condition by FPLC-gel ﬁltration 
on a Superdex S-200 chromatography column (Amersham Pharmacia, Freiburg, Germany). 
Integrity of cG250-TNF in vitro 
Structural integrity of cG250-TNF was assessed by sandwich-ELISA as described [13]. In 
brief, 96-well ﬂat-bottom microtiter plates were coated overnight (4°C) with Inﬂiximab 
(antihuman TNF antibody), plates were blocked with 1.5% gelatine in PBS and the indicated 
reagents solved in PBS were added in serial dilutions (60 min, RT) and the bound cG250-
TNF using a murine anti-cG250 anti-idiotypic antibody (1 µg/ml, 1 hr, room temperature) as 
described previously [13]. 
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TNF-receptor 1 mediated apoptosis was investigated on TNF- sensitive ‘‘WEHI-164 S’’ 
and on partially TNF-resistant [34] ‘‘WEHI-164 R’’ as described [13]. 5 x 105 WEHI cells were 
cultured in 96-well plates in the presence of the indicated reagents. Apoptotic cells were 
identiﬁed by annexin V staining by ﬂow staining as described [13].  
Synergistic bio-activity of cG250-TNF and IFNγ in vitro 
Synergistic cytotoxic interaction of cG250-TNF and IFNγ was demonstrated by reduction 
of Me-180 cervical carcinoma cell viability as described [25,35]. Measurement of H2O2 
release by stimulated human polymorphonuclear leukocytes (PMN) prepared from venous 
blood of healthy donors was done as described [13]. Samples were taken at selected time 
points after incubation with triggering agents (37°C over 180 min in air). Activation of HUVEC 
endothelial cells cultured at second or third passage was done by incubation (6–24 hr at 
37°C) with effectors at indicated dilutions and harvested as described [13]. IP-10 expression 
levels were analyzed by RT-PCR (forward: AATCA AACTG CGATT CTGAT TTGC; reverse: 
AGGAG ATCTT TTAGA CATTT CCTT) and GADPH (forward: GTGAA GGTCG GAGTC 
AACGG ATTT; reverse: CTCCT TGGAG GCCAT GTGGG CCAT). Expression levels of 
tissue factor and ICAM-1 were detected by Western blot analysis. 
Xenograft models, biodistribution and treatment protocols 
Biodistribution and efﬁcacy studies were done on xenografted 6–8-week-old athymic 
BALB/c nu/nu mice (Charles River Laboratories, Central Animal Facility, University Medical 
Center Nijmegen, The Netherlands). Renal cell tumor engraftment was achieved by 
subcutaneous injection of 5 x 106 SK-RC-17, SK-RC-52, or transplantation of NU-12 
xenografts. The studies were approved by the local Animal Welfare Committee and 
performed in accordance with their guidelines. 
Protein was radioiodinated with 131I or 125Iodine (MDS Nordion, Fleurus, Belgium) 
according to the IodoGen method and the immune-reactive fraction of the radiolabeled 
preparations was determined by Lindmo analysis with minor modiﬁcations as described [7] 
and was 80–95%. Mice bearing subcutaneously established tumors were intravenously 
injected with 5, 25, or 50 µg of radioiodinated constructs. Cohorts of animals were sacriﬁced 
at predetermined timepoints after injection and tissues harvested, weighted and the uptake of 
125I-cG250-TNF or 131I-cG250, respectively, was determined in a gamma-counter as 
described [36]. Therapeutic efﬁcacy of cG250-TNF alone or in combination with IFNγ was 
investigated in mice xenografted with G250-positive or -negative or both renal cell 
carcinomas and analyzed by daily monitoring of health and body weight of mice and 
measurement of tumor size on treatment days. Differences between treatment groups were 
tested for statistical signiﬁcance by Student’s t test. 
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Results 
Production and characterization of cG250-TNF
We established an antibody fusion protein named cG250-TNF that consists of human TNF 
and chimeric antibody cG250. The N- terminal domain of human TNF was linked to the IgG 
hinge region as described [13]. The variable domains of cG250 were inserted through 
speciﬁc restriction sites into the pEE6.4 and pEE12.4 plasmids. The vector construct was 
conﬁrmed by DNA sequencing (Fig. 1a). High-level expression of the recombinant fusion 
protein using NSO cells was achieved with about a 270 mg/l of culture supernatant and a 
speciﬁc productivity of 12.46 pg/cell/day (data not shown). The immunocytokine was puriﬁed 
using a sequential 2-step afﬁnity chromatography with Protein A (ﬂow-through) and Protein G 
(capture), respectively. Deletion of the CH2- and the CH3-domains of cG250 and their 
replacement with TNF-molecules reduced substantially the afﬁnity of cG250-TNF to Protein 
A. During the ﬁrst pass of the dialyzed sample over Protein A column, contaminating residual 
bovine globulins were captured. The ﬂow through still contained the cG250-TNF fraction, and 
the construct was captured by a second pass over Protein G column. Fractions 
corresponding to dimeric species were collected during gel-ﬁltration chromatography (Fig. 
1b). Purity and identity of parental cG250 (Fig. 1b: lanes 1, 3, 5, 7) and cG250-TNF (Fig. 1b: 
lanes 2, 4, 6, 8) were characterized using SDS-PAGE under reducing and nonreducing 
conditions and Western blotting with anti-TNF. The recombinant heavy chain of cG250-TNF 
migrates with an apparent molecular weight of 47 kDa (Fig. 1b, lane 2) and is slightly smaller 
than a natural IgG heavy chain (Fig. 1b, lane 1). The human light chain is not altered with an 
apparent MW of 28 kDa. Western blotting of SDS-PAGE gels under both conditions and 
subsequent staining with anti-TNF identiﬁes the heavy-chain of cG250-TNF (Fig. 1b, lanes 4 
and 8). As expected, staining with anti-TNF failed to detect cG250 (Fig. 1b, Lanes 3 and 7). 
Correct folding of cG250-TNF hybrid protein was conﬁrmed by sandwich ELISA with 
recognition of the TNF-part by Inﬂiximab (antihuman TNF antibody) and by binding of the 
antibody part to an anti-cG250 anti-idiotypic antibody (Fig. 1c). The afﬁnity constant for the 
targeted G250 antigen was identical for the cG250-TNF (Ka = 2.5 x 109 M-1) and parental 
cG250 (Ka = 2.2 x 109 M-1) construct as measured by ELISA and Scatchard analysis (data 
not shown). The capacity of dimerized TNF subunits in triggering TNF-receptor 1 (TNF-R1) 
dependent signaling was determined by WEHI-164 cytotoxicity assay system. With regard to 
different molarities of cG250-fused dimeric TNF and recombinant trimeric TNF, assays were 
performed at TNF-equivalent doses. In agreement with our previous results on dimeric TNF 
fusion proteins, TNF-R1 mediated cytotoxicity of cG250-TNF was approximately 10-fold 
lower when compared with trimerized, commercially available recombinant human TNF 
(rhTNF; Fig. 1d). 
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Figure 1. Schematic model, expression 
and functional characterization of cG250-
TNF. (a) The Fc-region (CH2 and CH3) of 
the parental chimeric G250-IgG antibody 
has been replaced by two human TNF 
molecules. (b) Coomassie Brillant Blue 
staining of SDS–PAGE Gel of puriﬁed 
cG250 (Lanes 1 and 5) and cG250-TNF 
(Lanes 2 and 6) and Western Blot 
analysis under reducing (left) and 
nonreducing (middle) conditions stained 
with anti-TNF antibodies (Lanes 3 and 7 
for cG250, Lanes 4 and 8 for cG250-
TNF). Fast protein liquid chromatography 
elution proﬁle of cG250-TNF after 
sequential Protein A and Protein G 
puriﬁcation (right). (c) Structural integrity 
of puriﬁed cG250-TNF was studied by 
sandwich ELISA. Complexes of dimeric 
cG250-TNF and coated antihuman TNF 
antibody were visualized using a murine 
anti-cG250 anti-idiotypic antibody. 
cG250, rhTNF, and anti-FAP-TNF served 
as control as indicated. Standard 
deviations are indicated by bars. (d) TNF-
receptor 1 mediated activity of cG250- 
TNF was investigated on TNF-sensitive 
(closed symbols) or TNF-resistant (open 
symbols) WEHI cells. Cells were 
incubated with indicated amount of 
reagents for 12 hr at TNF-equivalent 
doses and numbers of apoptotic cells 
were analyzed by annexin V staining. 
Standard deviation is indicated by bars. 
Synergistic biological activity of cG250-TNF and IFNγ in vitro 
We next determined the capacity of dimeric cG250-TNF to induce tumoricidal activities 
with IFNγ in synergistic manner, as it is known for IFNγ and homotrimeric physiological TNF 
[26]. As expected, incubation of the human cervical cancer cell line Me-180 with either IFNγ 
or cG250-TNF as single substances was rather ineffective even at high concentrations 
[25,35], but combined incubation with IFNγ and cG250-TNF resulted in dose-dependent cell 
death (Fig. 2a). However, the efﬁcacy of the combined administration of TNF and IFNγ as 
antitumor strategy depends rather on its effects on tumor vessels [27] than on lysis of the 
malignant cells themselves. We, therefore, investigated the effect of cG250-TNF and IFNγ on 
key regulators of early and late events in vessel destruction. Activated polymorphonuclear 
leukocytes (PMN) participate in endothelial cell injury through generation of reactive oxygen 
species. On stimulation with hydrogen peroxide (H2O2) and under direct inﬂuence of TNF and 
IFNγ,  endothelial cells  upregulate  expression  of adhesion molecules such as ICAM-1 (inter 
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cellular adhesion molecule 1) on their surface, thus rendering endothelial cells more 
susceptible to neutrophil-mediated endothelial cell injury. Combined incubation of PMN with 
cG250-TNF and IFNγ-induced persistent generation of H2O2 to a signiﬁcant higher extend, 
when compared with single TNF activity and H2O2 release induced by single IFNγ treatment 
was negligible (Fig. 2b). Addition of IFNγ to HUVEC endothelial cells incubated with TNF or 
cG250-TNF also enhanced up-regulation of ICAM-1 expression (Fig. 2c, Lanes 7 and 8). 
Figure 2. Synergistic effects of cG250-TNF and IFNγ. (a) Me-180 cervix carcinoma cells were 
incubated with indicated concentrations of IFNγ and cG250-TNF (37°C, 24 hr). Viable cells were 
visualized by trypan blue exclusion. Standard deviation is indicated by bars. (b) Activation of 
adherent human granulocytes from healthy donors were stimulated with indicated amount of 
reagents and H2O2-release was measured at 37°C over 3 hr as described [13]. IFNγ was used at a 
concentration of 100 U/ml, all other reagents at 10 µg/ml. PMA served as positive control. 
Standard deviations are indicated by bars. HUVEC endothelial cells were treated with cG250-TNF 
and IFNγ and the expression level of ICAM-1 and tissue factor was analyzed by Western Blotting 
(c) and IP-10 by RT-PCR (d). HUVEC endothelial cells were incubated over 6 hr (tissue factor), 12 
hr (IP-10) or 24 hr (ICAM-1) respectively at 37°C with (1) rhu TNF (1 ng/ml), (2) cG250-TNF (1 
ng/ml), (3) rhu TNF (100 ng/ml), (4) cG250-TNF (100 ng/ml), (5) rhu TNF (1 ng/ml) plus IFNγ (100 
IE), (6) cG250-TNF (1 ng/ml) plus IFNγ (100 IE), (7) rhu TNF (100 ng/ml) plus IFNγ (100 IE), (8) 
cG250-TNF (100 ng/ml) plus IFNγ (100 IE), (9) IFNγ (100 IE) and (10) culture medium without 
effectors. 
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Figure 3. Biodistribution of 
radiolabeled cG250-TNF in BALB/c 
nu/nu mice xenografted with RCC 
tumors. In all biodistribution 
experiments, indicated tissue (n = 3 
animals) was analyzed at each time 
point and bars indicate standard 
deviation. (a) 5 µg of I-125 labeled 
cG250-TNF were administered and 
percent of injected dose (%ID/g) was 
measured within 24 hr. Tissue-to-
blood ratios were calculated for 
applied 125-I-cG250-TNF (b) and 131-
I-cG250 (c) to compare the respective 
biodistribution proﬁles. Tumor uptake 
was similar for radiolabeled cG250-
TNF and cG250. Transient 
accumulation of I-125-cG250-TNF in 
the stomach was because of free 
iodide accumulation. 
Staining of ICAM-1 was more intensive, after stimulation of HUVEC cells using trimeric TNF 
(Lanes 1, 3, 5, 7) when compared with cG250-fused dimeric TNF (Lanes 2, 4, 6, 8). This 
effect was evident following treatment with single substances and using the combination 
regimen. Different levels of TNF-R1-mediated up-regulation of key regulators in response to 
receptor triggering by dimeric or trimeric TNF conﬁrm our results obtained from the WEHI 
assay system. In addition to the activation loop between PMN and endothelial cells, we 
investigated the effects of the combined regimen on endothelial expression of IP-10 and 
tissue factor. IP-10 contributes to IFNγ-dependent tumor angiostasis promoting tumor 
rejection by inhibition of neo-vascularization, while endothelial tissue factor represents the 
key event for the activation of the extrinsic coagulation cascade initiating thrombotic infarction 
of established tumor vessels. Treatment with cG250-TNF or with rhuTNF in combination with 
IFNγ resulted in synergistic upregulation of IP-10 (Fig. 2c) and tissue factor (Fig. 2d). In 
addition to this procoagulant activity, endothelial cells undergo striking morphological 
changes  [37] together  with changes. in vascular permeability following exposure to TNF and 
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IFNγ [27]. Combined treatment of HUVEC cells with cG250-TNF and IFNγ changed cell 
morphology from a conﬂuent cobblestone mono-layer to a spindle endothelial cell 
morphology with interrupted conﬂuence (data not shown). In summary, the combination 
regimen of dimeric TNF fused to cG250 and IFNγ induced important cellular response 
programs displaying antitumor activities in a synergistic manner. 
Biodistribution of cG250-TNF in vivo 
To investigate the in-vivo behavior of cG250-TNF, biodistribution experiments were 
performed in BALB/c nu/nu mice grafted with NU-12 solid renal cell carcinomas as described 
[38]. On the basis of our experience with cG250 IgG, each animal received 5 µg of 
radiolabeled antibody. Because the half-life of IgG is mainly determined by the CH2/CH3 
constant regions, exchange of these by TNF was expected to lead to a dramatic alteration of 
the clearance rate. Mice were sacriﬁced within 24 hr post injection, tissues were harvested 
and uptake of 125I-cG250-TNF was measured. cG250-TNF tissue levels were no greater than 
those in blood, with a rapid decrease of percent of injected dose per gram tissue (%ID/g) and 
similar tissue-to-blood ratios over time (Fig. 3a). In contrast, tumor-to-blood ratios increased 
over time, demonstrating speciﬁc accumulation and retention of both cG250-TNF (Fig. 3b) 
and the parental cG250 antibody (Fig. 3c) at the tumor site. To determine whether similar 
tumor-to-blood ratios could be reached for cG250-TNF and cG250 antibody, dual labeling 
Figure 4. Dual labeling experiments 
to evaluate the impact of CH2/CH3 
exchange by TNF molecules on half-
life of the constructs. (a) Similar 
tumor-to-blood ratios could be 
reached for simultaneously applied 
131-I-cG250 and 125-I-cG250-TNF at 
5 µg doses. (b) %ID/g of 125-I-
cG250-TNF was much lower when 
compared with 131-I-cG250. 
Distribution proﬁles show comparable 
targeting properties for both agents 
with a shortened half-life of the 
CH2/CH3-deleted TNF-construct. 
Indicated tissue of animals (n = 3) 
grafted with RCC tumors was 
analyzed following simultaneous 
application of differently labeled 
antibodies and standard deviations 
are indicated by bars. 
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experiments were performed with 131I-labeled cG250 IgG and 125I-cG250-TNF. Indeed, 
tumor-to-blood ratios of the parental cG250 IgG and the  cG250-TNF fusion protein were 
similar (Fig. 4a), though %ID/g for cG250-TNF was much lower (Fig. 4b). These effects are 
due to the shorter half-life and the accelerated clearance of cG250-TNF leading to a short 
time period where cG250-TNF can accumulate at the tumor environment. In view of the rapid 
blood clearance, we performed a dose-escalation study, because higher cG250-TNF doses 
might result in higher tumor uptake levels. Cohorts of animals received 5, 25 or 50 µg 
radioiodinated cG250-TNF. Tissue-to-blood ratios remained stable at all dose levels and for 
almost all tissues, with exception of stomach uptake, attributed to free iodine in gastric 
mucosa (Fig. 5a). In contrast, relative as well as absolute amounts of cG250-TNF more than 
doubled in the tumors with increasing protein doses, reaching absolute levels comparable 
with the parental cG250 IgG (Fig. 3c). To ensure G250-antigen speciﬁc targeting, we 
performed a complementary biodistribution study in BALB/c nu/nu mice simultaneously 
grafted with solid G250-negative renal cell carcinoma. Minimal but not signiﬁcant uptake of 
cG250-TNF was seen in antigen-negative tumors. Biodistribution in organs did not differ 
between animals carrying G250-positive or G250-negative tumors. Most notably, tumor-to-
blood ratios were signiﬁcantly lower for G250-negative than for antigen-positive tumors, 
demonstrating G250-antigen speciﬁc accumulation (Fig. 5c).  
Figure 5. Effect of dose escalation 
on tumor targeting and construct 
enrichment. Cohorts of n = 3 animals 
received 5, 25, or 50 µg cG250-TNF 
and tissues were harvested, counted 
and weighed 24 hr after 
administration of radioiodinated 
construct. Standard deviation is 
indicated by bars. (a) Tissue-to-blood 
ratios remained stable for almost all 
tissues, with exception of stomach 
uptake, again attributed to free iodine 
in gastric mucosa. (a) Relative as 
well as (b) absolute amount of 
cG250-TNF accumulated in the 
tumors more than doubled with 
increasing protein dose, reaching 
absolute levels comparable to 
cG250. (c) Tumor uptake of 
radiolabeled cG250-TNF was 
investigated in mice simultaneously 
xenotransplanted with G250-positive 
and G250-negative renal cell 
carcinomas. Enrichment of the 
radiolabeled fusion protein was 
dependent on the presence of the 
targeted antigen. Standard deviations 
are indicated by bars. 
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Efﬁcacy of combined immunotherapy in vivo  
To compare the bioactivity of cG250-TNF with rhTNF at equimolar levels, we performed 
experiments at TNF-equivalent doses (30 µg of recombinant human TNF vs. 100 µg of 
cG250-TNF). Initial studies revealed that the toxicity proﬁle of cG250-TNF was analogous to 
our previously deﬁned LD50 of dimeric-TNF-fusion proteins such as anti-FAP-TNF for 
BALB/c nu/nu mice [33]. Tumor-bearing mice treated with 30 µg of rhTNF all died within 24 
hr and could not be challenged with a second injection. Mice treated with 100 µg of cG250-
TNF showed some signs of stress but all completed treatment without any lethal side effects. 
Further dose escalation of cG250-TNF led to signiﬁcant weight loss and alteration of 
behavior when applied in combination with IFNγ without improvement of therapeutic efﬁcacy 
(data not shown). Animals were simultaneously xenografted with solid growing G250-positive 
(SK-RC-52) and G250-negative (SK-RC-17) renal cell carcinomas on the opposite ﬂanks and 
therapeutic agents were administered three times per week. Repeated i.v. injections of 100 
µg of cG250-TNF resulted in a signiﬁcant growth retardation of G250- expressing RCC when 
compared with treatment with parental cG250 IgG at the 100 µg dose or to treatment with 
100 µg of control construct anti-FAP-TNF (p = 0.0001). Tumor size was controlled and 
remained stable during antigen-speciﬁc treatment without achieving complete remissions and 
tumor regrowth was only measurable after termination of cG250-TNF administration. In 
accordance to G250 antigen-restricted enrichment of radiolabeled cG250-TNF (Fig. 5c), the 
therapeutic activity of the unlabeled construct was also dependent on the presence of the 
targeted antigen as no therapeutic effect was seen on G250-negative tumors (Fig. 6a). A 
control fusion protein (anti-FAP-TNF) which does not recognize a relevant antigen in this 
model as well as the parental cG250 IgG failed to induce signiﬁcant antitumor responses 
(Fig. 6a). Combined application of cG250-TNF i.v. and low-dose IFNγ s.c. was signiﬁcantly 
superior to monotherapy (p = 0.01) as additional down-sizing of established xenografts could 
be induced. The groups receiving cG250-TNF or cG250-TNF in combination with IFNγ 
showed only progressive disease after termination of the treatment (Fig. 6b). Treatment at 
these dose levels could be completed without severe side effects. This clearly demonstrates 
that low dose IFNγ has a synergistic effect on cG250-TNF therapy in vivo and is well 
tolerated in combination with therapeutic cG250-TNF concentrations. 
 
Discussion 
Human clear cell carcinoma is the most common and aggressive renal tumor type. The 
recognition of hypoxia-inducible factor (HIF) related pathways involved in clear-cell RCC was 
the major breakthrough for the development of novel targeted therapies [4]. Activation of the 
HIF cascade leads to up-regulation of membrane bound G250/CAIX in more than 94% of 
clear-cell RCC [39]. Positron emission tomography (PET) imaging of patients with renal 
masses using 124I-cG250 could identify aggressive clear-cell RCC with 100% speciﬁcity and 
positive predictive accuracy  [10]. According to previous clinical trials using  iodinated cG250, 
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even metastatic spread of the disease could be visualized [8,10]. These prospective trials 
support the potency of cG250 for tumor detection and the preclinical study presented here 
establishes cG250 for the targeted delivery of TNF to xenotransplanted renal cell carcinoma. 
The cG250-based TNF fusion protein was designed in analogy to a previously generated 
IgG-TNF construct allowing for efﬁcient systemic TNF administration [13,33]. Intensity of 
TNF-R1 mediated signaling in vitro using the cytotoxicity assay system was comparable with 
the well-known range of the formerly characterized dimeric TNF-construct [13] Overall, 
cG250-TNF displays bioactivity in tumoricidal effector systems in vitro like induction of 
respiratory burst and triggering of endothelial cell injury. These effects, which play an 
important role in the antitumor efﬁcacy of TNF in vivo, are further up-regulated by IFNγ 
leading to synergistic rather than additive stimulation of key regulators responsible for 
antitumor effectiveness in vivo. Biodistribution studies in xenografted nude mice 
demonstrated the tumor-vasculature speciﬁc uptake of cG250-TNF and its enrichment over 
time exclusively at the tumor site. The labeling did not affect the immuno-reactivity of the 
protein, i.e., the pharmacokinetic behavior as measured by counting the radioactivity in 
harvested organs was a representation of true cG250-TNF targeting. Of note, part of the 
puriﬁed labeled material consisted of aggregates and thus, some uptake of aggregated 
material in liver and spleen was anticipated. The radioactivity measured in stomach was 
Figure 6. Treatment of BALB/c nu/nu 
mice simultaneously xenografted with 
G250-antigen positive (SK-RC-52) 
and -negative (SK-RC-17) renal cell 
carcinomas. Groups of n = 7 mice 
were treated every three days with 
i.v. injections cG250-TNF (100 µg), 
uncoupled cG250 antibody (100 µg) 
or with anti-FAP-TNF (100 µg) and 
tumor diameters were measured 
(mm). Treatment period is indicated 
by arrow (day 15 to day 78). (a) 
Therapeutic efficacy was dependent 
on the presence of the targeted 
G250-antigen and application of 
cG250-TNF and resulted in 
significant remission of established 
xenografts during treatment period. 
(b) Response to treatment was 
significantly improved by combined 
application of IFNg (300 ng) s.c., 
every 3 days and cG250-TNF (p = 
0.01). Standard deviations are 
indicated by bars. 
63
Processed on: 28-10-2016
505946-L-bw-Wakka
Chapter 3 
likely due to free iodide accumulation in this tissue [40]. We conclude that the shorter 
clearance time of cG250-TNF in comparison to the full-size IgG-format together with its lower 
TNF activity because of the dimeric TNF-structure led to the favorable low-toxicity proﬁle. 
These properties allowed for the present dose dense application regimen and targeting TNF 
as a truncated IgG-construct induced signiﬁcant antitumor responses in the xenograft RCC 
nude mouse model. Moreover, therapeutic potency of cG250-TNF could circumvent 
previously reported limitations of TNF-based immunotherapy in nude mice: Preclinical and 
clinical data suggest production of endogenous IFNγ as a central triggering antitumor 
mechanism in response to treatment with TNF [41,42]. As activated T cells seem to play the 
major role for triggering synergistic endogenous IFNγ release, nontargeted TNF alone, or 
even in combination with chemotherapy failed to induce antitumor effects in athymic nude 
mice bearing human xenografts [43]. Similarly, no antitumor effect was observed for the 
combination of targeted trimeric TNF at lower doses and an alkylating agent. Only the 
additional application of exogenous IFNγ improved the response rate to targeted TNF in 
these trials [44]. In this study, however, the dose dense administration schedule of cG250-
TNF resulted in signiﬁcant size reduction of xenotransplanted renal cell carcinomas and led 
to disease control during treatment. The combination of IFNγ and cG250-TNF could even 
improve treatment efﬁcacy further resulting in a signiﬁcant advantage of the combination 
regimen when compared to cG250-TNF monotherapy. Other trials reported up-regulation and 
enhanced shedding of TNF-receptors in response to IFNγ or TNF treatment [45,46]. Thus, 
the release of TNF receptors represents a counter-regulatory mechanism potentially 
contributing to a decrease in therapeutic TNF activity [47]. Antitumor efﬁcacy of single agent 
treatment with cG250-TNF was not limited by such undesirable effects. Furthermore, addition 
of IFNγ at clinically well-tolerated doses used in our trial was already sufﬁcient to further 
improve the good results obtained from the single agent treatment and alteration of soluble 
TNF-R1 levels is almost negligible in response to such low doses of IFNγ [45]. Furthermore, 
the TNF part of cG250-TNF consists of two human TNF subunits thereby circumventing 
murine TNF-R2 binding with concomitant inhibition [48]. In summary, administration of 
cG250-TNF alone or in combination with IFNγ displayed impressive therapeutic efﬁcacy. 
Initial reduction in tumor size and therapeutic control over established renal cell carcinomas 
was observed throughout continued administration of cG250-TNF. The phenomenon that 
withdrawal of targeted therapy provoked tumor regrowth is a common feature also observed 
in other therapeutic tumor vascular targeting settings [49]. The schedule of treatment and 
dosage of combined drugs is very critical for biological effects of applied cytokines [50]. The 
large therapeutic window and its antitumor efﬁcacy qualify cG250-TNF for further trials with 
potent co-effectors. Moreover, the very limited progression-free survival of patients suffering 
from metastatic disease promotes treatment strategies basing on cG250-TNF [51]. The 
encouraging targeting and antitumor properties of cG250-TNF and the strong and stable 
expression pattern of CAIX/G250 in sporadic and inherited forms of RCC warrant clinical 
evaluation of this construct. 
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Abstract 
Objective To investigate the effect of three different tyrosine kinase inhibitors (TKIs) on the 
biodistribution of chimeric monoclonal antibody (mAb) cG250, which identifies carbonic 
anhydrase IX (CAIX), in nude mice bearing human renal cell carcinoma (RCC) xenografts. 
TKIs represent the best, but still suboptimal treatment for metastatic RCC (mRCC) and 
combined therapy or sequential therapy might be beneficial. CAIX is abundantly over 
expressed in RCC and clinical trials have shown abundant and specific tumour accumulation 
of cG250. Combining a TKI with mAb cG250, involved in a different effector mechanism, 
might lead to improved tumour responses and survival in patients with mRCC. 
 
Materials and methods Nude mice bearing human RCC xenografts were treated orally with 
0.75 mg/day sunitinib, 1 mg/day vandetanib, 1 mg/day sorafenib or vehicle control for 7 or 14 
days. At 7 days, mice were injected i.v. with 185 kBq/5 µg 125I-cG250. Mice were killed at 
predetermined days and cG250 biodistribution was determined. Tumours were analysed by 
immunohistochemistry for the presence of endothelial cells, laminin, smooth muscle actin, 
CAIX expression and uptake of mAb cG250. 
 
Results While on TKI treatment, tumour uptake of cG250 decreased dramatically, tumour 
growth was slightly inhibited and vascular density decreased considerably as judged by 
various markers. When treatment was stopped at 7 days, there was robust 
neovascularization, mainly at the tumour periphery. Consequently, cG250 uptake also 
recovered, albeit cG250 uptake appeared to be restricted to the tumour periphery where 
vigorous neovascularization was visible. 
 
Conclusions Simultaneous administration of a TKI and mAb cG250 severely compromised 
mAb accumulation. However, shortly after discontinuation of TKI treatment mAb 
accumulation was restored. Combined treatment strategies with TKI and mAb should be 
carefully designed. 
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Introduction 
RCC is the most common renal malignant neoplasm in adults, accounting for ~85% of 
renal tumours and 2% of all adult malignancies [1]. About one third of newly diagnosed 
patients present with metastatic disease (mRCC) and for these patients prognosis is poor 
with a 5-year survival of < 10%. Clinical management of patients with mRCC has changed 
dramatically since the introduction of the antiangiogenic receptor tyrosine kinase inhibitors 
(TKIs), sorafenib and sunitinib [2]. Treatment with these drugs significantly prolongs the 
progression-free survival of patients with mRCC. Clinical responses mainly comprise partial 
responses and stabilization of disease but the effects of the antiangiogenic therapy on overall 
survival are unclear. Most patients develop resistance to these drugs and currently no 
therapy is effective in this situation. Therefore, there is still an urgent need to develop 
additional strategies that improve antitumour effects and induce long lasting responses. 
Combined therapy that consists of agents that target different pathways might act 
additively or synergistically. A TKI combined with chemotherapy has shown significant 
synergistic activity in glioma, colon-, and breast carcinoma [3–5]. Improved delivery of 
therapeutic molecules through vascular normalization and reduced tumour interstitial fluid 
pressure [6] has been suggested as a plausible explanation for this synergistic effect. 
However, RCC is unresponsive to chemotherapy. 
Monoclonal antibody-based targeted therapies are becoming important treatment 
methods. Significant antitumour efficacy has been reported in the treatment of non-Hodgkin’s 
lymphoma, breast cancer and chronic lymphocytic leukaemia. Chimeric monoclonal antibody 
(mAb) G250 (cG250) targets carbonic anhydrase IX (CAIX), which is specifically up-
regulated in clear cell RCC (ccRCC). Various clinical studies have reported excellent 
accumulation in ccRCC [7,8]. In different phase II efficacy studies in patients with mRCC an 
increase in median survival and overall survival rates has been reported [9,10]. However, 
despite the excellent targeting capability, cG250 treatment rarely showed antitumour efficacy. 
In the present study, we investigated the effect of three different TKIs on the 
biodistribution of cG250 in nude mice bearing human RCC xenografts. 
Material and methods 
Reagents 
The following compounds were used: sorafenib (Bay 43–9006, Nexavar®, Bayer 
Pharmaceuticals, Germany), which inhibits phosphorylation of vascular endothelial growth 
factor receptor 2 (VEGFR-2), VEGFR-3, platelet-derived growth factor receptor β (PDGFRβ), 
transmembrane FMS-like tyrosine kinase 3 receptor (FLT-3), tyrosine kinase receptor c-kit, c-
RAF-1 and B-RAF [2,11]; sunitinib (Su11248, Sutent®, Pfizer, USA), which inhibits 
phosphorylation of VEGFR-2, PDGFRβ, FLT-3 and c-kit [2,12]; and vandetanib (ZactimaTM, 
Astra Zeneca, UK) is a potent and selective inhibitor of VEGFR-2, epidermal growth factor 
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receptor and RET tyrosine kinases [2,13]. 
Sorafenib, sunitinib and vandetanib were generously provided by Bayer, the Ludwig 
Institute for Cancer Research, New York, USA, and Astra Zeneca, respectively. 
 
Radiolabeling of cG250 
The isolation, characteristics and the immunohistochemical reactivity of mouse mAb G250 
have been described earlier [14]. The antigen (CAIX/G250/MN) is expressed on the cell 
surface of virtually all ccRCC and absent on most normal tissues [14–16]. The generation of 
cG250 has been described elsewhere [8]. 
The cG250 (generously provided by Wilex AG, Germany) was labelled with 125I 
(Amersham) according to the Iodogen method [8]. The radiochemical purity of the 125I-
labelled cG250 (125I-cG250) preparations was determined by instant thin-layer 
chromatography (ITLC) using ITLC silica gel strips (Gelman Sciences, USA) and 0.1 M citrate 
buffer (pH 6.0) as the mobile phase. The immunoreactive fraction (IRF) was determined on 
freshly trypsinized SKRC52 RCC cells at infinite antigen excess essentially as described by 
Lindmo et al. [17], with minor modifications [8]. 
 
Animal experiments 
Female BALB/c nu/nu mice, aged 6–8 weeks, were obtained from the local central animal 
facility. The mice were grafted s.c. with freshly excised NU12 RCC xenograft pieces [18] of 
~1 mm3. Institutional guidelines were strictly followed for maintenance of animals and 
experimental procedures were approved by the Institutional Animal Care and Use 
Committee. NU12 tumours have a ccRCC phenotype and previous studies have shown that 
it is an excellent model to study mAb G250 targeting. Treatment with a TKI was started when 
tumours had reached a volume of ~100 mm3. 
Sorafenib and sunitinib were prepared as described [11]. Vandetanib was dissolved in 1% 
Tween-80 (Sigma) and prepared fresh every week. 
Mice received the equivalent of 35 mg/kg (0.75 mg/200 µL) sunitinib orally per day for 7 or 
14 days or 50 mg/kg (1 mg/200 µL) sorafenib orally per day for 14 days or 50 mg/kg (1 
mg/100 µL) vandetanib orally per day for 14 days. 
 
Biodistribution studies 
When the NU12 tumours reached the desired volume, mice were divided into groups of 
four to five mice. Mice were treated with a TKI or vehicle once a day until they were killed 
(continuous treatment, Fig. 1A). After 7 days, all mice were injected i.v. with 125I-cG250 (185 
kBq/5 µg/mouse). Treatment and control groups of four to five mice were killed at 1, 2, 4 and 
7 days after mAb injection; and blood, tumour, muscle, liver, lung, spleen, kidney, stomach 
and intestine were collected, weighed and counted in a γ-counter (Wizard; Pharmacia-LKB). 
The activity in the samples was expressed as percentage injected dose per gram tissue (% 
ID/g). In one experiment, sunitinib treatment was stopped after 7 days (7d sunitinib, Fig. 1B), 
mice were injected i.v. with 125I-cG250 mAb and cG250 biodistribution was determined as 
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described above. 
 
 
 
 
 
 
Immunohistochemical analysis 
For immunohistochemical analysis, harvested tumours were formalin fixed and embedded 
in paraffin, snap-frozen and stored at –80 °C. For morphological analyses, sections were 
stained with haematoxylin and eosin. Primary antibodies used were: cG250 to detect CAIX 
(Wilex, Germany, 10 µg/mL), rat-anti-mouse CD34 (Hycult Biotechnology, 5 µg/mL) or rat 
monoclonal 9F1 [19] (supernatant 1:50) to detect endothelial cells, mouse-anti-smooth 
muscle actin (SMA; α-SM1, A2547 Sigma, 1:15000) to detect perivascular cells, polyclonal 
rabbit-anti-laminin (Z0097,Dako, Denmark, 1:3000) to visualize basement membrane, rabbit 
anti-Glut-1 (A3536, Dako, Denmark, 1:200) to detect hypoxia and mouse anti-human Ki-67 
(Mib-1, M7240, Dako, Denmark, 1:100) to detect proliferating cells. For visualization of CAIX 
expression, 4 µm cryostat sections were acetone fixed and incubated with cG250, followed 
by peroxidase labelled rabbit-anti-human IgG (P214, Dako) as secondary antibody. 
To detect in vivo accumulated injected cG250, cryostat sections were incubated with 
rabbit-anti-human IgG–peroxidase only and 3,3'-diaminobenzidine (DAB) was used as 
developing agent (PowerDAB, Immunologic, Duiven, the Netherlands) . 
Endothelial cells were visualized with 9F1 or anti-CD34; 9F1 staining was performed on 
acetone fixed 4 µm cryostat sections. After blocking with avidin, biotin and normal rabbit 
serum, primary antibody 9F1 was applied for 1 h at room temperature. After washing 
procedures, secondary antibody was applied (biotinylated anti-rat antibody, Vector) 
supplemented with 4% normal mouse serum. Subsequently, sections were incubated with 
avidin/biotinylated enzyme complex (ABC)-peroxidase with PowerDAB as developing agent. 
CD34/SMA double staining was performed as described previously [20]. For laminin 
staining, paraffin sections were pretreated with 0.1% pronase in PBS for 10 min at 37 °C. 
Immunohistochemistry for Glut-1 and Ki-67 was performed on paraffin sections as described 
Figure 1. Treatment schedule of nude mice. A, continuous TKI treatment; B, 7 day sunitinib 
treatment. b, biodistribution time point. 
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previously [20]. After blocking with avidin and biotin, sections were blocked with either normal 
goat serum (for laminin and Glut-1) or normal horse serum (for Mib-1) and incubated 
overnight at 4 °C with the primary antibody (anti-laminin, Glut-1 or Mib-1). Subsequently, 
sections were incubated with the appropriate secondary antibody, ABC-peroxidase was 
applied and AEC (aminoethylcarbazole in dimethylformamide) reagent was used as the 
developing agent. 
All sections with the exception of the double-stained CD34/SMA sections were 
counterstained with haematoxylin. 
 
Statistical analysis 
The results are given as the mean (SD). Differences in mAb cG250 uptake between 
treatment and control at each time-point were tested for statistical significance using the 
Mann–Whitney U-test. Statistical significance was set at a P-value of 0.05, without 
adjustments for multiple testing. All tests were two-sided. 
 
Results 
 Continuous treatment of NU12 tumours with sunitinib, sorafenib, or vandetanib caused 
substantial inhibition of tumour growth (Table 1), regardless of the tumour volume at the 
initiation of the TKI treatment. After 14 days of treatment, mean tumour volumes for the 
sunitinib-, vandetanib- and sorafenib-treated groups were 129%, 86% and 103%, 
respectively, of the baseline value (100%). By contrast, the tumour volumes of the control 
groups were 241%, 195%, and 171%, respectively. 
 
 
 
Table 1 Mean (SD) volume of NU12 tumours during treatment with sunitinib, sorafenib or vandetanib 
   Mean (SD) volume*, mm3 at: 
Duration of    
treatment Treatment  0 days  7 days  14 days 
7 days Sunitinib  168 (72)  208 (97) ND 
 Control  148 (73)  241 (104) 
Continuous Sunitinib  91 (38)  126 (61) 118 (54) 
 Control  96 (37)  180 (67) 232 (111) 
 Vandetanib  63 (34)    69 (37)   54 (34) 
 Control  64 (29)    95 (33) 125 (19) 
 Sorafenib  117 (66)    91 (50) 121 (52) 
 Control  112 (63)  125 (68) 192 (61) 
*Volume (mm3) of the tumours calculated using the formula: length x width x depth x π/6. ND, not 
determined. 
 
 
 
In Fig. 2A the biodistribution of 125I-cG250 (IRF 82%) in sunitinib- and untreated NU12-
tumour bearing mice is shown. The amount of accumulated cG250 in the tumours of the 
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control mice were in the expected range, 40 (10)%, 44 (4)%, 35 (9)% and 21 (5)% at 1, 2, 4 
and 7 days after injection, respectively, but these values were reduced to 11 (4)%, 12 (5)%, 9 
(2)%, 8 (1)% in the treated mice, respectively. This translates into a relative decrease of 
73%, 73%, 74% and 62% of cG250 accumulation, respectively (Table 2). 
When sunitinib treatment was discontinued at the time of 125I-cG250 injection (IRF 92%) 
there was a different distribution pattern (Fig. 2B). In tumours of control mice %ID/g cG250 
were 34 (5)%, 31 (6)%, 30 (3)%, and 12 (3)% at 1, 2, 4 and 7 days after injection, 
respectively. By contrast, cG250 accumulation values for the tumours harvested from the 
sunitinib-treated mice were 21 (3)%, 25 (7)%, 29 (8)%, 27 (11)% at 1, 2, 4 and 7 days after 
injection, respectively, i.e. this translates to a relative decrease of 38%, 19%, 3% and an 
increase of 125%, respectively (Table 2). Sunitinib treatment did not alter cG250 distribution 
in other organs. 
 
 
 
 
 
 
To investigate whether the effects of sunitinib on cG250 tumour accumulation could be 
reproduced with other TKIs, NU12-tumour bearing nude mice were treated with sorafenib or 
vandetanib and the biodistribution of 125I-cG250 (IRF 125I-cG250 91% and 87%, respectively) 
was determined (Fig. 2C,D). Indeed, the same inhibitory effect on tumour uptake was seen at 
all time points in the sorafenib- and vandetanib-treated mice. Sorafenib reduced cG250 
Figure 2. Biodistribution of 125I-cG250 in Balb/c nu/nu mice xenografted with NU-12 (G250+) 
tumours. A, continuous sunitinib treatment; B, 7 day sunitinib treatment; C, continuous sorafenib 
treatment; D, continuous vandetanib treatment. Data from groups of four to five mice are expressed 
as the mean (SD). Statistical analysis was based on the Mann–Whitney test comparing treatment 
with control at each timepoint.  
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uptake by 88%, 64%, and 68% at 1, 4 and 7 days, respectively. Finally, vandetanib treatment 
resulted in reduction of cG250 uptake of 83%, 81%, 68%, and 71% at 1, 2, 4 and 7 days 
respectively (Table 2). There was normal blood clearance in all experiments. As expected, 
there was no uptake of cG250 in muscle (Fig. 2) or any other tissues (results not shown). 
 
Table 2 Relative decrease in mAb cG250 uptake after treatment with sunitinib, sorafenib or 
vandetanib 
 Time after injection, days                   
  
Treatment  1  2  4  7 
Mean (SD) % ID/g: 
 sunitinib, continous  11 (4)  12 (5)    9 (2)    8 (1) 
 control  40 (10)  44 (4)  35 (9)  21 (5) 
Relative decrease, %*  73  73  74  62 
P   0.008  0.008  0.016  0.008 
 
Mean (SD) % ID/g: 
 sunitinib, 7 days  21 (3)  25 (7)  29 (8)  27 (11) 
 control  34 (5)  31 (6)  30 (3)  12 (3) 
Relative decrease, %*  38  19    3  – 125 
P   0.016  0.310  0.905  0.056 
 
Mean (SD) % ID/g: 
 sorafenib, continous  6 (1)  ND  13 (7)    7 (3) 
 control  49 (26)  ND  37 (11)  22 (6) 
Relative decrease, %*  88  –  64  68 
P   0.016  –  0.008  0.008 
 
Mean (SD) % ID/g 
 vandetanib, continous  7 (3)  10 (3)  12 (3)  11 (6) 
 control  42 (23)  53 (6)  51 (15)  37 (13) 
Relative decrease, %*  83  81  68  71 
P   0.016  0.095  0.016  0.063 
*Relative decrease, (% ID/g control – % ID/g treatment)/% ID/g control x 100 %; ND, not determined. 
 
 
 
Immunohistochemistry 
Because the studied TKIs are known antiangiogenic molecules, we analysed the tumours 
for the distribution of vascular markers. Additionally, tumours were analysed for CAIX 
expression, cG250-uptake, laminin, Ki-67 and Glut-1. Comparison of tumours harvested from 
TKI-treated mice with control tumours showed a dramatic decrease in vasculature as judged 
by CD34 or 9F1 analysis (Fig. 3G-I). There was vigorous outgrowth of endothelium in the 
tumour periphery, but not in the tumour centre in mice in which sunitinib treatment was 
stopped at 7 days (compare with Fig. 3H, I). Vascular density was considerably decreased in 
tumours from continuously treated mice (Fig. 3H, blue staining) as compared with control 
mice (Fig. 3G). TKI treatment of 7 or 14 days resulted in a slight decrease of SMA-positive 
cells (presumably pericytes, characteristic for mature vessels), but this decrease was less 
pronounced than the decrease seen with CD34 (Fig. 3G,H; red colour). 
CAIX expression was homogeneous in tumours of treated and control mice (Fig. 3A–C), 
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i.e. expression of the cG250 target was not altered due to the TKI treatment. In vivo 
accumulated cG250 was clearly detectable in untreated mice throughout the tumours (Fig. 
3D). However, accumulation of the injected cG250 could not be visualized in the tumours of 
mice under continuous sunitinib treatment (Fig. 3E). In contrast, when sunitinib treatment 
was discontinued, accumulation of the injected cG250 could readily be seen in the 
tumours(Fig. 3F), predominantly in the tumour periphery in areas with vigorous vascular 
outgrowth.  
 In Fig. 3J–L the expression pattern of laminin is shown. The nicely organized structure of 
laminin in the tumours of the control mice (Fig. 3J) was lost in the tumours of the mice treated 
with sunitinib for 14 days (Fig. 3K). This network was restored 7 days after treatment was 
stopped (Fig. 3L). 
Microscopic analysis of the NU12 tumours of untreated mice showed a typical 
micronodular phenotype (Fig. 4A). Sunitinib treatment resulted in loss of this phenotype and 
in the appearance of more dispersed necrotic areas (Fig. 4D). Tumours of the vandetanib- 
(Fig. 4G) and the sorafenib-treated mice (Fig. 4J) showed widespread necrosis. 
TKI treatment with sunitinib, sorafenib or vandetanib did not lead to differences in cell 
proliferation in viable tumour tissue as judged by Mib-1 (Ki-67) staining (Fig. 4C, F, I, L). 
Glut-1 expression was not visible in the control tumours but clearly visible in the mice 
treated with sunitinib for 14 days (Fig. 4B, E), most prominently adjacent to necrotic areas. 
With the exception of more extensive expression of Glut-1 (Fig. 4H, K), analysis of the 
tumours of the sorafenib- and of the vandetanib-treated mice showed similar results as 
tumours from sunitinib-treated mice (not shown). 
 
Discussion 
Treatment of patients with metastasized ccRCC has changed dramatically since the 
introduction of TKIs. Of the two frequently used drugs, sunitinib treatment can result in 
significant tumour responses. Although this is a major advancement in the clinical 
management of these patients, unfortunately, durable responses are rare and it is currently 
unclear whether TKI treatment improves overall survival. Advanced RCC remains an 
incurable disease and therefore new (combined) therapies are still needed. It might be more 
effective to combine therapies that differ in their working mechanism, e.g. bevacizumab 
combined with erlotinib [21] or interferon α combined with bevacizumab [22] or sorafenib 
[23,24]. These treatment regimens lead to improved response rates, but toxicity was also 
augmented. 
In the present study, we combined TKIs with the tumour-specific cG250, which targets 
CAIX, ubiquitously expressed in ccRCC. With this combination two different pathways are 
‘hit’, which might prove beneficial. Before embarking on combined therapy studies, we 
studied the influence of TKI treatment on the pharmacokinetic behaviour of cG250. In 
general, all three TKIs tested had very similar effects. There was already a significant 
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decrease in cG250 tumour accumulation after 7 days of treatment with TKI, regardless of 
which TKI was used. In vitro analysis showed that antibody accretion was dramatically 
diminished in tumours of the TKI-treated mice. Most probably, the decreased cG250 tumour 
accumulation  is caused by the  loss of vascular  integrity as shown by the marked decreased 
 
 
 
 
Figure 3. Immunohistochemical analysis of NU-12 tumours treated with sunitinib. Tumours were 
harvested 14 days after the start of treatment. A, D, G, J, untreated mice; B, E, H, K, continuously 
treated (14 days) mice; C, F, I and L, 7 day treated mice. A, B, C, CAIX expression. D, E, F, In vivo 
accumulated cG250. G, H, Staining of endothelium (CD34) in blue and staining of SMA (pericytes, 
characteristic for mature vessels) in red. I, staining of endothelium (9F1). J, K, L, Expression of 
laminin. Inserts show higher magnifications. Please note dramatic decrease of endothelium in 
continuously treated mice and vigorous outgrowth of endothelium in the tumour periphery when 
sunitinib treatment was stopped (compare H, I). There was no outgrowth of endothelium in the 
central region of the tumours. cG250 accumulation could barely be visualized (black arrows) during 
continuous sunitinib treatment (E). In contrast, cG250 accumulation was clearly visible in tumours 
of 7-day treated mice, predominantly in areas with endothelial outgrowth (I). A–F, x50; G–L, x25; 
A–L inserts, x100. 
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expression of components of more mature vessels. In addition, most tumours of TKI-treated 
mice had necrotic areas, which is concordant with inhibited neovascularization. It is unlikely 
that the decreased accumulation was the consequence of the higher necrotic content of TKI-
treated tumours: CAIX expression in the viable tumour remained high and we have 
previously reported that CAIX expression is necessary for cG250 accumulation [25]. The 
present observations are in agreement with those of Chang et al. [26] who reported that TKI 
treatment resulted in enhanced hypoxia due to destruction of tumour vasculature, thereby 
Figure 4. Immunohistochemical analysis of control NU-12 tumours (day 14, A–C) tumours treated 
with sunitinib (day 14, continuous treatment, D–F), vandetanib (day 14, G–I) and sorafenib (day 14, 
J–L). A, D, G, J, haematoxylin and eosin staining; B, E, H, K, Glut-1 expression; C, F, I, L, Ki-67 
expression; original magnifications x100. N, necrotic tumour; V, viable tumour. There was no 
difference in Ki-67 expression when comparing the different agents. Glut-1 expression was higher 
in tumours when mice were treated with sorafenib or vandetanib, mainly near necrotic areas. 
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compromising the access of antibody to the tumour. 
Strikingly, there was a rapid outgrowth of endothelium (neovascularization) when sunitinib 
treatment was discontinued. Thus, the nutrient supply to the tumour cells rapidly recovered. 
This same phenomenon may occur in patients treated with sunitinib: the current treatment 
schedule for patients with RCC involves 4 weeks ‘on’ and 2 weeks ‘off’ sunitinib. During the 
‘drug-holiday’ period rapid neovascularization may also occur, which may explain why 
patients eventually progress on sunitinib treatment. Additionally, the schedule may lead to an 
antiangiogenic resistant RCC phenotype. 
Discontinuation of sunitinib treatment lead to enhanced uptake of antibody 7 days after TKI 
treatment (Fig. 2B). This is similar to studies in a colorectal cancer model showing enhanced 
antibody tumour accumulation in mice treated with STI571 (imatinib) 3 days after treatment 
was stopped [27]. Although in the present study this effect occurred later, this might be 
explained by the specificity of the TKI used and the slightly different dosing schedule. 
It has been suggested that antiangiogenic therapy might result in normalization of tumour 
vasculature [6] and to increased uptake of therapeutic modalities. Preclinical studies 
indicated that beneficial effects of TKI on the tumour vasculature almost exclusively concern 
VEGFR-TKI combined with chemotherapeutics [3,4]. These studies have convincingly shown 
improved growth inhibition or increased tumour distribution of the (relatively small) 
chemotherapeutic drugs. In the present murine model, closely resembling human ccRCC, 
there was no normalization, but instead simultaneous administration of TKI and mAb G250 
severely compromised mAb accumulation, probably the result of the destruction of the 
tumour vasculature. These results suggest that major differences may exist between different 
tumour types or, alternatively, that the window of opportunity for increased uptake is very 
narrow for larger molecules such as antibodies. Possibly, a narrow time window exists in 
which lowered interstitial fluid pressures precedes tumour vasculature destruction. During 
this period, increased flow might lead to increased mAb accumulation. Alternation of a TKI 
and mAb administration might then lead to destruction of the central tumour mass by TKI 
treatment and tumour cell kill at the tumour periphery. Alternatively, entrapment of the 
antibody by allowing antibody localization to occur before antiangiogenic therapy, a scheme 
used successfully in colorectal xenografts [28], might be beneficial. 
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Abstract 
 
Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive 
increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC 
remains largely incurable. We combined sunitinib, targeting the endothelial cells, with 
Girentuximab, (monoclonal antibody cG250, recognizing carbonic anhydrase IX (CAIX) 
targeting the tumor cells, to study the effect of sunitinib on the biodistribution of Girentuximab 
because combination of modalities targeting tumor vasculature and tumor cells might result 
in improved effect. Nude mice with human RCC xenografts (NU12, SK-RC-52) were treated 
orally with 0.8 mg/day sunitinib, or vehicle for 7-14 days. Three days before start or cessation 
of treatment mice were injected i.v. with 0.4 MBq/5 μg 111In-Girentuximab followed by 
biodistribution studies.  Immunohistochemical analyses were performed to study the tumor 
vasculature and CAIX expression and to confirm Girentuximab uptake. 
NU12 appeared to represent a sunitinib sensitive tumor: sunitinib treatment resulted in 
extensive necrosis and decreased microvessel density (MVD). Accumulation of Girentuximab 
was significantly decreased when sunitinib treatment preceded the antibody injection but 
remained unchanged when sunitinib followed Girentuximab injection. Cessation of therapy 
led to a rapid neovascularization, reminiscent of a tumor flare. SK-RC-52 appeared to 
represent a sunitinib-resistant tumor: (central) tumor necrosis was minimal and MVD was not 
affected. Sunitinib treatment resulted in increased Girentuximab uptake, regardless of the 
sequence of treatment. These data indicate that sunitinib can be combined with 
Girentuximab. Since these two modalities have different modes of action, this combination 
might lead to enhanced therapeutic efficacy. 
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Introduction 
 
Renal cell carcinoma accounts for approximately 3% of all cancers and was diagnosed in 
over 115,000 individuals in Europe in 2012 [1]. Most RCC (70%) are of the clear cell type 
(ccRCC) that is characterized by high expression levels of Vascular Endothelial Growth 
Factor (VEGF) and, consequently, a hypervascular phenotype. Over the last few years, anti-
VEGF therapies have significantly changed the standard of care for patients with advanced 
RCC [2]. Sunitinib [3], sorafenib [4], axitinib [5], pazopanib [6] and bevacizumab + interferon 
[7] have all been registered for the treatment of advanced RCC. Additionally, the mTOR 
inhibitors Temsirolimus and Everolimus have been registered for poor risk RCC patients 
[8,9]. Implementation of these new treatment modalities has lead to an impressive increase 
in progression-free survival [10]. Nevertheless, because eventually treatment resistance 
occurs, metastatic RCC remains largely incurable. Additionally these chronic treatments may 
coincide with significant toxicity which increases to unacceptable levels when combination 
treatment is applied [11]. Sequential therapy may be more promising but the most optimal 
sequence therapy has not been established.  
There is considerable evidence that anti-VEGF and anti-VEGF receptor (VEGFR) drugs 
cause remodeling of the aberrant tumor vessels, resulting in a “normalized vasculature” [12]. 
This phenomenon may improve tumor perfusion and reduce tumor interstitial fluid pressure, 
thereby improving uptake of other drugs. Indeed, addition of bevacizumab to first-line 
chemotherapy in advanced colorectal cancer resulted in an overall survival benefit [13]. 
However, caution is warranted regarding unanticipated effects since studies with VEGFR-
targeting compounds in murine models provided evidence for increased metastatic 
propensity [14,15]. 
Chimeric monoclonal antibody G250 (cG250/Girentuximab) targets human carbonic 
anhydrase IX (CAIX), a transmembrane protein which which catalyzes the reaction CO2 + 
H2O↔HCO3- + H+. Expression of CAIX is regulated by hypoxia-inducible factor 1-alpha, 
which in turn is regulated by the Von Hippel Lindau (VHL) protein (pVHL), a gene affected in 
the vast majority of ccRCC patients. The molecular link between pivotal molecular events in 
ccRCC explains the ubiquitous expression of CAIX  in ccRCC. In non-RCC tumors, CAIX is 
activated following hypoxia. In view of the favorable tissue distribution, the potential of CAIX 
targeting of RCC for diagnosis or therapy has been studied extensively [16-19]. Clinical trials 
have demonstrated high, specific tumor accumulation of Girentuximab, and 
radioimmunotherapy (RIT) with 177Lu-Girentuximab can stabilize previously progressive 
metastatic ccRCC [20]. Combination of sunitinib with 177Lu-Girentuximab RIT may act 
synergistically since these compounds simultaneously target the tumor blood vessel- and 
tumor cell compartment in patients with mRCC. We have previously shown that simultaneous 
administration of sunitinib and Girentuximab severely compromised mAb accumulation in 
mice [21], an effect that could be reiterated in patients treated with sorafenib [22]. However, 
shortly after discontinuation of tyrosine kinase inhibitor (TKI) treatment, mAb accumulation 
was restored, mainly in the tumor periphery [21]. This suggests that sequential administration 
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of TKIs and Girentuximab may be better than simultaneous administration. The aim of this 
study was to explore how tumor targeting by Girentuximab is influenced by sunitinib 
treatment in sequential treatment protocols.  
Material and Methods 
Cell lines and reagents 
The human Renal Carcinoma cell line SK-RC-52 was established from a mediastinal 
metastasis of a primary RCC [23]. The cell line was cultured in RPMI1640 (Gibco, Bleiswijk, 
The Netherlands) supplemented with 10% fetal bovine serum (Sigma, Zwijndrecht, The 
Netherlands) and 2 mM glutamine (Gibco). Human renal cell carcinoma xenograft model 
NU12 [24] was maintained by passing freshly excised tumor pieces (1-2 mm3) 
subcutaneously (s.c.) in mice. Both SK-RC-52 and NU12 express high levels of CAIX [25]. 
Conjugation and radiolabeling of Girentuximab 
The isolation, characteristics and the immunohistochemical reactivity of mouse mAb G250 
(mG250) have been described earlier [26]; mAb G250 has a high affinity for CAIX (Ka = 4 x 
109 M-1) which is expressed on the cell surface of >95% of ccRCC and absent on most 
normal tissues. The generation of Girentuximab has been described elsewhere [27].  
The conjugation of Girentuximab (generously provided by Wilex AG, München, Germany) 
to ITC-DTPA has been described earlier [28]. The Girentuximab-ITC-DTPA conjugate (1 
mg/ml) was radiolabeled with 111InCl3 (Mallinckrodt, The Netherlands) as described 
previously [28]. 
After PD10 purification the radiochemical purity of the 111In-Girentuximab preparations 
was determined using ITLC silica gel strips (Biodex, Shirley, NJ) and 0.1 M citrate buffer pH 
6.0 as the mobile phase. The radiochemical purity was 97 ± 3 %. The immunoreactive 
fraction (IRF), determined on freshly trypsinized SK-RC-52 RCC cells at infinite antigen 
excess essentially as described by Lindmo et al. [29] with minor modifications [27], was 87 ± 
7%. 
Animal experiments 
Institutional guidelines were strictly followed for maintenance of animals and experimental 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC). 
Female BALB/c nu/nu mice, 6-8 weeks of age, were obtained from Janvier, France, and 
maintained at the local central animal facility. Animals were either grafted s.c. with freshly 
excised NU12 RCC xenograft pieces [24] of approximately 1-2 mm3 or injected s.c. with 
2*106 freshly trypsinized SK-RC-52 cells. Treatment with sunitinib (SU11248, Sutent®, Pfizer, 
NY) was started when tumors had reached a tumor volume of 100-200 mm3. 
Sunitinib was dissolved in 0.1 M Na-citrate, pH 4.5 and freshly prepared every week. 
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Mice received the equivalent of 40-50 mg/kg (0.8-1 mg/200 µl) sunitinib or vehicle orally 
per day for 7-14 days. 
 
Biodistribution studies and SPECT/CT analysis 
Once tumors reached the desired volume, mice were divided into groups of 4-5 mice (in 
one experiment 8-9 mice). Mice were treated with sunitinib or vehicle control every day for 7-
14 days. Mice were injected intravenously with 111In-Girentuximab (0.4 MBq, 5 µg) 3 days 
pre-sunitinib or 3 days post-sunitinib treatment. Mice were euthanized 3, 7, 10, 14 or 17 days 
post Girentuximab injection. Alternatively, mice were injected intravenously with 111In-
Girentuximab (0.4 MBq, 5 µg) 3, 7 or 10 days post-sunitinib treatment. Mice were euthanized 
3 days post-injection. Animals were dissected, tissues harvested (tumor, blood, muscle, liver, 
spleen, kidney, stomach, lung, colon, small intestine), weighed and counted in a gamma 
counter (Wizard; Pharmacia-LKB, Perkin-Elmer, Boston, MA). The activity in the samples 
was expressed as % injected dose per gram tissue (%ID/g). 
SPECT/CT analysis was performed to visualize the biodistribution and the intra-tumoral 
distribution of the radiolabeled antibody; sixteen mice bearing SK-RC-52  were injected with 
111In-Girentuximab with a specific activity of 22,5 MBq/5 μg, 3 days before start or 3 days 
after stop of treatment with sunitinib  or vehicle for 7 days. SPECT/CT analysis (USPECT-
II/CT scanner (MILabs, Utrecht, The Netherlands) was performed 3, 7 or 14 days after 
injection of the radiolabeled antibody with a 1.0-mm-diameter pinhole rat collimator tube. The 
animals were placed in the scanner in supine position. SPECT scans were acquired for 30-
120 min, followed by CT scans for anatomic reference (65 kV; 612 μA; exposure time, 240 
ms). 3, 7 or 14 days after injection of the radiolabeled antibody. 
 
 
Antibodies and immunohistochemical analysis 
Harvested tumors were snap-frozen and stored at -80°C. 4-µm cryostat sections were cut 
and stored at -80°C until use. Haematoxylin-Eosin staining was performed for morphological 
analysis of the tumors. 
Primary antibodies used were: Girentuximab (Wilex, Germany, 10 µg/ml), rat-anti-mouse 
mAb 9F1, hybridoma supernatant 1:50 [30] , and rabbit-anti-human mAb Ki67 (clone 
sp6/RM-9106-S, Thermo Scientific, Astmoor Runcorn, UK, 1:200). All antibodies were diluted 
in 1% BSA in 50 mM phosphate buffered saline, pH 7.4, unless mentioned otherwise. 
For visualization of CAIX expression, sections were acetone fixed and incubated with 
Girentuximab, washed and incubated with peroxidase (PO) conjugated rabbit-anti-human 
IgG (P214, Dako, Heverlee, Belgium), 1:100 as secondary antibody. To detect in vivo 
accumulated injected Girentuximab, cryostat sections were incubated with rabbit-anti-human 
IgG–PO only. Antibody 9F1 was used to detect mouse endothelial cells. After acetone 
fixation, primary antibody 9F1 was applied for 1 h at RT. After washing, secondary antibody 
goat-anti-rat-PO (Sigma) 1:100, supplemented with 4% normal mouse serum, was applied. 
All sections were developed with powerDAB (Immunologic, Duiven, The Netherlands) and 
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counterstained with haematoxylin. Microscopic evaluation was performed on an Axioskop 
microscope (Zeiss, Sliedrecht, The Netherlands) and pictures were taken with the Axiocam 
mrc5 (Zeiss) with Axio vs40 version 4.8 2.0 software (Axiovision, Zeiss). 
Triple immunofluorescence was performed to visualize cell proliferation and endothelial 
cells simultaneously. After acetone fixation, cells were pretreated for 30 min with  1% 
BSA/0.2 %Triton X100 in PBS. Subsequently sections were incubated overnight at 4°C with 
an antibody cocktail consisting of Ki67 and 9F1 diluted in 1% BSA/0.2 %Triton X100 in PBS. 
After washing, sections were incubated with the secondary antibody cocktail consisting of 
goat-anti-rabbit Alexa 568, 1:200 and goat-anti-rat Alexa  488, 1:200 (Molecular probes, Life 
technologies, Bleiswijk, The Netherlands). Finally, sections were incubated with DRAQ5 
(Biostatus DR50051, Leicestershire, UK, 1:200) to visualize nuclei. Microscopic evaluation of 
triple immunofluorescence was performed on a high content microscope (Leica, Rijswijk, The 
Netherlands, DMI6000B inverted microscope extended with a motorized x-y scanning stage, 
Leica EL6000 illumination source), equipped with a high-resolution Leica DFC360 FX CCD 
camera. 
Microvessel density measurements 
Density of microvascular profiles was assessed automatically as described previously [31] 
using an AxioCam MRc  connected to an AxioPhot microscope (Zeiss). Images were 
acquired using a 20x objective (Plan Apochromat, NA=0.32), resulting in a specimen level 
pixel size of 0.53 µm. Microvessel density (MVD) was defined as the percentage of 
microvessel area/total tumor area. All image acquisition and processing was performed using 
custom written macros in KS400 image analysis software (Zeiss). 
RT-PCR 
VEGF-A/RT-PCR was performed on NU12 and SK-RC-52 cells as well as on harvested 
xenografts of both sunitinib-treated as control animals. Total RNA was isolated from frozen 
tumor sections or cultured cells using TRIzol Reagent (Life Technologies), according to the 
manufacturer's protocol. RNA integrity was checked by 1.0% agarose gel electrophoresis. 
RNA samples (2 μg) were DNAse treated (Invitrogen, Life Technologies) and reverse-
transcription was performed at 42°C for 60 min, using SuperScriptTM II (Invitrogen). Two μl of 
the reaction product was subjected to standard PCR amplification using Super Taq 
polymerase (Sphaero, Gorinchem, The Netherlands)  and VEGF-A-primers 5′-GCA CCC 
ATG GCA GAA GGA GGA-3′ (sense) and 5′-TCA CCG CCT CGG CTT GTC AC-3′ (exon 8 
specific, antisense). Reaction mixture was heated 1 min at 94°C followed by 30 cycli for 30 s 
at 94 °C, 1 min at 61 °C, 1 min at 72 °C and 10 minutes at 72 °C. 
This primer set amplifies all VEGF-A isoforms simultaneously, except VEGF165b. 
Expected product lengths with this primer set are 367 bp (VEGF-121), 436 bp (VEGF-145), 
496 bp (VEGF165) and 568 bp (VEGF189). cDNAs were also subjected to a PCR for 
GAPDH as control housekeeping gene. VEGF165b was analyzed in a separate RT-reaction 
with forward primer as mentioned above and a reverse primer recognizing an alternative 
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exon in VEGF: 5’-TCA GTC TTT CCT GGT GAG AGA TCT GCA-3’. 
Statistical analysis 
Results are presented as means with standard deviations (SD). For the statistical 
analysis, all sunitinib treated animals were clustered together to increase the number of 
animals. This was also done with the control animals. Differences in Girentuximab uptake 
and MVD between treatment and control mice at each time-point were tested for statistical 
significance using the two-way ANOVA with factors treatment, time and interaction. When 
interaction was not significant it was removed from the model and two-way ANOVA without 
interaction was applied. p < 0.05 was considered significant. 
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Results 
 
Decreased uptake of 111In-Girentuximab and decreased micro vessel density when 
mice with NU12 tumors were treated with sunitinib 
Treatment of NU12 tumors with sunitinib caused substantial decrease of tumor growth (p 
< 0.05; figure S1). In SK-RC-52, sunitinib treatment resulted in stabilization of tumor growth 
(p=0.056; figure S2). To study the influence of sunitinib treatment on the tumor uptake of 
Girentuximab, biodistribution studies were performed using 111In-Girentuximab in BALB/c 
athymic mice xenografted with NU12 or SK-RC-52 (Fig. 1 and supplementary table S1-5). In  
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Figure 1. Biodistribution of cG250 in nude mice with NU12 and SK-RC-52 tumors. 111In-
Girentuximab biodistribution in BALB/c nu/nu mice shows decreased uptake with sunitinib in NU12 
tumors and increased pt ke with sunitinib in SK-RC-52 tumors. Treatment schedules shown on 
top of graphs. Groups of 4-5 mice (in F: 8-9 mice) were treated with sunitinib every day for 1 week 
(A,D,F) or until they were euthanized (B,E). Three days before start or 3d (in one experiment also 
7d or 10d) after stop of treatment, mice were injected  with 111In-Girentuximab (0.4 MBq, 5 µg) and 
mice were euthanized at various timepoints. The activity in the samples was expressed as % 
injected dose per gram tissue (% ID/g). A: Biodistribution of NU12 mice with sunitinib treatment 
preceding 111In-Girentuximab injection, B: Biodistribution of NU12 mice injected with 111In-
Girentuximab before sunitinib treatment, C: G250 antibody uptake was plotted for individual tumors 
from experiment. A Red open circles: control tumors; black closed circles: sunitinib treated tumors   
A, D: Biodistribution of SK-RC-52 mice treated with sunitinib preceding 111In-Girentuximab 
injection, E: Biodistribution of SK-RC-52 mice treated with  sunitinib followed by 111In-Girentuximab, 
F: Biodistribution of SK-RC-52 mice with 111In-Girentuximab injection 3 days, 7 days or 10 days 
after cessation of sunitinib, G: G250 antibody uptake was plotted for individual tumors from 
experiment F. * p < 0.05, ** p < 0.01 , *** p < 0.005. P-values shown for the biodistribution are 
based on all sunitinib treated animals (N= 15, 9, 28, 18, 25 for fig 1A, B, D, E and F respectively) 
compared to all control animals (N=13, 16, 30, 18, 27 for fig 1A, B, D, E and F respectively). 
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Figure 2. Phenotypic analysis of NU12 and SK-RC-52 tumors. Phenotypic analysis of NU12 and 
SK-RC-52 tumors of mice treated with sunitinib shows necrosis, decreased accumulated cG250 
and decreased number of microvessels in NU12 tumors and very limited necrosis, increased 
accumulated cG250 and unchanged number of microvessels in SK-RC-52 tumors. A-D, NU12 
control tumors; E-H, NU12 sunitinib treated tumors; I-L, SK-RC-52 control tumors; M-P, SK-RC-52 
sunitinib treated tumors. HE staining in A, E, I and M. Sunitinib treatment did not modify CAIX 
expression in either NU12 or SK-RC-52 (B,F and J,N). In NU12 control tumors (A-D), 
homogeneous accumulation of cG250 (C) was observed. D: tumor vasculature visualized by 
staining with 9F1. In sunitinib treated NU12 tumors (E-H), extensive necrosis was present as 
judged by HE (E) and accumulated cG250 (G) and microvessels (H) were only observed in the 
tumor rim. SK-RC-52  control tumors (I-L), revealed focal accumulation of injected cG250 (J) and 
moderate microvessel density (MVD) as visualized by staining with 9F1 (L). Accumulation of 
cG250 was increased in sunitinib treated SK-RC-52 tumors (O vs. K) and MVD appeared to be 
increased (P vs. L). Necrosis was limited regardless of treatment (I, M). N: necrosis. Original 
magnification X25 and X200. 
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the NU12 model, tumor uptake of 111In-Girentuximab decreased when sunitinib treatment 
preceded the antibody injection (Fig. 1A; p < 0.005 and supplementary table S1). Because 
previous experiments have shown that Girentuximab uptake inversely correlates with tumor 
volume [32], and sunitinib stabilizes tumor growth, Girentuximab uptake was plotted for 
individual tumors. This analysis demonstrated that at similar tumor volumes antibody uptake 
in the tumors of sunitinib-treated mice was lower than that in the control mice, most notably 
at day 10 (Fig. 1C). 
Sunitinib treatment following 111In-Girentuximab injection did not influence antibody uptake 
in the NU12 model (Fig. 1B, p=0.7959 and supplementary table S2, Fig. S3). Tumors were 
analyzed by immunohistochemistry (IHC) for the presence of vasculature, CAIX expression 
and intratumoral distribution of Girentuximab (Fig. 2, 3). Extensive necrosis was observed in 
the majority of sunitinib treated NU12 tumors, as judged by HE staining (Fig. 2E). Necrosis 
was minimal in untreated tumors (Fig. 2A). CAIX, the Girentuximab target, was expressed in 
all viable NU12 tumor cells, regardless of sunitinib treatment (Fig. 2B, F). Interestingly, CAIX 
could still be detected in necrotic tumor areas. In accordance with earlier studies, 
homogeneous accumulation of Girentuximab was observed in non-treated NU12 tumors (Fig. 
2C). NU12 tumors harvested from non-treated animals were well vascularized (Fig. 2D). In 
contrast, NU12 tumors of sunitinib-treated mice displayed extensive central necrosis and 
Girentuximab accumulation was limited to the rim of the tumors (Fig. 2G). Quantitative 
microscopic analysis confirmed that the viable tumor area was markedly reduced in tumors 
from sunitinib-treated animals. Microvessel density in the centre of these tumors was very 
low as compared to control tumors (Fig. 3A, p < 0.001), whereas in the viable tumor rim a 
rebound effect was seen (Fig. 2H). Triple immunofluorescence staining for cell proliferation, 
endothelial cells and nuclei revealed low proliferation index of NU12 tumor cells, both in 
control as well as in tumors of sunitinib-treated mice (Fig. 3C and D respectively). 
Increased uptake of 111In-Girentuximab and unchanged micro vessel density when 
mice with SK-RC-52 tumors were treated with sunitinib 
Sunitinib treatment of mice bearing SK-RC-52 tumors affected Girentuximab accumulation 
regardless of the sequence: Antibody uptake in the tumors of the sunitinib-treated animals 
was higher than in untreated animals (Fig. 1D, 1E, p = 0.0059 and p = 0.026 respectively, 
supplementary tables S3, S4). Plotting of antibody accumulation against the tumor volume 
demonstrated that at similar tumor volumes Girentuximab uptake in tumors of sunitinib-
treated mice was higher than or at least equal to tumor uptake in control mice (Fig. 1G). To 
establish whether extension of the time interval between sunitinib treatment and antibody 
injection would improve Girentuximab tumor accumulation, mice were injected with 
Girentuximab 3, 7 and 10 days post-sunitinib, and were euthanized 3 days later (6, 10 and 
13 days, respectively). In all cases Girentuximab accumulation in the SK-RC-52 tumor was 
higher in sunitinib-treated animals (Fig. 1F, p = 0.0114, supplementary table S5). Extension 
of the time interval beyond 3 days did not further improve antibody accumulation.  
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Occasionally necrosis was observed in SK-RC-52 tumors in untreated and in sunitinib 
treated animals (Fig. 2I, M). Immunohistochemical analysis of SK-RC-52 tumors revealed 
Figure 3. Microvessel density analysis. Density of microvascular profiles was assessed 
automatically as described previously [31] using an AxioCam MRc connected to an AxioPhot 
microscope (Zeiss). Microvessel density (MVD) was defined as the percentage of microvessel 
area/total tumor area. All image acquisition and processing was performed using custom written 
macros in KS400 image analysis software (Zeiss). Sunitinib treatment resulted in significant 
decrease in % of microvessels in NU12 tumors (A) but no change in % of microvessels in SK-RC-
52 tumors (B). Triple immunofluorescence staining of NU12 control (C) and sunitinib treated tumor 
(D) and SK-RC-52 control (E) and sunitinib treated tumor (F). Low proliferation of NU12 tumor cells 
(nuclei in blue as visualized by DRAQ5) as visualized by Ki67 staining (red) is observed, both in 
controls (C) as well as in sunitinib treated tumors (D). Please note decrease of endothelium (9F1 
staining) in sunitinib treated NU12 tumor (green). In SK-RC-52, triple immunofluorescence staining 
revealed high proliferation of SK-RC-52 tumor cells, both in controls (E) as well as in sunitinib 
treated tumors (F). Necrosis was minimal. **** p < 0.001. 
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homogeneous CAIX expression regardless of sunitinib treatment (Fig. 2J, N). Control tumors 
showed focal elevated accumulation of Girentuximab (Fig. 2K) and moderate MVD, as 
visualized by staining with 9F1 (Fig. 2L). Accumulation of Girentuximab was higher in 
sunitinib-treated SK-RC-52  tumors (Fig. 2O) but MVD was comparable to that in control 
tumors (Fig. 2P, 3F). Triple immunofluorescence staining revealed high proliferation index of 
SK-RC-52 tumor cells, both in controls as well as in sunitinib-treated tumors (Fig. 3E and F 
respectively).  
In previous studies we have shown that Girentuximab is internalized relatively rapidly by 
SK-RC-52 cells [33] precluding detection of Girentuximab beyond day 3 by 
immunohistochemistry. To investigate the distribution of the radiolabeled antibody in the 
animals, SPECT/CT analysis was performed. In agreement with the biodistribution results, 
more radiolabel was observed in the sunitinib treated SK-RC-52 than in control tumors (Fig. 
4A). The localization of the radiolabeled antibody was not restricted to a specific 
compartment in the tumor, but rather distributed homogenously throughout the tumor. No 
differences between the various treatment groups were observed (Fig. 4B).  
Figure 4. SPECT/CT imaging of mice with SK-RC-52 tumors. SPECT/CT analysis was performed to 
visualize the biodistribution and the intra-tumoral distribution of the radiolabeled antibody. Sixteen 
mice bearing SK-RC-52 were treated with sunitinib for 7 days and injected with 111In-Girentuximab with
a specific activity of 22,5 MBq/5 μg, 3 days before start or 3 days after stop of treatment. Micro-
SPECT images of mouse bearing SK-RC-52 tumor on right flank (arrow) at 7 d after injection of 111In-
girentuximab show that in addition to tumor uptake, minimal uptake in other organs was observed. 
More radiolabel was observed in the sunitinib treated tumors than in vehicle (A).This is in concordance 
with the biodistribution data. In all groups radiolabel was distributed throughout the tumor and no 
difference in radiolabel distribution was observed in the various treatment groups (B). 
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VEGF expression of NU12 and SK-RC-52 tumors 
In view of the observed differences between the two RCC xenograft models, we 
investigated VEGF-A expression as different VEGF-A expression levels might explain the 
observed differences. Non-quantitative RT-PCR did not show differences in VEGF-A 
expression in both tumor models, regardless of sunitinib treatment (Fig. 5). 
Discussion 
Sunitinib treatment can result in significant tumor control in approximately 40% of patients 
with mRCC [34]. This is a major improvement in the clinical management of these patients as 
overall survival (OS) of responding patients is significantly improved [34]. However, the 
prognosis of non-responding patients remains poor with a mean OS of 14.5 months [34]. 
Therapy with other TKI, mTOR inhibitors and Bevacizumab + Interferon show similar results 
[35]. Unfortunately, TKI combination therapies are not feasible due to unacceptable toxicity 
and therefore current efforts are aimed at sequential therapy regimens and/or the 
combination of surgery and TKI treatment [11]. Moreover, therapy resistance occurs almost 
inevitably in all patients, highlighting the need for other therapies. Combination therapy 
aiming at different tumor components such as tumor vasculature and the tumor cells might 
improve therapy outcome. 
Figure 5. Expression of VEGF-A isoforms in NU12 and SK-RC-52 tumors. VEGF-A/RT-PCR  was 
performed on NU12 and SK-RC-52 cells as well as on harvested xenografts of both sunitinib-
treated (from 2 days up to 7 days) as untreated animals. After correction for loading differences (as 
judged by GAPDH), no differences in VEGF-A expression were observed between tumor models, 
regardless of sunitinib treatment. 
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CAIX has been recognized as a potential useful target for ccRCC [36]. Diagnostic images 
with Girentuximab, an antibody which targets CAIX, were superior to CT [37], and 
radioimunotherapy with 177Lu-labeled Girentuximab resulted in disease stabilization [20]. The 
failure to significantly influence disease progression and lack of partial/ complete responses 
might be due to the tumor bulk present. Additionally, central regions of larger tumor masses 
might be less accessible for Girentuximab, as central regions are poorly perfused. 
Unfortunately adjuvant treatment of nephrectomized RCC patients with unlabeled 
Girentuximab who have a high risk of relapse (ARISER trial) did not meet its primary 
endpoint: improvement in median DFS. However, with increasing CAIX expression in tumor 
tissue, as quantified by a CAIX score, the treatment was more effective [38]. Possibly only 
high density CAIX RCC cells can be killed by antibody-dependent cellular cytotoxicity in this 
adjuvant setting. 
The combination of Girentuximab, aimed at tumor cells and sunitinib, aimed at the tumor 
vasculature, might therefore lead to superior therapy outcome. However, simultaneous 
administration of sunitinib and Girentuximab severely compromised mAb accumulation [21]. 
Since the anti-tumor effect of Girentuximab depends on tumor cell accessibility from the 
vascular compartment, we studied the effect of sunitinib on the biodistribution of 
Girentuximab when administered with a short time delay between sunitinib and antibody 
administration. This short drug holiday mimics TKI treatment cycles in men and might allow 
re-establishment of the tumor vasculature, which would permit adequate mAb delivery and 
accumulation.  
In the NU12 model, sunitinib treatment followed by a 3-day drug holiday resulted in a 
reduction in antibody uptake in the tumor. Microscopic analysis showed that the amount of 
viable tumor cells was considerably lower in sunitinib-treated tumors, apparently due to 
massive destruction of tumor microvessels. This decrease in antibody uptake was less 
pronounced than when the antibody was administered at the same time as the sunitinib 
treatment [21]. Thus, a time delay between sunitinib treatment and antibody administration 
did increase Girentuximab uptake, albeit that accumulation did not reach the level of 
untreated controls. The reduced antibody uptake is probably due to the accessibility of fewer 
viable  cells in the NU12 tumors in sunitinib-treated animals, while tumor volume was not 
affected. Despite the presence of CAIX in necrotic areas after sunitinib treatment, 
Girentuximab did not accumulate in those areas, showing that the vasculature in the necrotic 
regions was not restored. The results suggest that despite the lower Girentuximab uptake in 
the tumor, all viable tumor cells present at the tumor periphery are targeted. Antibody uptake 
was not affected when administered before sunitinib treatment. This is not unexpected 
because the pharmacokinetics of the mAb in sunitinib treated animals were not affected: 
maximum and homogeneous accumulation can be established before treatment with 
sunitinib is initiated. This suggests that sunitinib after Girentuximab administration might be 
preferred over sunitinib before Girentuximab injection. However, in this scenario almost all 
tumor cells are viable and the amount of targeted Girentuximab molecules per viable tumor 
cell is substantially lower. This will amount to higher radiation levels per tumor cell with 
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Girentuximab-guided radioimmunotherapy. Thus, viable tumor cells remaining at the tumor 
rim after anti-angiogenic therapy can be efficiently targeted and potentially lethally damaged 
when Girentuximab radioimmunotherapy is applied.  
Unexpectedly, antibody uptake in the SK-RC-52 tumors increased in the sunitinib treated 
animals, regardless of sequence of the treatment. In contrast to NU12, tumor cell viability 
was not affected by sunitinib treatment. The increased uptake in combination with 
unchanged MVD after sunitinib treatment suggests functional changes in the 
microvasculature in this tumor. The increased uptake was not only the consequence of the 
smaller tumor volume, as tumors with comparable volumes of sunitinib-treated animals 
showed equal or higher tumor uptake of Girentuximab. Whether the increased uptake is the 
consequence of tumor vessel normalization (and reduced interstitial fluid pressure) as 
suggested in previous studies [39,40] or the consequence of increased vascular permeability 
is unclear. 
Also in this model sunitinib treatment before antibody injection appears preferable when 
combination therapy is considered: Girentuximab uptake post-sunitinib is significantly higher 
than Girentuximab uptake pre-sunitinib. 
The two RCC models used in the present studies might be very valuable in studying 
resistance to TKI, a phenomenon occurring in most mRCC patients as they appear to reflect 
the extremes that can be observed in patients: some patients respond favorably, whereas 
other patients do not respond. Also, in some mRCC patients unexpected rapid progression 
and tumor related complaints after discontinuation of oral angiogenesis inhibitors can be 
observed [41]. This might be explained by an increase of vascular density, tumor blood flow 
rate and vascular permeability. In NU12 tumors a substantial part of the tumor endothelium is 
destroyed after sunitinib treatment, representative of a highly sensitive tumor, and cessation 
of therapy led to a rapid neovascularization, reminiscent of a tumor flare. SK-RC-52 appears 
to represent a sunitinib-resistant tumor, with little impact of sunitinib treatment on the 
microvessel density, but with physiological changes of blood vessels, in concordance with 
the hypothesis put forward by Jain et al. [12].  
The disparity to sunitinib treatment between these models is striking. Because the 
vasculature of the two xenograft models has the same murine origin, this implies that the 
differences might be due to different angiogenic gene expression profiles in the tumors. Non-
quantitative RT-PCR did not demonstrate any difference in VEGF-A expression levels 
between sunitinib-treated and non-treated NU12 cells and SK-RC-52 cells nor between 
NU12 xenografts and SK-RC-52 xenografts. Also gene expression profiles of SK-RC-52 and 
NU12 determined with the RT2 Profiler™ PCR Array Human Angiogenesis (PAHS-24Z, 
Qiagen) did not show differences in VEGF-A expression ( Ct 22.0 and 20.4,  respectively). In 
this assay 5 genes involved in angiogenesis were differentially expressed between NU12 
and SK-RC-52. VEGF-C levels were ~100-fold lower in NU12 cells compared to SK-RC-52. 
VEGF-C is one of the main growth factors implicated in lymphangiogenesis, signals through 
VEGFR-3 and plays a secondary role in angiogenesis. Expression levels of placental growth 
factor (PGF), a homolog to vascular endothelial growth factor and PTGS1 (prostaglandin-
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endoperoxidase synthetase 1) were higher in NU12. PGF can function as decoy receptor for 
VEGF which may explain the observed sunitinib sensitivity of NU12. EFNA1 and PLAU were 
over-expressed in the non-responder cell line SK-RC-52. EFNA1 is a member of the ephrin 
(EPH) family, comprising the largest subfamily of receptor protein-tyrosine kinases. High 
EFNA1 levels may aid cells in resisting TKI challenge. Moreover, high plasminogen activator 
urokinase (PLAU) levels support fractional survival of cancer cells [42]. Also, expression 
levels of PGF and PTGS1 were lower in SK-RC-52 as in NU12. Collectively, the high 
expression of EFNA1 and PLAU together with low expression of PGF and PTGS1 may 
explain the resistance of SK-RC-52 in comparison to NU12.  
Anti-angiogenic therapies can reduce tumor perfusion and uptake of chemotherapeutics: 
bevacizumab treatment of patients with non-small cell lung cancer showed rapid and 
significant reduction of tumor perfusion and docetaxel uptake [43]. Moreover, preclinical 
(ovarian and esophageal cancer) and clinical studies (RCC) with bevacizumab [44] and 
sorafenib [45] demonstrated that antibody-uptake in the tumor is hampered when 
administered immediately after cessation of anti-angiogenic therapy. The investigators 
emphasize that administration schedules should be carefully designed to optimize 
combination treatment of anti-angiogenic therapy with other treatment modalities. Our results 
show that TKI and mAbs can be combined, provided a short drug holiday is introduced, 
regardless of TKI sensitivity: for TKI sensitive tumors TKI treatment leads to central necrosis 
and Girentuximab can then effectively target the remaining viable RCC cells in the tumor, 
whereas in TKI-resistant tumors Girentuximab tumor accumulation is increased, leading to 
higher antibody levels and correspondingly higher radiation dose in the tumor. Because TKI 
and Girentuximab are directed against different target cells, and the toxicity profile differs, 
combination of both drugs might prove beneficial. Stabilization of previously progressive 
mRCC appears possible with 177Lutetium-Girentuximab and combination with TKI might lead 
to better and durable responses. In view of our results, initial treatment with TKI followed by 
177Lutetium-Girentuximab may be better than the reverse: administration of Girentuximab to 
patients with TKI-sensitive tumors will lead to massive cell death and the remaining viable 
cells in the tumor periphery will be effectively targeted  by the radiolabeled antibody, whereas 
administration of Girentuximab to patients with TKI-insensitive tumors will lead to more 
effective 177Lutetium-Girentuximab accumulation, resulting in higher radiation doses.  
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Figure S2. Mean % of growth of SK-RC-52 tumors during treatment with sunitinib. Treatment with 
sunitinib was started when tumors had reached a tumor volume of 100-200 mm3 (day-10) and
continued until day -3. Three days later mice were injected with 111In-cG250. Percentage 
tumorgrowth was set at 100% at start of treatment with sunitinib.Tumorgrowth is stablized by 
sunitinib treatment (black line) in comparison to control (red line). 
Figure S1. Mean % of growth of NU12 tumors during treatment with sunitinib. Treatment with 
sunitinib was started when tumors had reached a tumor volume of 100-200 mm3 (day-10) and
continued until day -3. Three days later mice were injected with 111In-cG250. Percentage 
tumorgrowth was set at 100% at start of treatment with sunitinib. Tumorgrowth is strongly inhibited 
by sunitinib treatment (black line) in comparison to control (red line). 
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Figure S3. Phenotypic analysis of NU12 tumors. Phenotypic analysis of NU12 tumors of mice 
treated with sunitinib. Mice were injected intravenously with 111In-Girentuximab (0.4 MBq, 5 µg) 3
days pre-sunitinib treatment. Accumulation of Girentuximab remained unchanged when sunitinib 
followed Girentuximab injection. Tumors shown were harvested at day 7 (4 days after start of 
sunitinib treatment). A, C: HE staining of untreated and sunitinib treated tumor respectively; B, D: 
Girentuximab accumulation. Original magnification X25 and X200. 
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Table S1 Biodistribution of Girentuximab in nude mice with NU12 tumors treated with sunitinib 
3 * 7 10 3 7 10 
blood 9,7 ± 3,2 3,7 ± 2,7 3,2 ± 1,5 13,0  ± 3,3 6,6 ± 1,7 3,6  ± 0,4 
muscle 1,0 ± 0,2 0,4 ± 0,3 0,4 ± 0,1 1,2  ± 0,4 0,7 ± 0,2 0,3  ± 0,1 
tumor 89,8 ± 29,1 99,5 ± 51,9 134,5 ± 55,6 59,9  ± 38,8 68,8 ± 30,2 40,5  ± 22,0 
liver 9,2  ± 3,2 7,8 ± 3,7 3,9 ± 0,7 7,2  ± 1,3 5,5 ± 0,3 2,2  ± 0,7 
spleen 5,7  ± 4,0 3,6 ± 0,9 2,0 ± 0,4 3,9  ± 0,5 3,4 ± 0,5 1,7  ± 0,4 
kidney 4,9  ± 1,0 3,8 ± 1,0 1,8 ± 0,5 5,6  ± 0,6 3,3 ± 0,3 1,4  ± 0,1 
stomach 1,4  ± 0,5 0,8 ± 0,3 0,6 ± 0,1 1,6  ± 0,6 1,2 ± 0,4 0,6  ± 0,1 
lung 6,7  ± 2,3 2,4 ± 1,8 2,9 ± 1,2 7,2  ± 1,5 4,6 ± 1,4 2,2  ± 0,3 
small intestine 1,6  ± 0,6 0,6 ± 0,3 0,5 ± 0,2 2,1  ± 0,4 0,9 ± 0,2 0,4  ± 0,1 
Biodistribution data supplementing  figure 1A 
* time post injection of  111  In-girentuximab in days
#  % ID/g: mean percentage injected dose per gram tissue ± standard deviation 
% ID/g  #
control sunitinib 
Table S2 Biodistribution of Girentuximab in nude mice with NU12 tumors treated with sunitinib 
3 * 7 14 7 14 
blood 9,4 ± 1,7 3,5 ± 0,8 1,0 ± 0,7 5,3 ± 1,4 2,2  ± 1,2 
muscle 1,0 ± 0,3 0,4 ± 0,1 0,1 ± 0,1 0,6 ± 0,2 0,2  ± 0,1 
tumor 113,8 ± 13,7 96,4 ± 41,2 61,2 ± 30,6 90,6 ± 9,6 61,5  ± 19,5 
liver 3,7  ± 0,8 5,5 ± 3,1 1,7 ± 0,3 4,3 ± 1,7 2,7  ± 0,6 
spleen 3,6  ± 0,6 2,8 ± 1,8 1,3 ± 0,4 3,2 ± 0,7 1,1  ± 0,4 
kidney 4,3  ± 0,8 2,9 ± 0,7 1,1 ± 0,3 2,7 ± 0,3 2,4  ± 0,7 
stomach 1,4  ± 0,4 0,7 ± 0,2 0,3 ± 0,1 0,9 ± 0,2 0,4  ± 0,2 
lung 4,7  ± 1,9 2,9 ± 1,2 1,0 ± 0,5 3,4 ± 0,8 1,6  ± 0,9 
small intestine 1,3  ± 0,3 0,7 ± 0,2 0,2 ± 0,1 1,1 ± 0,3 0,5  ± 0,2 
colon 1,0  ± 0,3 0,5 ± 0,1 0,2 ± 0,1 0,7  ± 0,5 0,3  ± 0,1 
Biodistribution data supplementing  figure 1B. 
* time post injection of 111  In-girentuximab in days
#  % ID/g: percentage injected dose per gram tissue ± standard deviation 
% ID/g 
#
control sunitinib 
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Table S3 Biodistribution of Girentuximab in nude mice with SK-RC-52 tumors treated with sunitinib 
3 * 7 10 14 17 3 7 10 14 17
blood 7,6 ± 4,4 2,1 ± 1,9 0,1 ± 0,03 0,05 ± 0,02 0,03 ± 0,01 7,9  ± 1,5 2,7 ± 2,1 1,0 ± 0,6 0,4 ± 0,5 0,06 ± 0,04
muscle 0,9 ± 0,4 0,3 ± 0,1 0,1 ± 0,02 0,04 ± 0,03 0,04 ± 0,05 1,0  ± 0,3 0,3 ± 0,2 0,2 ± 0,2 0,1 ± 0,05 0,07 ± 0,04
tumor 51,0 ± 9,7 47,3 ± 17,2 11,64 ± 3,6 5,5 ± 1,8 3,4 ± 1,5 65,3  ± 9,0 44,8 ± 18,7 42,8 ± 23,3 11,61 ± 5,82 7,0 ± 6,6
liver 13,5  ± 4,5 12,4 ± 3,7 8,6 ± 2,7 4,8 ± 0,9 3,9 ± 0,1 10,1  ± 2,4 9,2 ± 1,8 7,0 ± 1,4 2,8 ± 0,9 3,6 ± 1,8
spleen 5,1  ± 1,3 4,8 ± 1,7 3,2 ± 1,0 2,4 ± 0,7 1,8 ± 0,5 3,5  ± 0,3 3,2 ± 1,2 3,2 ± 2,2 1,6 ± 0,5 1,9 ± 1,4
kidney 3,6  ± 1,3 1,9 ± 0,4 0,8 ± 0,1 0,7 ± 0,03 0,6 ± 0,1 3,7  ± 0,2 2,1 ± 0,4 1,4 ± 0,3 0,6 ± 0,02 0,6 ± 0,2
stomach 1,0  ± 0,4 0,4 ± 1,4 0,1 ± 0,03 0,1 ± 0,05 0,1 ± 0,03 1,1  ± 0,2 0,5 ± 0,2 0,3 ± 0,2 0,2 ± 0,1 0,1 ± 0,1
lung 4,5  ± 2,0 1,8 ± 0,4 0,3 ± 0,1 0,2 ± 0,01 0,1 ± 0,1 4,8  ± 1,1 2,0 ± 1,1 0,9 ± 0,47 0,4 ± 0,3 0,3 ± 0,3
1,6  ± 0,5 0,6 ± 0,2 0,1 ± 0,02 0,1 ± 0,04 0,04 ± 0,01 1,4  ± 0,2 0,5 ± 0,3 0,3 ± 0,1 0,1 ± 0,1 0,08 ± 0,1
colon 0,8  ± 0,4 0,3 ± 0,3 0,1 ± 0,01 0,1 ± 0,01 0,04 ± 0,01 0,9  ± 0,1 0,4 ± 0,2 0,2 ± 0,1 0,1 ± 0,1 0,07 ± 0,05
Biodistribution data supplementing  figure 1D. 
*  time post injection of 111  In-girentuximab in days 
# % ID/g: percentage injected dose per gram tissue ± standard deviation 
control sunitinib
 % ID/g  # 
3 * 7 10 14 17 7 10 14 17
blood 12,0 ± 1,0 3,8 ± 2,2 1,7 ± 2,1 0,6 ± 1,5 0,2 ± 0,3 6,1 ± 1,2 3,1  ± 2,4 3,1  ± 1,7 1,6  ± 1,6
muscle 1,2 ± 0,1 0,4 ± 0,2 0,2 ± 0,2 0,1 ± 0,1 0,1 ± 0,01 0,6 ± 0,1 0,5  ± 0,2 0,3  ± 0,2 0,2  ± 0,1
tumor 93,1 ± 28,6 80,0 ± 29,2 42,4 ± 36,4 24,9 ± 55,6 23,4 ± 34,2 86,3 ± 36,0 47,4  ± 30,2 66,2  ± 33,0 53,7  ± 49,9
liver 8,1  ± 2,6 10,1 ± 4,8 7,9 ± 2,1 5,2 ± 0,7 4,9 ± 0,7 6,5 ± 2,1 6,5  ± 2,6 3,9  ± 1,0 4,1  ± 1,4
spleen 4,6  ± 0,3 3,5 ± 0,5 2,8 ± 0,6 2,6 ± 0,4 1,9 ± 0,9 3,8 ± 0,6 3,5  ± 0,8 3,4  ± 0,4 2,8  ± 0,7
kidney 4,5  ± 0,5 1,8 ± 0,5 1,3 ± 0,5 0,8 ± 0,5 0,6 ± 0,2 2,4 ± 0,4 1,6  ± 0,8 1,5  ± 0,4 0,9  ± 0,4
stomach 1,7  ± 0,2 0,7 ± 0,3 0,3 ± 0,3 0,2 ± 0,1 0,1 ± 0,1 1,0 ± 0,2 0,6  ± 0,4 0,6  ± 0,2 0,3  ± 0,2
lung 6,3  ± 0,6 2,8 ± 1,4 1,4 ± 1,4 0,6 ± 1,2 0,4 ± 0,3 4,0 ± 0,6 2,7  ± 2,0 2,5  ± 1,2 1,0  ± 0,9
small intestine 1,7  ± 0,3 0,6 ± 0,2 0,4 ± 0,3 0,2 ± 0,2 0,1 ± 0,1 1,2 ± 0,4 0,6  ± 0,4 0,7  ± 0,3 0,3  ± 0,2
colon 1,1  ± 0,2 0,4 ± 0,2 0,3 ± 0,2 0,1 ± 0,2 0,1 ± 0,01 0,6 ± 0,1 0,4  ± 0,2 0,3  ± 0,1 0,2  ± 0,1
Biodistribution data supplementing  figure 1E. 
*  time post injection of  111  In-girentuximab in days 
# % ID/g: percentage injected dose per gram tissue ± standard deviation 
control sunitinib
 % ID/g # 
Table S5 Biodistribution of Girentuximab in nude mice with SK-RC-52 tumors treated with sunitinib 
d3 d7 d10 d3 d7 d10 
blood 2,9 ± 3,1 4,3 ± 1,2 6,0 ± 2,6 7,4  ± 1,4 8,2 ± 1,4 8,2  ± 2,4 
muscle 0,5 ± 0,2 0,6 ± 0,1 0,7 ± 0,2 0,9  ± 0,2 0,9 ± 0,2 1,2  ± 0,1 
tumor 42,3 ± 11,9 47,0 ± 12,7 45,5 ± 13,7 62,6  ± 14,5 60 ± 11,4 55,8  ± 18,5 
liver 14,3  ± 2,2 13,3 ± 2,3 7,8 ± 3,2 7,4  ± 1,9 6,1 ± 1,9 8,3  ± 3,0 
spleen 5,4  ± 2,2 4 ± 0,6 3,4 ± 0,7 2,9  ± 0,6 2,9 ± 0,5 3,9  ± 0,3 
kidney 2,5  ± 0,4 2,7 ± 0,4 3,8 ± 0,7 3,3  ± 0,8 3,8 ± 0,4 5,0  ± 0,9 
stomach 0,7  ± 0,2 0,8 ± 0,2 1,3 ± 0,4 1,2  ± 0,2 1,6 ± 0,3 1,6  ± 0,2 
lung 2,4  ± 0,8 3,2 ± 0,7 4,0 ± 1,3 4,3  ± 0,9 5,2 ± 0,8 5,5  ± 1,6 
small intestine 0,7  ± 0,3 0,9 ± 0,4 1,2 ± 0,6 1,0  ± 0,2 1,6 ± 0,3 1,8  ± 0,4 
colon 0,4  ± 0,1 0,6 ± 0,1 1,0 ± 0,4 0,8 ± 0,1 0,9  ± 0,2 1,1  ± 0,2 
Biodistribution data supplementing  figure 1F. 
*  time post first injection of 111  In-girentuximab in days 
# % ID/g: percentage injected dose per gram tissue ± standard deviation 
control sunitinib 
% ID/g  #
small intestine 
Biodistribution of Girentuximab in nude mice with SK-RC-52 tumors treated with sunitinib Table S4 
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Abstract 
Purpose:  Implementation of sunitinib as treatment for patients with metastatic renal cell 
carcinoma (mRCC) has lead to impressive gains in efficacy. However, therapeutic progress 
has been primarily palliative in nature. Additionally, treatment can coincide with significant 
toxicity. Combination therapy with tyrosine kinase inhibitors (TKI) has not been successful 
due to increased toxicity. Treatment of progressive mRCC patients with 177Lu-cG250 
radioimmunotherapy (RIT) is well-tolerated and results in stabilization of disease in 74% of 
mRCC patients. The aim of this study was to enhance efficacy in mRCC by combining anti-
angiogenic with anti-tumor cell therapy.  
Experimental design: Nude mice with subcutaneous human RCC xenografts (NU12, SK-
RC-52) were treated with sunitinib and injected i.v. with low doses of 177Lu-cG250 for 1 or 2 
cycles. Tumor growth was monitored and immunohistochemical analyses were performed.  
Results: The best response in mice with SK-RC-52 tumors was observed with two 
combination treatment cycles. All animals survived the observation period with almost 
complete tumor ablation. Nevertheless, more treatment cycles are necessary to ablate 
tumors completely. In the NU12 model, 2 cycles of 177Lu-cG250-RIT and 2 cycles of 
combination treatment were equally effective (100% survival). The 177Lu-cG250-RIT was 
probably too effective, despite the low dose, obscuring improved survival of the combination 
treatment.  
Conclusions: Combination of anti-angiogenic and anti-tumor cell treatment was superior 
over either treatment alone for SK-RC-52 tumors. Our findings provide a promising new 
therapeutic strategy for patients with advanced RCC.  
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Introduction 
Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI), targeting VEGFR 
is standard treatment for patients with metastatic renal cell carcinoma (mRCC) [1-4]. 
Implementation of TKI with the tumor vascular bed as the primary target, has improved 
objective response rates (ORR) and median progression free survival (PFS) substantially 
[5,6]. However, complete responses are extraordinary rare and not all patients benefit as 
some patients are unresponsive and some patients experience major toxicities leading to 
dose reduction or treatment cessation [3]. To improve therapeutic outcome, combinations of 
sunitinib with cytokines [7,8], bevacizumab [9] or mTOR inhibitors [10,11] were tested, but 
these combinations proved to be too toxic. Additional specific inhibitors are emerging [12], 
but until now, no substantial improvement in efficacy has been observed. Unfortunately, 
almost invariably tumors become therapy-resistant in time. Current second-line therapies 
include treatment with axitinib, sorafenib or everolimus, but responses are usually short-term. 
Recently nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was approved as 
second-line therapy.  Among patients with previously treated advanced RCC, overall survival 
was longer (25.0 vs. 19.6 months) and toxicity was lower with nivolumab than with 
everolimus [13]. Although improvement is substantial, therapeutic progress is still palliative in 
nature.  
Chimeric monoclonal antibody G250 (cG250) targets CAIX, a protein highly expressed in 
ccRCC. In radioimmunotherapy clinical trials with 177Lu-labeled cG250, (177Lu-cG250) 
stabilization of previously progressive mRCC patients was observed. Previously we have 
shown that the biodistribution of cG250 is influenced by sunitinib treatment [14], but 
regardless of TKI sensitivity, TKI and mAbs can be combined, provided a short drug holiday 
is introduced; in TKI ‘sensitive’ tumors the remaining viable RCC cells were effectively 
targeted by cG250, whereas in TKI-‘resistant’ tumors cG250 tumor accumulation was 
increased, leading to higher antibody levels. Since stabilization of previously progressive 
mRCC is possible with 177Lu-cG250 [15] and sunitinib [1,4] the aim of this study was to 
investigate whether sunitinib combined with 177Lu-cG250 RIT at low 177Lu activity doses could 
improve therapeutic outcome. 
Material and Methods 
Cell lines and reagents 
The human Renal Carcinoma cell line SK-RC-52 was established from a mediastinal 
metastasis of a primary RCC [16]. The cell line was cultured in RPMI1640 (Gibco, Bleiswijk, 
The Netherlands) supplemented with 10% fetal bovine serum (Sigma) and 2 mM glutamine 
(Gibco). Human renal cell carcinoma xenograft model NU12 [17] was maintained by passing 
freshly excised tumor pieces (1-2 mm3) subcutaneously (s.c.) in mice. Both SK-RC-52 and 
NU12 express high levels of CAIX [18]. 
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Conjugation and radiolabeling of cG250 
The generation of cG250 has been described earlier [19].  Chimeric G250 has a high 
affinity for CAIX (Ka = 4 x 109 M-1) which is expressed on the cell surface of >95% of ccRCC 
The conjugation of cG250 (generously provided by Wilex AG, Munich, Germany) to 
isothiocyanato-benzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (ITC-DOTA) 
was performed essentially as described by Lewis et al. [20]. In brief, cG250 was conjugated 
with ITC-DOTA (Macrocyclics, Dallas, TX) in 0.1 M NaHCO3, pH 9.5 for 1 hour at room 
temperature, using a 15-fold molar excess of ITC-DOTA. To remove unbound ITC-DOTA, 
the reaction mixture was dialyzed against 0.25 M ammoniumacetate buffer, pH 5.5. 
The cG250-ITC-DOTA conjugate (150-350 µg) was radiolabeled with 200-450 MBq 177Lu, 
no-carrier-added (ITG isotope technologies, Garching GmbH, Germany) in 0.1 M MES 
buffer, pH 5.4 for 20 min at room temperature under strict metal-free conditions. After 
incubation, 50 mM EDTA was added to a final concentration of 5 mM [21,22].  
Labeling efficiency of the 177Lu-cG250 preparations was determined using Instant Thin 
Layer Chromatography (ITLC) silica gel strips (Agilent technologies, Amstelveen, The 
Netherlands) and 0.1 M citrate buffer, pH 6.0 as the mobile phase. When labeling efficiency 
was below 95%, the reaction mixture was purified on a PD-10 column (GE, Woerden, The 
Netherlands). The radiochemical purity exceeded 95% in all experiments. The 
immunoreactive fraction (IRF), determined on freshly trypsinized SK-RC-52 RCC cells at 
infinite antigen excess essentially as described by Lindmo et al.[23] with minor modifications 
[19], was 87 ± 7%. 
In vivo therapy experiments 
Institutional guidelines were strictly followed for maintenance of animals and experimental 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC, RU-
DEC 2012-038 and RU-DEC 2012-267). All procedures were performed using the guidelines 
from the Institute of Laboratory Animal Research [24]. Female BALB/c nu/nu mice, 6-8 
weeks of age, were obtained from Janvier, France, and maintained at the local central animal 
facility. Animals were either grafted s.c. with freshly excised NU12 xenograft pieces [17] of 
approximately 1-2 mm3 or injected s.c. with 2*106 freshly trypsinized SK-RC-52 cells.  
Once tumors reached the desired volume (50-150 mm3 ) mice were divided into groups of 
13-14 mice randomly and treatment was initiated. Sunitinib (SU11248, Sutent®, Pfizer) was 
dissolved in 0.1 M Na-citrate, pH 4.5.  
In Fig. 1, the treatment schedule is depicted for both SK-RC-52 as NU12. In short, mice 
received the equivalent of 40 mg/kg (0.8 mg/200 µl) sunitinib orally per day for 14 days. 
Three days thereafter, animals received 6.5 MBq/10 μg 177Lu-cG250 (1/3 of Maximum 
Tolerated Dose) by intravenous injection (1st cycle). Six to seven weeks (NU12 and SK-RC-
52 respectively) after start of the 1st cycle another cycle of treatment was administered (Su + 
Lu-cG250 2x). Comparator groups were treated with 1 cycle of combined treatment (Su + Lu-
cG250 1x), 1 or 2 cycles of 177Lu-cG250 (Lu-cG250 1x/ 2x), 2 cycles of sunitinib (Su 2x) or 
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were left untreated (control). Tumor volumes were determined twice a week, using a caliper 
by an evaluator blinded to the treatment groups. Tumor volume was estimated using the 
following formula: (length x width x depth) x π/6. The last observed tumor volume was used 
to calculate average tumor volumes, i.e., when mice were killed, because the tumor volume 
exceeded 1500 mm3 (a predetermined humane endpoint). 
 
 
 
 
 
 
 
 
Mice were euthanized when either tumor burden reached 1500 mm3 or when mice 
reached a predetermined humane endpoint. After the animals were euthanized, tumors were 
dissected and analyzed. Kaplan-Meier curves for overall survival (OS) were generated. Mice 
that were sacrificed because of other reasons than reaching maximal tumor burden were 
excluded. Included number of mice with SK-RC-52 tumors was: 13, 10, 11, 12, 13 and 10 for 
Su+177Lu-cG250 1 cycle, Su+177Lu-cG250 2 cycles, 177Lu-cG250 1 cycle, 177Lu-cG250 2 
cycles, Su 2 cycles, and Control respectively. For NU12, included number of mice was 12, 
13, 14, 14, 14 and 14 for Su+177Lu-cG250 1 cycle, Su+177Lu-cG250 2 cycles, 177Lu-cG250 1 
cycle, 177Lu-cG250 2 cycles, Su 2 cycles, and control respectively. 
 
Immunohistochemical analysis 
Harvested tumors were snap-frozen and stored at -80°C and/or formalin-fixed and paraffin 
embedded. Four µm cryostat sections were cut and stored at -80°C until use. Haematoxylin-
Eosin staining was performed for morphological analyses of the tumors. 
Primary antibodies used were: mAb cG250 (Wilex, 10 µg/ml) and rabbit-anti-human mAb 
Ki67 (clone sp6/RM-9106-S, Thermo Scientific, 1:200,). All antibodies were diluted in 1% 
BSA in 50mM phosphate buffered saline, pH 7.4 unless mentioned otherwise.  
For visualization of cell proliferation, paraffin sections were deparaffinized and rehydrated. 
Endogenous peroxidase was blocked with 3% H202 in PBS for 5 min. Slides were washed 
with PBS and antigen retrieval was performed in 0.1 M citrate buffer, pH 6.0 for 10 min. 
Subsequently sections were blocked with 20% normal swine serum and incubated for 1-2 hrs 
with primary antibody Ki67 diluted in 1% BSA/ PBS. After washing, sections were incubated 
with PO conjugated swine-anti-rabbit IgG (Dako), 1:100. Sections were developed with Bright 
DAB (Immunologic) and counterstained with haematoxylin. Microscopic evaluation was 
Figure 1. Treatment schedule of mice with SK-RC-52 or NU12 tumors 
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performed on an Axioskop microscope (Zeiss) and images acquired on the Axiocam mrc5 
(Zeiss) with Axio vs40 version 4.8 2.0 software (Axiovision, Zeiss). 
Statistical analysis 
A mixed model analysis was used to compare the tumor growth in the six treatment 
groups. For each treatment group the development in time was described with a fifth degree 
polynomial (fixed effects). The individual mice were allowed to follow their own curve (all six 
coefficients for the polynomial function in time were random). Using this model the geometric 
mean tumor volume at the end of sunitinib 1st cycle (Day 14), start of 2nd cycle (day 42 or 48), 
end of sunitinib 2nd cycle (day 55/62), evaluation of 2nd cycle (day 91/98) and end of 
experiment (day147/160) for NU12/SK-RC-52 respectively was compared between treatment 
groups for selected hypotheses. Correction for multiple comparisons was done per day using 
Holm’s method (improved Bonferroni method) [25]. 
For survival analysis, p-values were calculated from the log rank or Gehan-Breslow-
Wilcoxon test corrected for multiple comparisons. 
Results 
To study efficacy and duration of response of combination treatment, BALB/c nu/nu mice, 
xenografted with SK-RC-52 or NU12, were treated with 1 or 2 cycles of sunitinib and 177Lu-
cG250 RIT. To be able to evaluate the additive or synergistic effect of the combination the 
177Lu activity dose was reduced to one-third of the maximum tolerated dose that was 
previously described for SK-RC-52 [22].  
Treatment of mice with SK-RC-52 tumors 
Approximately 4 weeks after tumor cell inoculation, tumor volumes reached 80 mm3 ± 35 
mm3 and treatment was started. In Fig. 2, the tumor growth curves of individual mice (A-F) as 
well as the average tumor volumes (G) of the SK-RC-52 tumors treated with different 
treatment regimens are shown. The median values of the tumor volumes are shown in table 
1. In mice with established SK-RC-52 tumors, no significant delay of tumor growth was
observed when they were treated with one cycle of sunitinib (Su) (p = 0.168; day 14 and p = 
0.442; day 48) or 1 cycle of 177Lu-G250 (p = 0.126; day 48). In contrast, 1 cycle of Su+177Lu-
cG250 did result in a significant tumor growth delay (p < 0.001; day 48) which lasted even 
without retreatment (Fig 2A, G, Table 1, p = 0.024 at day 98).Two cycles of 177Lu-cG250 
resulted in a moderate, but not significant growth delay of SK-RC-52 tumors (p = 0.123; day 
98). On the other hand, 2 sequential combination treatments resulted in almost complete 
tumor stasis (p<0.001). At day 160, when the experiment was finalized, mean tumor volume 
of mice treated with 1 or 2 cycles Su+177Lu-cG250 was substantially lower (135.7 mm3 and 
40.9 mm3 respectively) than of mice treated with  1 or 2 cycles of Lu-cG250 (573.8 mm3 and  
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Table 1 
207 mm3 respectively). Moreover, 85% and 100% of the mice were alive when treated with 1 
or 2 cycles of combination treatment, (Fig. 2H). When mice received 2 cycles of 177Lu-G250 
75% of mice survived. Treatment with either 1 cycle of Lu-cG250, 2 cycles of Su or no 
treatment resulted in 54-60% survival of mice. No vital tumor could be detected at the end of 
treatment as revealed by Haematoxylin/Eosin and KI67 staining in 7 animals: 2 mice treated 
with 2 cycles of Su+Lu-cG250, one mouse each treated with one cycle of Su+Lu-cG250 or 1 
cycle of Lu-cG250 and 3 mice which were treated with 2 cycles of sunitinib. In all other mice, 
vital tumors were present. 
Control 101.6 72.6 142.1 163.5 103.5 258.2 200.8 119.8 336.5 323.2 145.0 720.3 310.8 68.1 1417.7
Su 2x 88.0 62.9 123.2 127.2 80.5 200.9 151.5 90.4 253.8 261.0 117.4 580.3 279.3 63.4 1230.3
Lu-cG250 1x 109.6 78.3 153.4 101.1 63.9 159.9 122.2 72.6 205.8 314.5 138.4 714.4 573.8 123.2 2672.4
Lu-cG250 2x 103.0 73.6 144.2 91.6 58.0 144.6 86.8 51.8 145.4 92.6 41.6 205.8 207.0 48.7 880.1
Su + Lu-cG250 1x 72.7 52.0 101.8 57.5 36.4 90.8 51.7 30.9 86.6 57.7 26.0 128.3 135.7 33.2 554.5
Su + Lu-cG250 2x 58.8 42.0 82.2 42.6 27.0 67.3 35.3 21.0 59.1 26.6 11.9 59.6 40.8 9.4 178.1
median
95% confidence
interval median
95% confidence
intervalmedian
95% confidence
interval median
95% confidence
interval
Day
14 48 62 98 160
median
95% confidence
interval
SK-RC-52 tumor volumes by treatment group and follow up day with 95% confidence limits 
(uncorrected) A mixed model analysis was used for comparing the tumor growth between the six 
treatment groups. For each treatment group the development in time was described with a fifth 
degree polynomial (fixed effects). The individual mice were allowed to follow their own curve (all six 
coefficients for the polynomial function in time were random). Using this model the median tumor 
volume at days 14 (end 1st cycle of Su), 48 (start 2nd cycle), 62 (end 2nd cycle of Su), 98 (evaluation 
2nd cycle) and 160 was compared between treatment groups for selected hypotheses. Correction for 
multiple comparisons was done per day using Holm’s method (improved Bonferroni method). 
Figure 2. Tumor growth and survival of SK-RC-52 tumors during treatment with sunitinib and/or 
177Lu-cG250 RIT. Treatment with sunitinib was started when tumors reached a volume of 80 mm3 ±
35 mm3 (day 0) and continued until day 14. Three days later mice were injected with 6,5 MBq/10
μg 
177Lu-cG250 by intravenous injection (1st cycle, Su+Lu-cG250). Seven weeks (day 48) after
start of the 1st cycle a 2nd cycle of treatment was administered (Su+Lu-cG250 2x). A-F: Growth
curves of individual mice. A: Su+Lu-cG250 1 cycle, B: Su+Lu-cG250 2 cycles, C: Lu-cG250 1 
cycle, D: Lu-cG250 2 cycles, E: Su 2 cycles, F: Control. G: Mean tumor volume of all treatment 
groups, * p < 0.05, *** p < 0.001. P-values shown are Holm’s adjusted for the comparison of mean 
tumor volumes for comparisons of all treatment groups vs control group on day 98 (end of 2nd
cycle) H: overall survival of treatment groups. Mice that were sacrificed because of other reasons 
than reaching maximal tumor burden, were excluded. Included number of mice was: 13, 10, 11, 12, 
13 and 10 for Su+Lu-cG250 1 cycle, Su+Lu-cG250 2 cycles, Lu-cG250 1 cycle, Lu-cG250 2 cycles, 
Su 2 cycles, and Control respectively. Overall comparison of survival curves was significant with 
p<0.05. P-values shown for the Su+Lu-cG250 1x and 2x, and Lu-cG250 2x all vs Control were 
calculated from the log rank or Gehan-Breslow-Wilcoxon test corrected for multiple comparisons (p 
= 0.0124 for Su+Lu-cG250 2x vs Control, p = 0.0468 for Su+Lu-cG250 1x vs Control and p = 0.129 
for Lu-cG250 2x vs Control). 
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Treatment of mice with NU12 tumors 
Approximately 17 days after mice were grafted with fresh NU12 tumor pieces,  tumor 
volumes reached 44 mm3 ± 27 mm3 and treatment was started. In Fig. 3, the tumor growth 
curves of individual mice (A-F) and the average tumor volumes (G, H) of the treatment  
groups with NU12 tumors treated with various treatment regimens are shown. In table 2, the 
median values of the tumor volumes are depicted. 
Table 2 
A significant tumor growth delay was observed in mice treated with 1 or 2 cycles of either 
Su, 177Lu-cG250 or Su+177Lu-cG250 (P<0.001; d14, and d48). Mean tumor volumes ranged 
from 44 to 88 mm3 for the various treatment groups and were 261 mm3 for the control group. 
Treatment with a 2nd cycle of sunitinib resulted in an additional tumor response (Fig. 3E, G), 
but tumor growth resumed immediately after cessation of sunitinib treatment. Growth of the 
Control 261.3 172.3 396.3 1455.6 800.8 2645.7 2856.6 1419.9 5746.8
Su 2x 63.6 42.6 95.0 351.9 199.9 619.5 489.4 259.3 923.7 1253.3 463.6 3388.2 4371.1 323.3 59090.0
Lu-cG250 1x 72.1 48.4 107.6 63.2 35.9 111.2 49.0 26.0 92.5 33.6 13.0 87.2 56.3 9.9 319.1
Lu-cG250 2x 88.5 59.3 131.9 79.8 45.3 140.4 61.9 32.8 116.7 24.9 9.6 64.4 3.1 0.6 17.2
Su + Lu-cG250 1x 46.0 30.7 68.8 55.1 31.0 98.1 51.0 26.7 97.4 47.9 18.0 127.5 233.5 38.0 1436.9
Su + Lu-cG250 2x 59.3 39.8 88.5 70.1 39.8 123.3 60.3 32.0 113.8 27.7 10.6 72.7 1.9 0.3 11.2
Day
91 147
95% confidence
interval median
95% confidence
intervalmedianmedian
95% confidence
interval median
95% confidence
interval
14 42 55
median
95% confidence
interval
NU12 tumor volumes by treatment group and follow up day with 95% confidence limits (uncorrected). 
A mixed model analysis was used for comparing the tumor growth between the six treatment groups. 
For each treatment group the development in time was described with a fifth degree polynomial (fixed 
effects). The individual mice were allowed to follow their own curve (all six coefficients for the 
polynomial function in time were random). Using this model the median tumor volume at days 14 
(end 1st cycle of Su), 42 (start 2nd cycle), 55 (end 2nd cycle of Su), 91 (evaluation 2nd cycle) and 
147 was compared between treatment groups for selected hypotheses. Correction for multiple 
comparisons was done per day using Holm’s method (improved Bonferroni method). 
Figure 3. Tumor growth and survival of NU12 tumors during treatment with sunitinib and/or 177Lu-
cG250 RIT. Treatment with sunitinib was started when tumors reached a volume of 44 mm3 ± 27
mm3 (day 0) and continued until day 14. Three days later mice were injected with 6.5 MBq/10 μg
177Lu-cG250 by intravenous injection (1st cycle, Su+Lu-cG250). Seven weeks (day 42) after start of
the 1st cycle a 2nd cycle of treatment was started (Su+Lu-cG250 2x). A-F: Growth curves of
individual mice. A: Su+Lu-cG250 1 cycle, B: Su+Lu-cG250 2 cycles, C:  Lu-cG250 1 cycle, D: Lu-
cG250 2 cycles, E: Su 2 cycles, F: Control. G,H: Mean tumor volume of all treatment groups. *** P< 
0.001. P-values shown are Holm’s adjusted for the comparison of mean tumor volumes for 
comparisons of all treatment groups vs control group on day 91 (end of 2nd cycle) I: overall survival
of treatment groups. Mice that were sacrificed because of other reasons than reaching maximal 
tumor burden, were excluded. Included number of mice was: 13, 12, 14, 14, 14 and 14 for Su+Lu-
cG250 1 cycle, Su+Lu-cG250 2 cycles, Lu-cG250 1 cycle, Lu-cG250 2 cycles, Su 2 cycles and 
Control respectively. Overall comparison of survival curves was significant with p<0.0001. P-values 
shown for all treatment groups vs Control were calculated from the log rank or Gehan-Breslow-
Wilcoxon test corrected for multiple comparisons (**** p<0.0001). 
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NU12 tumors in mice treated with one cycle of 177Lu-cG250 or 1 cycle of Su+177Lu-cG250, 
resumed 9 to 10 weeks after cessation of therapy and tumors grew steadily thereafter (Fig. 
3A, C, G, H). In contrast, when animals were treated with 2 cycles of 177Lu-cG250 or 2 cycles 
of Su+177Lu-cG250 complete tumor regression was observed, which continued until the 
experiment was finalized, without additional treatment (p < 0.001; day 91).  
At the end of the experiment (day 147), treatment with 2 cycles of Su+177Lu-cG250 or 2 
cycles of 177Lu-cG250 resulted in 100% survival (Fig. 3I). Seventy one percent of mice 
survived when treated with one cycle of 177Lu-cG250. Treatment with one cycle of Su+177Lu-
cG250 resulted in 54% survival. Only 14% of mice treated with 2 cycles of Su and none of 
the untreated mice survived.  
To determine whether mice were cured or remnants of viable tumor cells were still 
present, harvested tumor areas were analyzed. Based on morphology by HE and cell 
proliferation evaluation, 83% and 86% of the mice treated with 2 cycles of Su+177Lu-cG250 or 
2 cycles of 177Lu-cG250 were cured: no viable tumor cells were detected. Although 71% of 
mice survived during the experimental period when treated with one cycle of 177Lu-cG250, 
only 29% were cured with no evidence of disease. Fourteen percent and 8% of mice were 
cured when treated with 2 cycles of Su or one cycle of Su+177Lu-cG250 respectively. None of 
the control mice survived. 
Discussion 
To improve the treatment of patients with mRCC new approaches are urgently needed. 
We studied the combination of sunitinib with 177Lu-cG250 RIT in nude mice with RCC to 
determine whether a combined attack on tumor vasculature and tumor cells might be 
beneficial. We show in two RCC models that when sunitinib is combined with 177Lu-G250 RIT 
tumors can be ablated. 
When 177Lu-cG250 RIT was combined with sunitinib a pronounced effect on SK-RC-52 
tumor growth was observed. One cycle of sunitinib combined with Lu-cG250 was sufficient to 
induce significant tumor growth inhibition, emphasizing that targeting blood vessels and 
tumor cells is more effective than targeting either compartment alone. This effect was 
superior compared to 2 cycles of sunitinib and to 177Lu-cG250 RIT alone. Implementation of a 
second combination treatment cycle induced a long-lasting tumor response: PFS increased 
to ~150 days and OS increased to 100%. SK-RC-52 is considered sunitinib resistant and 
treatment with sunitinib leads to increased antibody accumulation in the tumors [14]. 
Consequently, tumor radiation doses are increased when sunitinib and 177Lu-cG250 RIT are 
combined, explaining the superiority of the combination treatment in this model. 
Nevertheless, most animals were not tumor free, indicating that more treatment cycles are 
necessary to achieve complete cure. 
In the fast growing NU12 tumor, a pronounced effect on tumor growth was observed when 
animals were treated with sunitinib leading to NU12 tumor regression, whereas SK-RC-52 
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tumors stabilized. NU12 is considered as a sunitinib sensitive tumor, with extensive necrosis 
after sunitinib treatment [14]. Although in vitro experiments showed a 5-fold higher sunitinib 
sensitivity for NU12 compared to SK-RC-52 (IC50 0.6 µM vs. 3 µM, data not shown), 
continued sunitinib treatment was necessary to induce a long-lasting response: drug 
withdrawal lead to rapid induction of tumor growth. One cycle of low dose 177Lu-cG250 RIT 
was sufficient to increase PFS to ~65 days and OS increased to 71% compared to 14% for 
sunitinib treated animals. Remarkably, 2 cycles of low dose 177Lu-G250 resulted in 100% 
survival and complete cures in 86% of mice: no viable tumor cells could be detected by 
microscopic analysis. Sunitinib combined with low dose 177Lu-cG250 RIT and low dose 177Lu-
cG250 RIT alone were equally effective, indicating that the addition of sunitinib did not 
enhance the anti-tumor effect of the low-dose 177Lu-cG250 RIT. Two cycles of Su+177Lu-
cG250 were equally effective (100% survival and 83% cures), suggesting that most probably 
the anti-tumor effect of the combination treatment was accountable to 177Lu-cG250. 
Apparently, NU12 is both sunitinib and 177Lu sensitive. In this “sensitive” model, the 6.5 MBq 
dose of 177Lu most likely was too high to observe improved survival of the combination 
treatment. 
Animals with a small tumor load responded better to 177Lu-cG250 RIT than animals with 
higher tumor burden. It is well established that RIT performs better in small volume disease 
[26-28]. In previous studies three fold higher doses of 177Lu (18.5 MBq (=MTD) vs. 6.5 MBq) 
were required to induce a tumor response in SK-RC-52 [22]. Since high dose RIT leads to 
bone marrow toxicity and can deplete the bone marrow reserve in (a subset of) patients, 
repeated high dose RIT is not feasible [29]. In the current study two cycles of low activity 
177Lu-cG250 RIT were insufficient to control tumor outgrowth although progression free 
survival increased to approximately 80 days and OS to 69%. However in combination with 
sunitinib tumors regressed. The recommended treatment for patients with mRCC currently 
exists of 50 mg of sunitinib per day for 4 weeks followed by 2 weeks off-treatment (Schedule 
4/2). Combination with low dose 177Lu-cG250 RIT may be relatively easy as bone marrow 
toxicity will be substantially reduced compared to high dose 177Lu-cG250 RIT.  
Several studies have confirmed the feasibility and enhanced efficacy of combination of 
antibody and TKI. Kelly et al. [30] observed that combination of 177Lu-hu3S193 RIT with 
EGFR inhibitor AG1478 significantly improved efficacy in mice with prostate carcinoma. The 
enhanced effect with the EGFR inhibitor was attributed to the simultaneous targeting of 
tumor cells by two different drugs. In a recently performed meta analysis for the treatment of 
non-small cell lung cancer, the authors showed that chemotherapy or EGFR-TKIs with 
bevacizumab significantly prolonged PFS and OS as first-line treatment for NSCLC 
compared with chemotherapy or TKIs alone, indicating that combinations can be more 
efficacious [31]. In our study, combining antibody with TKI also lead to a substantial 
improvement of efficacy, but in our case two different cell types were targeted (tumor and 
endothelium). Whether this combination is superior to simultaneous targeting of tumor cells 
with different drugs remains to be established.  
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Although sunitinib alone showed little SK-RC-52 tumor growth inhibition, an additive effect 
was observed when combined with 177Lu-cG250 RIT, possibly due to the enhanced uptake of 
G250 antibody [14]. Recently, Jedeszko et al. [32] investigated the combination of pazopanib 
and chemotherapy in an orthotopic RCC mouse model and claimed that pazopanib 
enhanced the intracellular uptake of a chemotherapeutic drug by a direct sensitization effect 
on tumor cells. It is possible that a similar effect applies to our studies and that sunitinib has 
a direct sensitization effect on SK-RC-52 tumor cells, leading to increased uptake of mAb 
G250. The enhanced uptake was not observed in NU-12 tumors, but this can be explained 
by different internalization rates of the two tumor cell types [18]. In SK-RC-52, cG250 
internalization and subsequent metabolization plays a role whereas internalization is almost 
absent in NU-12. 
There are several limitations to our study results. Whether this combination is superior in 
NU-12-like tumors is uncertain, because the activity dose we used was too effective to begin 
with. Additional therapeutic experiments with even lower doses of 177Lu should be performed 
to confirm our hypothesis. We are currently investigating the optimal dose schedule for 
treatment of mRCC patients. Furthermore, future experiments are needed to elucidate the 
mechanism leading to enhanced uptake of antibody by treatment with sunitinib. Once we 
know the mechanism of action, it will be easier to design efficacious therapy strategies. 
In conclusion, since for patients with mRCC the efficacy of targeted agents such as TKI is 
limited by both intrinsic and acquired resistance improvement is needed. Enhanced 
therapeutic efficacy can be reached when two agents that on their own do not induce 
satisfactory response levels in preclinical models resembling sunitinib and RIT sensitive 
tumors are combined. Our findings provide a promising new therapeutic strategy for patients 
with advanced RCC. 
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Summary 
 
The aim of this thesis was to investigate new therapeutic strategies with chimeric 
monoclonal antibody G250 (cG250/Girentuximab) in preclinical models for patients with 
advanced RCC. 
Chimeric G250 recognizes a conformational epitope on carbonic anhydrase IX (CAIX), a 
transmembrane protein which is expressed at high levels in clear cell renal cell carcinoma 
(ccRCC). 
 
 
Chapter 2 reviews preclinical and clinical studies with mAb G250 since the original 
description in 1986. Preclinical studies indicated excellent targeting in RCC xenografts and 
clinical studies confirmed the outstanding targeting ability of mAb G250. cG250-based 
immunoPET imaging holds great promise for the future as diagnostic modality in detecting 
localized and advanced disease and possibly in monitoring therapy response.  
Despite the outstanding accumulation levels of cG250, radioimmunotherapy (RIT) trials 
have been somewhat disappointing. Responses in progressive mRCC patients were limited 
to stabilization of disease and cures were not observed. 177-Lutetium labeled cG250 RIT 
might be of use for treatment of patients with small-volume disease.  
Clinical therapy studies showed that multiple doses of unmodified cG250 were well 
tolerated and combination with low dose IL-2 resulted in disease stabilization, indicating that 
the antibody could lyse tumor cells by antibody-dependent cellular cytotoxicity (ADCC). The 
results of a large adjuvant trial indicate that cG250 alone may be of value to reduce 
recurrence of disease in high risk patients with high CAIX expression. Confirmatory studies 
are needed to substantiate the value of the antibody.  
 
 
Prior studies showed that the therapeutic efficacy of tumor specific antibodies could be 
enhanced by gene fusion to tumor necrosis factor (TNF). In Chapter 3, the construction, 
expression and purification of a cG250-TNF fusion protein is described. In this way cG250 is 
used as a carrier for site specific delivery of TNF to human RCC xenografts. Genetically 
engineered TNF constructs were designed as CH2/CH3 truncated cG250-TNF fusion 
proteins and eukaryotic expression was optimized. The cG250-TNF construct was 
characterized in-vitro by biochemical analysis and bioactivity assays. Specific accumulation 
and retention of cG250-TNF in the tumor was observed, resulting in growth control of 
established human RCC xenografts in vivo. In addition, combined administration of cG250-
TNF and IFNγ significantly increased the antitumor response resulting in improved 
progression free survival and overall survival. Moreover, since TNF subunits were forced to 
form a dimer, toxicity was significantly lower than observed with wild type TNF or trimeric 
TNF antibody constructs. Considering the poor outcome of patients with advanced RCC, 
cG250-TNF-based immunotherapeutic approaches justify clinical investigation. 
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With the development and approval of targeted agents such as sunitinib, sorafenib, 
bevacizumab and pazopanib, the therapeutic landscape has changed dramatically for 
patients with mRCC. These agents are aimed at inhibition of the tumor vasculature. Although 
an impressive increase in progression-free survival is observed for patients with mRCC, 
patients remain largely incurable, due to the development of treatment resistance. 
Additionally, these chronic treatments may coincide with significant toxicity which increases 
to unacceptable levels when combination treatment is applied. Sequential therapy may be 
more promising but the most optimal sequence therapy has not been established.  
 
The combination of a tyrosine kinase inhibitor (TKI) with mAb cG250, involved in a distinct 
effector mechanism, might lead to improved tumor responses and survival in patients with 
mRCC. In Chapter 4 the combination of TKI with mAb cG250 was investigated. The effect of 
sunitinib, sorafenib and vandetanib treatment on the accumulation of cG250 was studied in 
nude mice with human RCC xenografts . Mice were treated with TKI for 1-2 weeks followed 
by injection with radiolabeled cG250. While on TKI treatment, tumor uptake of cG250 
decreased dramatically, tumor growth was slightly inhibited and vascular density decreased 
considerably as judged by various markers. When treatment was stopped there was robust 
neovascularization, mainly at the tumor periphery. Consequently, cG250 uptake recovered, 
albeit that cG250 uptake appeared to be restricted to the tumor periphery where vigorous 
neovascularization was visible. These results indicate that simultaneous administration of a 
TKI and cG250-RIT is unfavorable. Thus, a time-delay between the two modalities is 
required when designing combined treatment strategies with TKI and mAb G250. 
 
In Chapter 5 the effect of sunitinib on the biodistribution of cG250 when administered with a 
short time delay after sunitinib treatment was studied. Mice were injected with 111In-cG250 
either 3 days before initiation or 3 days after cessation of sunitinib treatment to assess the 
optimal sequence in RCC xenografts. Differences in response to sunitinib were observed in 
the two xenograft models used. One model represented a sunitinib-sensitive tumor; sunitinib 
treatment resulted in extensive necrosis and decreased microvessel density (MVD). 
Accumulation of cG250 was significantly decreased when sunitinib treatment preceded the 
antibody injection but remained unchanged when sunitinib followed cG250 injection. 
Cessation of therapy led to a rapid neovascularization, reminiscent of a tumor flare. The 
other RCC xenograft model studied represented a sunitinib-resistant tumor: (central) tumor 
necrosis was minimal and MVD was not affected. Sunitinib treatment resulted in increased 
cG250 uptake, regardless of the sequence of treatment. Thus, regardless of TKI sensitivity, 
TKI and mAbs can be combined, provided a short drug holiday is introduced. Since these 
two treatment modalities have different modes of action, the combination of sunitinib and 
cG250-RIT could lead to enhanced therapeutic efficacy. 
 
In chapter 6 the combination of sunitinib treatment with 177Lutetium-cG250 RIT (at 1/3 of 
previously used doses) was studied in mice with established human RCC xenografts. In the 
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fast growing sunitinib-sensitive RCC xenograft, the effect of 2 cycles of 177Lu-cG250 was 
comparable to 2 cycles of sunitinib + 177Lu-cG250, indicating that the anti-tumor effect was 
achieved by the radiolabel. Apparently this tumor is both sunitinib and 177-Lutetium 
sensitive. In this sunitinib-sensitive model the 177-Lutetium dose was probably too high to 
observe a difference between these two therapy regimens, indicating that in patients with 
small tumorload and/or in patients with sunitinib-sensitive tumors, the addition of 177Lu-cG250 
to sunitinib might not improve response. In contrast, in the sunitinib-resistant model, superior 
tumorgrowth inhibition was achieved when sunitinib and 177Lu-cG250 were combined, 
substantiating the hypothesis that targeting both bloodvessels and tumorcells is more 
effective than either treatment alone. Collectively this indicates that the combination of these 
two therapeutic entities can be beneficial in a patient setting. However, whether cG250-
based RIT can be combined with TKI in patients, which constitutes the current standard 
treatment for mRCC, needs to be established in large randomized clinical trials. 
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Het doel van dit proefschrift was het testen van nieuwe therapeutische strategieën met 
monoklonaal antilichaam chimeer G250 (cG250/Girentuximab) in preklinische modellen voor 
patiënten met uitgezaaid niercelcarcinoom. Chimeer G250 herkent een epitoop op carbonic 
anhydrase IX (CAIX), een transmembraan eiwit dat hoog tot expressie komt in heldercellige 
niercelcarcinomen (ccRCC).  
 
 
Hoofdstuk 2 geeft een overzicht van preklinische en klinische studies uitgevoerd met 
monoklonaal antilichaam G250 (mAbG250) vanaf de isolatie van het antilichaam in 1986 tot 
heden. Preklinische studies hebben aangetoond dat mAbG250 zeer goed accumuleert in 
humane niercelcarcinomen en met klinische studies is de uitzonderlijk goede accumulatie 
van mAbG250 in ccRCC bewezen. Klinische studies hebben laten zien dat positon emissie 
tomografie met cG250 (cG250-immunoPET) veelbelovend is voor de detectie van 
gelokaliseerde en gemetastaseerde ziekte en voor het meten van het therapie effect. 
Ondanks de superieure accumulatie van cG250 vallen de uitkomsten van de 
radioimmuuntherapie (RIT) studies enigszins tegen. In patiënten met progressieve ziekte 
werd vooral stabilisatie van ziekte maar geen genezing waargenomen. RIT met 177Lu-cG250 
is waarschijnlijk het meest effectief in patiënten met minimale ziekte. 
Klinische therapie studies hebben aangetoond dat meerdere doses van ongemodificeerd  
cG250 goed verdragen worden. In combinatie met lage doses Interleukine-2 kan dit leiden 
tot stabilisatie van ziekte; wat doet vermoeden dat het antilichaam de tumorcellen kan 
vernietigen d.m.v. “antilichaam-afhankelijke cellulaire cytotoxicity” (ADCC). De adjuvante 
studies met ongemodificeerde cG250 suggereren dat monotherapie met cG250 van waarde 
kan zijn om terugkeer van ziekte in patiënten met hoge CAIX expressie te verminderen. 
Klinische studies met grote patiëntencohorten moeten deze resultaten bevestigen.  
 
Eerdere studies hebben aangetoond dat de therapeutische werkzaamheid van tumor 
specifieke antilichamen vergroot kan worden door genfusie met tumor necrose factor (TNF). 
In Hoofdstuk 3 wordt de constructie, expressie en zuivering van het cG250-TNF fusie eiwit 
beschreven. Hiermee wordt de specificiteit van cG250 gebruikt om TNF specifiek naar 
humane niertumoren te leiden. Het cG250-TNF fusie eiwit werd geconstrueerd door de CH2-
CH3 staart van het parentale cG250 antilichaam te vervangen door twee humane TNF 
moleculen. Vervolgens werd de eukaryotische expressie geoptimaliseerd, zijn biochemische 
analyses uitgevoerd en is de bioactiviteit van het fusie eiwit gemeten. In vivo werd specifieke 
accumulatie van cG250-TNF in de tumor en groeiremming van humane niercelcarcinomen 
waargenomen. Toediening van cG250-TNF met Interferon-γ leidde tot een verhoogde 
antitumor response met een verbetering van zowel progressievrije overleving als algehele 
overleving. Bovendien was de toxiciteit van het cG250-TNF significant verlaagd t.o.v. het wild 
type TNF of trimeer TNF antilichaam constructen, waarschijnlijk omdat de TNF subeenheden 
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geforceerd worden tot dimerisatie. Gezien de slechte vooruitzichten voor patiënten met 
mRCC lijkt het zinvol om nader klinisch onderzoek te doen naar immunotherapeutische 
toepassingen die op cG250-TNF gebaseerd zijn. 
Voor patiënten met mRCC is het therapeutisch landschap aanzienlijk gewijzigd door de 
ontwikkeling en goedkeuring van doelgerichte middelen zoals sunitinib, sorafenib, 
bevacizumab and pazopanib. Deze middelen remmen het ontstaan van nieuwe bloedvaten 
in de tumoren. Hoewel er een grote toename van de progressievrije overleving van patiënten 
met mRCC is waargenomen, treedt geen genezing op doordat tumoren op den duur 
ongevoelig worden voor deze middelen. Deze chronische behandelingen gaan bovendien 
vaak gepaard met bijwerkingen die zeer ernstig kunnen zijn wanneer deze behandelingen 
gecombineerd worden. Sequentiële therapie zou beter kunnen werken maar tot op heden is 
de meest optimale therapie niet vastgesteld. 
 
De combinatie van een doelgericht middel, zoals een tyrosine kinase remmer (TKI), met 
antilichaam cG250, zou in patiënten met mRCC tot verbeterde tumor responses en 
overleving kunnen leiden omdat ze gericht zijn tegen verschillende tumorcomponenten. In 
Hoofdstuk 4 is de combinatie van TKIs met cG250 onderzocht. Het effect van sunitinib, 
sorafenib en vandetanib behandeling op de accumulatie van cG250 werd bestudeerd in 
immuundeficiënte muizen met humane niercelcarcinomen. Muizen werden 1-2 weken 
behandeld met TKI waarna ze geïnjecteerd werden met radioactief gelabeld cG250. Analyse 
toonde aan dat door behandeling met TKI de accumulatie van cG250 in de tumor drastisch 
afnam, de tumorgroei enigszins verminderde en de bloedvat dichtheid substantieel 
verminderde. Op het moment dat behandeling gestopt werd werden veel nieuwe bloedvaten 
gevormd, voornamelijk aan de rand van de tumor. Als gevolg daarvan nam de cG250 
opname vooral in de tumor rand toe, daar waar vorming van nieuwe bloedvaten zichtbaar 
was. Uit deze resultaten blijkt dat gelijktijdige toediening van een TKI en cG250-RIT 
ongunstig is. Wanneer behandeld wordt met een combinatie van TKI en cG250, dan is een 
tijdsinterval tussen toediening van de twee modaliteiten noodzakelijk.  
 
In Hoofdstuk 5 is het effect van sunitinib op de biodistributie van cG250 bestudeerd. Na 
behandeling met sunitinib werd een korte pauze ingelast waarna cG250 toegediend werd. 
Muizen werden 3 dagen voor het begin of 3 dagen na het einde van de sunitinib behandeling 
met 111In-cG250 geïnjecteerd om de optimale volgorde te bepalen in twee humane 
niercelcarcinomen. In de twee gebruikte tumor modellen werden verschillen gevonden in de 
response op sunitinib behandeling. Eén tumor was sunitinib-gevoelig: Sunitinib behandeling 
leidde tot uitgebreide necrose en verminderde microvasculaire dichtheid (MVD). Accumulatie 
van cG250 was significant verlaagd wanneer sunitinib behandeling vóór de antilichaam 
injectie plaatsvond maar bleef ongewijzigd wanneer sunitinib na de cG250 injectie gegeven 
werd. Het beëindigen van de therapie leidde tot snelle bloedvatvorming, waardoor een 
explosieve tumorgroei plaatsvond. De andere tumor was sunitinib-resistent; (centrale) tumor 
necrose was minimaal en MVD veranderde niet. Sunitinib behandeling resulteerde in 
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verhoogde opname van cG250, ongeacht de volgorde van behandeling. Dit betekent dat 
ongeacht gevoeligheid voor TKI, antilichamen en TKI gecombineerd kunnen worden als een 
korte pauze wordt ingevoerd. Omdat deze twee middelen verschillende 
werkingsmechanismen hebben, kan de combinatie van sunitinib met cG250-RIT potentieel 
tot verbeterde therapeutische effecten leiden.  
In hoofdstuk 6 is de combinatie van sunitinib behandeling met 177Lutetium-cG250 RIT (op 
1/3 van de vroegere effectieve dosis) onderzocht in muizen met humane niercelcarcinomen. 
In de snel groeiende sunitinib-gevoelige tumor was het effect van 2 cycli 177Lu-cG250 
vergelijkbaar met die van 2 cycli sunitinib + 177Lu-cG250; d.w.z. het anti-tumor effect was 
waarschijnlijk het gevolg van het radioactieve label (177Lu-cG250). Klaarblijkelijk is deze 
tumor zowel sunitinib als 177-Lutetium gevoelig. In dit model was de 177-Lutetium dosis 
waarschijnlijk te hoog om een verschil tussen deze twee behandelingsmethoden te zien. Dat 
betekent dat in patiënten met een kleine tumormassa en/of in patiënten met sunitinib-
gevoelige tumoren de toevoeging van 177Lu-cG250 misschien niet tot een verbeterde 
response zal leiden. Daarentegen werd in de sunitinib-resistente tumor superieure 
tumorgroei inhibitie bereikt wanneer sunitinib met 177Lu-cG250 gecombineerd werd. Hiermee 
wordt aangetoond dat behandeling met middelen die zowel de bloedvaten als de tumorcellen 
aanvallen effectiever is dan behandeling met elk middel afzonderlijk. Gezamenlijk betekent 
dit dat de combinatie van deze twee therapeutische middelen gunstig kan zijn voor patiënten 
met mRCC. Echter, of op cG250-gebaseerde RIT gecombineerd kan worden met de huidige 
standaard TKI behandeling van patiënten zal moeten worden onderzocht in grote 
gerandomiseerde klinische studies.  
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Future prospects 
Although significant progress has been made in the management of patients with 
advanced RCC, the treatment remains problematic: TKI treatment is mainly palliative and 
whether treatment with checkpoint inhibitors will lead to durable responses in the majority of 
patients is unclear. Whereas TKIs act predominantly on the tumor vasculature, checkpoint 
inhibitors unleash the immune system in a generalized fashion. While the inhibition of tumor-
specific immune cells is released, auto-reactive T cells are also activated, leading to graft-
versus-host like toxicities. Up to now, clinical investigations combining various targeted 
agents are disappointing because of enhanced toxicity and lack of improved efficacy. New 
therapeutic strategies specifically targeting the tumor cells might be highly beneficial for the 
treatment of advanced RCC. As described in this thesis, mAb cG250 and its target CAIX 
appear to be ideally suited to reach this goal. Earlier studies showed that advanced RCC 
patients could benefit from cG250 treatment in various regimens. Nevertheless, further 
improvements are needed to truly impact on the disease course of mRCC patients.  
G250-TNF 
Treatment of mice with CAIX+ human renal cell carcinoma xenografts with the fusion 
protein cG250-TNF, combining the targeting ability of cG250 with the cytolytic capacity of 
TNF, demonstrated impressive therapeutic efficacy. Therapy with cG250-TNF resulted in 
significant remission of established xenografts which was further improved by addition of low 
doses of IFNγ without significant increase in side effects. The encouraging targeting and 
strong anti-tumor properties of cG250-TNF (in combination with IFNγ) and the strong and 
stable expression pattern of CAIX/G250 in sporadic and inherited forms of RCC warrant 
further evaluation of this construct in a clinical setting.  
Combination of targeted therapy with checkpoint inhibitors 
The understanding of the mechanisms of T-cell activation and inhibition has led to the 
development of therapeutic antibodies targeting immune checkpoint pathways causing 
reduction of tumor growth and proliferation [1-3]. Clinical trials with CTLA-4 (ipilimumab), and 
PD-1/PD-L1 inhibitors (i.e. nivolumab and pembrolizumab) have shown clinical benefit in a 
subset of cancer patients with less toxicity than observed in previous immunotherapy with IL-
2 and/or IFNα [4,5]. The clinical activity of these drugs in melanoma, RCC and NSCLC has 
been confirmed [6-8]. Nivolumab is now approved as second-line therapy for patients with 
mRCC on the basis of a better overall survival (OS) and lower toxicity compared to 
everolimus [9]. New immune checkpoint inhibitors are in the developmental phase.  
This field is rapidly expanding with several clinical trials ongoing, in different stages. With 
checkpoint inhibitors durable clinical responses can be elicited. However, the majority of 
patients treated with anti-PD-1/PD-L1 monotherapies do not achieve objective responses, 
and most tumor regressions are partial rather than complete. Moreover toxicities can be 
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severe and managing of these toxicities is challenging. Especially with anti-CTLA-4 
blockade, care should be taken since this can lead to life threatening toxicities and death. 
Currently, multiple clinical studies combining checkpoint inhibition with targeted therapy 
are either planned or ongoing to improve response rates in patients with mRCC [1]. These 
include combinations of bevacizumab with nivolumab, atezolizumab or prembrolizumab, 
combinations of axitinib with avelumab or prembrolizumab, and combinations of cabozantinib 
with nivolumab or nivolumab and ipilimumab. The rationale of these combinations is that 
different pathways are targeted, possibly leading to improved responses. This was illustrated 
in the trial where nivolumab was combined with ipilimumab (N3I1 regimen) with an objective 
response rate of 48% [10]. The outcome of the phase III trial comparing 1st line sunitinib vs. 
N3I1 regimen will be of importance to demonstrate superiority of these new treatment 
modalities compared to current standard treatment.  
In designing these combinations one should consider dose regiments (concurrent or 
sequential), minimize treatment related toxicities and select appropriate end points to assess 
efficacy. Interestingly, targeted agents can upregulate tumor antigen presentation, T-cell 
infiltration and PD-1/PD-L1 expression, possibly priming a response to checkpoint inhibitors. 
Concurrent therapy may be most beneficial. However concurrent therapy can also induce 
greater and unexpected toxicities compared to sequential therapy [11]. Sequential treatment 
of targeted therapy followed by immunotherapy before disease progression might be a viable 
alternative. The challenge of the upcoming clinical trials is to establish optimal timing [1]. 
Finally, response definitions should be considered: In a subset of patients treated with 
checkpoint inhibitors ‘pseudoprogression’, a lag in response and initial increase in lesion 
size, was observed. Current response criteria such as Response Evaluation Criteria in Solid 
Tumors (RECIST) may not reflect efficacy of checkpoint inhibition therapy and response 
criteria may have to be modified to evaluate efficacy of checkpoint inhibitors [12,13]. 
Combination of cG250 based RIT with sunitinib 
The results described in this thesis suggest that combination of tyrosine kinase inhibitors 
with cG250 based RIT holds great promise for the future of patients with advanced RCC. Our 
animal studies indicate that by targeting both endothelial cells and tumor cells improved 
responses are achievable. Theoretically, the addition of cG250-RIT to the current sunitinib 
treatment schedule (4 weeks on/2 weeks off drug) appears to be feasible. Patients could 
receive the 177Lu-cG250 RIT during the second week off sunitinib .The observation that lower 
177Lu activity doses were effective suggests that bone marrow toxicity, the main toxicity of 
RIT, i.e. thrombocytopenia, can be largely prevented while keeping the efficacy at satisfying 
levels. However, even at low 177Lu-cG250 RIT doses (1/3 of MTD), low grade hematological 
toxicity was observed with a nadir at 6 weeks post injection [14]. Full recovery was observed 
12 weeks p.i. suggesting that when sunitinib is combined with 177Lu-cG250 RIT, the sunitinib-
free period should be prolonged. Whether patients with a sunitinib sensitive tumor will benefit 
from this combination needs to be established. Moreover, sunitinib-sensitive and sunitinib-
resistant patients may need to be stratified.  
140
Processed on: 28-10-2016
505946-L-bw-Wakka
Future prospects 
Combination of cG250 based RIT with checkpoint inhibitors 
As mentioned above, although encouraging results have been reported from clinical trials 
exploring combinations of PD-1 and PD-L1 inhibitors with radiation therapy, sunitinib or 
pazopanib, toxicity can be severe [15]. Combination of 177Lu-cG250 with checkpoint inhibitors 
may be another possibility: the initiation of specific tumor cell kill followed by T cell influx in 
combination with a checkpoint inhibitor may license the activation and expansion of tumor-
specific T cells in a more specific fashion that the combination TKI-checkpoint inhibitors. 
Since the MTD of 177Lu-cG250 has been well established, clinical investigations along these 
lines may be attractive.  
The severe toxicities observed with checkpoint immunotherapy combined with targeted 
therapy or other checkpoint immunotherapies may be reduced when checkpoint inhibition is 
combined with 177Lu-cG250 RIT. Although 177Lu-cG250 treatment can lead to grade 3-4 
myelotoxicity, in general the myelotoxicity has been transient. Also toxicity can be tailored to 
individual patients based on dosimetric analysis of the data acquired during the pretreatment 
imaging. This is likely to improve 177Lu-cG250 RIT [16,17]. Since 177Lu-cG250 RIT has a 
different mechanism of action than mAbs targeting immune checkpoints the combination 
might increase efficacy in patients with mRCC. Animal studies are needed to demonstrate if 
these treatment combinations show synergistic or additive effects. Careful development and 
rational design is necessary to determine the timing and sequencing of these agents. 
Combination of cG250 based RIT with clinical grade active NK-cells 
Clinical studies with unmodified cG250 with or without low dose IL-2 suggested that 
Natural killer (NK) cell-mediated cG250-dependent cellular-cytotoxicity (ADCC) was the 
mechanism that influenced the clinical course of mRCC patients. In progressive RCC 
patients stabilization of disease (SD) was observed when cG250 was administered. Similarly, 
when cG250 was combined with low-dose IL-2 a clinical benefit was noted. Collectively, 
results of the clinical trials with unmodified cG250, either as monotherapy or in combination 
with low dose IL-2, suggest that cG250 treatment can alter disease progression.  
NK cells are major effector cells of the innate immune system and play a key role in 
control against virus infection and tumor immunosurveillance. Recent advances in the 
isolation and expansion of pure, clinically applicable NK cells derived from umbilical cord 
blood-derived hematopoietic progenitor cells (HPC-NK) have paved the way to combine 
antibodies with these cells [18,19]. Indeed, functional analysis demonstrated that these 
active NK cells generate natural cytolysis and ADCC-dependent killing of cancer cells 
[20,21]. Preliminary experiments showed that HPC-NK cells generated from several donors 
showed high and dose dependent cytolytic activity for all RCC cell lines tested with >90% cell 
kill at Effector to Target ratio of 3:1. Addition of mAb cG250 enhanced cytotoxicity in CAIX+ 
cells but not in CAIX-  cells. Reactivity toward target cells was confirmed by elevated levels of 
granzyme B (~30%) and IFNγ secretion produced by NK cells (unpublished results). 
Combining the specific targeting of cG250 with adoptive transfer of highly activated NK cells 
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may become an effective therapy approach for patients with metastasized RCC or at high 
risk of recurrence. 
 
Thus, several options are available to improve therapy for patients with advanced RCC. 
The main challenge will be to select patients for a particular treatment: Personalized 
medicine. Currently, mRCC patients are stratified into different risk groups based on clinical 
parameters. This stratification has a clear prognostic value but is still far from optimal. 
Comparison of several risk models showed a concordance level of 0.66, indicating that a 
ceiling has been reached for clinical risk models to predict prognosis based solely on clinical 
factors [22,23]. Other and better prognostic and predictive biomarkers are needed to improve 
patient stratification and to abandon the current trial and error type of patient management. 
Current research is focusing on molecular biomarkers with better predictive ability. In a large 
FP7 funded program (EuroTARGET) data from several high throughput platforms are going 
to be integrated in an effort to identify and characterize biomarkers to predict responders 
from non-responders to targeted therapy with the ultimate goal to personalize medicine. 
Such biomarkers are pivotal because not all patients show clinical benefit from targeted 
therapy and since an increasing number of compounds and therapeutic options is becoming 
available, the choice of therapy and sequencing or combination is becoming extraordinary 
challenging. Continued effort is needed at the level of new therapies and biomarkers to 
personalize medicine for patients with mRCC to improve responses substantially in still a 
devastating disease. 
 
In the last decade major steps have been taken in the management of patients with 
mRCC. A large number of agents have been developed based on the improved molecular 
insight in this disease and several are now used as first or second line treatment. Clinical 
responses have improved dramatically in a subset of patients. However, up to now, 
monotherapy has not resulted in durable clinical responses in the majority of patients. 
Combination of agents targeting different pathways of the tumor is expected to ultimately 
lead to durable responses. The most challenging will be to select the right patient for the right 
combination to achieve personalized treatment. 
 
  
142
Processed on: 28-10-2016
505946-L-bw-Wakka
Future prospects 
References 
1. Hughes, P.E.; Caenepeel, S.; Wu, L.C. Targeted therapy and checkpoint immunotherapy
combinations for the treatment of cancer. Trends in immunology 2016, 37, 462-476.
2. Callahan, M.K.; Postow, M.A.; Wolchok, J.D. Targeting t cell co-receptors for cancer therapy.
Immunity 2016, 44, 1069-1078.
3. Nurieva, R.I.; Liu, X.K.; Dong, C. Yin-yang of costimulation: Crucial controls of immune tolerance
and function. Immunol Rev 2009, 229, 88-100.
4. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.;
Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B., et al. Safety, activity, and immune
correlates of anti-pd-1 antibody in cancer. New Engl J Med 2012, 366, 2443-2454.
5. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune checkpoint blockade: A common denominator
approach to cancer therapy. Cancer Cell 2015, 27, 450-461.
6. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.M.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.;
Camacho, L.H.; Kauh, J.; Odunsi, K., et al. Safety and activity of anti-pd-l1 antibody in patients
with advanced cancer. New Engl J Med 2012, 366, 2455-2465.
7. Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.;
McDermott, D.F.; Powderly, J.D.; Gettinger, S.N., et al. Predictive correlates of response to the
anti-pd-l1 antibody mpdl3280a in cancer patients. Nature 2014, 515, 563-565.
8. Motzer, R.J.; Rini, B.I.; McDermott, D.F.; Redman, B.G.; Kuzel, T.M.; Harrison, M.R.;
Vaishampayan, U.N.; Drabkin, H.A.; George, S.; Logan, T.F., et al. Nivolumab for metastatic
renal cell carcinoma: Results of a randomized phase ii trial. J Clin Oncol 2015, 33, 1430-1437.
9. Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi,
S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R., et al. Nivolumab versus everolimus in advanced
renal-cell carcinoma. New Engl J Med 2015, 373, 1803-1813.
10. Hammers, H.; Plimack, E.R.; Infante, J.R.; Ernstoff, M.S.; Rini, B.; Mcdermott, D.F.; Razak, A.;
Pal, S.K.; Voss, M.H.; Sharma, P., et al. Phase i study of nivolumab in combination with
ipilimumab (ipi) in metastatic renal cell carcinoma (mrcc). Bju Int 2014, 114, 8-8.
11. Ribas, A.; Hodi, F.S.; Callahan, M.; Konto, C.; Wolchok, J. Hepatotoxicity with combination of
vemurafenib and ipilimumab. New Engl J Med 2013, 368, 1365-1366.
12. Wolchok, J.D.; Hoos, A.; O'Day, S.; Weber, J.S.; Hamid, O.; Lebbe, C.; Maio, M.; Binder, M.;
Bohnsack, O.; Nichol, G., et al. Guidelines for the evaluation of immune therapy activity in solid
tumors: Immune-related response criteria. Clin Cancer Res 2009, 15, 7412-7420.
13. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity's roles in
cancer suppression and promotion. Science 2011, 331, 1565-1570.
14. Stillebroer, A.B.; Boerman, O.C.; Desar, I.M.E.; Boers-Sonderen, M.J.; van Herpen, C.M.L.;
Langenhuijsen, J.F.; Smith-Jones, P.M.; Oosterwijk, E.; Oyen, W.J.G.; Mulders, P.F.A. Phase 1
radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase ix monoclonal
antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol 2013, 64, 478-
485. 
15. Mahoney, K.M.; Rennert, P.D.; Freeman, G.J. Combination cancer immunotherapy and new
immunomodulatory targets. Nat Rev Drug Discov 2015, 14, 561-584.
16. Schwartz, J.; Humm, J.L.; Divgi, C.R.; Larson, S.M.; O' Donoghue, J.A. Bone marrow dosimetry
using i-124-pet. J Nucl Med 2012, 53, 615-621.
17. Stillebroer, A.B.; Zegers, C.M.L.; Boerman, O.C.; Oosterwijk, E.; Mulders, P.F.A.; O'Donoghue,
J.A.; Visser, E.P.; Oyen, W.J.G. Dosimetric analysis of lu-177-cg250 radioimmunotherapy in renal
cell carcinoma patients: Correlation with myelotoxicity and pretherapeutic absorbed dose
predictions based on in-111-cg250 imaging. J Nucl Med 2012, 53, 82-89.
18. Spanholtz, J.; Tordoir, M.; Eissens, D.; Preijers, F.; van der Meer, A.; Joosten, I.; Schaap, N.; de
Witte, T.M.; Dolstra, H. High log-scale expansion of functional human natural killer cells from
umbilical cord blood cd34-positive cells for adoptive cancer immunotherapy. Plos One 2010, 5,
e9221.
19. Spanholtz, J.; Preijers, F.; Tordoir, M.; Trilsbeek, C.; Paardekooper, J.; de Witte, T.; Schaap, N.;
Dolstra, H. Clinical-grade generation of active nk cells from cord blood hematopoietic progenitor
cells for immunotherapy using a closed-system culture process. Plos One 2011, 6, e20740.
20. Cany, J.; van der Waart, A.B.; Tordoir, M.; Franssen, G.M.; Hangalapura, B.N.; de Vries, J.;
Boerman, O.; Schaap, N.; van der Voort, R.; Spanholtz, J., et al. Natural killer cells generated
from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human
leukemia cells in nod/scid/il2rg(null) mice. Plos One 2013, 8,e64384.
143
Processed on: 28-10-2016
505946-L-bw-Wakka
Chapter 8 
21. Cany, J.; van der Waart, A.B.; Spanholtz, J.; Tordoir, M.; Jansen, J.H.; van der Voort, R.; Schaap,
N.M.; Dolstra, H. Combined il-15 and il-12 drives the generation of cd34(+)-derived natural killer
cells with superior maturation and alloreactivity potential following adoptive transfer.
Oncoimmunology 2015, 4, e1017701.
22. Grepin, R.; Ambrosetti, D.; Marsaud, A.; Gastaud, L.; Amiel, J.; Pedeutour, F.; Pages, G. The
relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary
tumors: A new method for the personalized treatment of renal cell carcinoma. Plos One 2014, 9,
e89449.
23. Ko, J.J.; Choueiri, T.K.; Rini, B.I.; Lee, J.L.; Kroeger, N.; Srinivas, S.; Harshman, L.C.; Knox, J.J.;
Bjarnason, G.A.; MacKenzie, M.J., et al. First-, second-, third-line therapy for mrcc: Benchmarks
for trial design from the imdc. Brit J Cancer 2014, 110, 1917-1922.
144
Processed on: 28-10-2016
505946-L-bw-Wakka
List of Publications
Processed on: 28-10-2016
505946-L-bw-Wakka
Processed on: 28-10-2016
505946-L-bw-Wakka
Publications 
List of Publications 
1. Oosterwijk E, Ruiter DJ, Wakka JC, Huiskens-van der Meij JW, Jonas U, Fleuren GJ,
Zwartendijk J, Hoedemaeker P, Warnaar SO: Immunohistochemical analysis of
monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell
carcinoma. Am J Pathol 1986;123(2):301-9
2. Oosterwijk E, Van Muijen GN, Oosterwijk-Wakka JC, Warnaar SO: Expression of
intermediate-sized filaments in developing and adult human kidney and in renal cell
carcinoma. J Histochem Cytochem 1990;38(3):385-92
3. Oosterwijk E, Kalisiak A, Wakka JC, Scheinberg DA, Old LJ.: Monoclonal antibodies
against Gal alpha 1-4Gal beta 1-4Glc (Pk, CD77) produced with a synthetic
glycoconjugate as immunogen: reactivity with carbohydrates, with fresh frozen human
tissues and hematopoietic tumors. Int J Cancer 1991;48(6):848-54
4. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson
SM, Warnaar SO, Fleuren GJ, et al.: Antibody localization in human renal cell
carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11(4):738-
50 
5. Kranenborg MH, Boerman OC, Oosterwijk-Wakka JC, de Weijert MC, Corstens FH,
Oosterwijk E. Development and characterization of anti-renal cell carcinoma x
antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell
carcinoma. Cancer Res 1995;55:5864s-5867s
6. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders
EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E: Targeting of renal
cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol
1997;15(4):1529-37
7. Kranenborg MH, Boerman OC, de Weijert MC, Oosterwijk-Wakka JC, Corstens FH,
Oosterwijk E. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal
antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997;80(12
Suppl):2390-7
8. Kranenborg MH, Boerman OC, Oosterwijk-Wakka JC, de Weijert MC, Corstens FH,
Oosterwijk E: Two-step radio-immunotargeting of renal-cell carcinoma xenografts in
nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies.
Int J Cancer 1998;75(1):74-80
147
Processed on: 28-10-2016
505946-L-bw-Wakka
Publications 
9. Shimazui T, Oosterwijk E, Akaza H, Bringuier P, Ruijter E, van Berkel H, Wakka JO, van
Bokhoven A, Debruyne FM, Schalken JA: Expression of cadherin-6 as a novel
diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell
carcinoma. Clin Cancer Res 1998;4(10):2419-24
10. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, Boerman OC, Debruyne
FM, Corstens FH, Oosterwijk E: Immunohistochemical analysis of tumor antigen
saturation following injection of monoclonal antibody G250. Anticancer Res
1999;19(2A):1197-200
11. Boerman OC, Kranenborg MH, Oosterwijk E, Griffiths GL, McBride WJ, Oyen WJ, de
Weijert M, Oosterwijk-Wakka J, Hansen HJ, Corstens FH: Pretargeting of renal cell
carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res
1999;59(17):4400-5
12. Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den
Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E: Phase I
radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric
monoclonal antibody G250. Clin Cancer Res 1999;5(10 Suppl):3268s-3274s
13. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A,
Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E:
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250.
Int J Cancer 2000;85(6):865-70
14. Shimazui T, Oosterwijk-Wakka J, Akaza H, Bringuier PP, Ruijter E, Debruyne FM,
Schalken JA, Oosterwijk E.: Alterations in expression of cadherin-6 and E-cadherin
during kidney development and in renal cell carcinoma. Eur Urol 2000;38(3):331-8
15. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema
GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF: Vaccination of patients with
metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous
tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002
;25(6):500-8
16. Nuininga JE, van Moerkerk H, Hanssen A, Hulsbergen CA, Oosterwijk-Wakka J,
Oosterwijk E, de Gier RP, Schalken JA, van Kuppevelt T, Feitz WF: Rabbit urethra
replacement with a defined biomatrix or small intestinal submucosa. Eur Urol
2003;44(2):266-71
148
Processed on: 28-10-2016
505946-L-bw-Wakka
Publications 
17. Nuininga JE, van Moerkerk H, Hanssen A, Hulsbergen CA, Oosterwijk-Wakka J,
Oosterwijk E, de Gier RP, Schalken JA, van Kuppevelt TH, Feitz WF:  A rabbit model to
tissue engineer the bladder. Biomaterials 2004;25(9):1657-61
18. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Voller MC, Melchior S, Warnaar SO,
Mala C, Beck J, Mulders PF: A clinical trial with chimeric monoclonal antibody WX-G250
and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol
2006;175(1):57-62
19. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Voller MCW, de Weijer K, Mulders,
PFA, Oosterwijk E: Preliminary Analysis of Patients With Progressive Renal Cell
Carcinoma Vaccinated With CA9-peptide-Pulsed Mature Dendritic Cells. J. of
Immunother 2007;30(1):116-122
20. Johanna Sandlund, Egbert Oosterwijk, Kjell Grankvist, Jeannette Oosterwijk-Wakka,
Börje Ljungberg and Torgny Rasmuson Prognostic impact of carbonic anhydrase IX
expression in human renal cell carcinoma. BJU Int 2007; 100: 556-560
21. Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wüest T, Stenner F,
Perani A, Cohen L, Knuth A, Divgi C, Jäger D, Scott AM, Ritter G, Old LJ, Renner C:
Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg.
Int. J. Cancer 2009;125:115-123
22. Oosterwijk-Wakka JC, Boerman OC, Mulders PFA, Oosterwijk E. Monoclonal antibody
G250 recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biological and
clinical studies. Bukowski RM, Figlin RA, Motzer RJ, editors. Renal Cell Carcinoma,
molecular targets and clinical applications. New York: Humana Press; 2009: P231-47
23. Oosterwijk-Wakka JC, Kats-Ugurlu G, Leenders WP, Kiemeney LA, Old LJ, Mulders
PF, Oosterwijk E: Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on
the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody
cG250. BJU Int 2011;107: 118-125
24. Cor HJ Lamers, Ralph A Willemsen, Pascal Elzakker, Sabine Steenbergen-Langeveld,
Marieke Broertjes, Jeannette Oosterwijk-Wakka, Egbert Oosterwijk, Stefan Sleijfer,
Reno Debets, and Jan Willem Gratama: Immune responses to transgene and retroviral
vector in patients treated with ex vivo engineered T cells. Blood 2011;117(1): 72-82
25. Oosterwijk-Wakka JC, Boerman OC, Mulders PFA, Oosterwijk E. Application of
Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell
Carcinoma. International Journal of Molecular Sciences 2013; 14(6):11402-11423.
149
Processed on: 28-10-2016
505946-L-bw-Wakka
Publications 
26. Kats-Ugurlu G, Oosterwijk E, Muselaers S, Oosterwijk-Wakka J, Hulsbergen-van de
Kaa C, de Weijert M , van Krieken H, Desar I, van Herpen C, Maass C, Mulders P,
Leenders W: Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and
Release of Circulating Tumor Fragments Neoplasia 2014;16(3): P221-8
27. Jeannette C. Oosterwijk-Wakka, Mirjam C.A. de Weijert, Gerben M. Franssen, William
P.J. Leenders, Jeroen A.W.M. van der Laak, Otto C. Boerman, Peter F.A. Mulders and
Egbert Oosterwijk: Successful combination of Sunitinib and Girentuximab in two renal
cell carcinoma animal models: a rationale for combination treatment of patients with
advanced RCC. Neoplasia 2015;17: 215–224
28. Oosterwijk E., Boerman OC, Oyen WJ, Oosterwijk-Wakka JC, Mulders PFA,. Carbonic
anhydrase IX and monoclonal antibody G250: Relevance as a clinical and biologic target
in renal cell carcinoma. Bukowski RM, Figlin RA, Motzer RJ, editors. Renal Cell
Carcinoma, molecular targets and clinical applications. New York: Humana Press; 2015:
P263-84
150
Processed on: 28-10-2016
505946-L-bw-Wakka
Curriculum Vitae
Processed on: 28-10-2016
505946-L-bw-Wakka
Processed on: 28-10-2016
505946-L-bw-Wakka
Curriculum Vitae 
Curriculum Vitae 
 
Jeannette Catharine Wakka is geboren op 16 augustus 1961 te Leiden. In 1979 behaalde 
zij haar VWO diploma aan de Vlietschans te Leiden. Daarna volgde zij de studie analytische 
chemie aan de Laboratorium school Rijnland te Leiderdorp, die ze in mei 1983 afsloot met 
een diploma. Aansluitend volgde zij de studie HTS-chemie aan het van ’t Hoff instituut te 
Rotterdam. Deze werd in mei 1985 cum laude afgesloten. Van september 1984 tot  maart 
1987 heeft ze als research analist gewerkt op de afdeling pathologie van het Leids 
Universitair Medisch Centrum aan de ontwikkeling van monoklonale antilichamen voor de 
behandeling van nierkanker. Vervolgens heeft ze van maart 1987  tot september 1991 als 
research analist gewerkt in het Memorial Sloan Kettering Cancer Center te New York in het 
laboratorium Human Immunology van Dr. L.J. Old gevolgd door een aanstelling bij het 
Ludwig Institute for Cancer Research, New York branch. Daar heeft zij o.a. gewerkt aan de 
eerste klinische studie van monoklonaal antilichaam G250. Van februari 1993 tot heden 
werkt zij als senior research analist op het laboratorium Experimentele Urologie, afdeling 
Urologie aan het Radboudumc  te Nijmegen aan onderzoek naar nieuwe therapeutische 
behandelingen van patiënten met nierkanker. In 2014 ontving ze de derde prijs voor “best 
abstract in Oncology” voor “Combination therapy with sunitinib and 177Lu-Girentuximab in 
RCC” op het congres van de European Association of Urology te Stockholm.  
Jeannette woont in Beuningen, is getrouwd met Egbert Oosterwijk en heeft 3 kinderen: 
Roos (1992), Roderick (1994) en Jesse (1997). 
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Eindelijk ligt het er dan, mijn proefschrift! Wat ben ik blij dat het af is. Mede dankzij de hulp 
van velen is dit boekje tot stand gekomen. Een aantal mensen wil ik persoonlijk bedanken. 
 
Prof. Dr. Peter Mulders. Beste Peter, super dat je me de kans hebt gegeven om het 
promotieonderzoek te doen wat tot dit boekje heeft geleid. De werkbesprekingen van de 
‘nierkanker groep’ op dinsdag om 11.00 uur waarin jij altijd zeer geïnteresseerd en kritisch 
was op de resultaten van experimenten waren zeer waardevol en hielden me scherp. Wat 
knap dat jij naast je taken als afdelingshoofd en je klinische taken ook nog tijd vindt om 
onderzoek te doen. Bedankt dat jij mijn promotor wil zijn. 
 
Dear Prof Dr. CR Divgi, dear Chetan, we both have a great interest in cG250 and you have 
been one of the driving forces to move clinical implementation forward. I feel honored that 
you are part of my defense committee.  
 
Beste Jack, nadat ik had aangegeven aan een nieuwe uitdaging toe te zijn en wilde 
promoveren heb jij me gestimuleerd om dat ook daadwerkelijk te doen. Dat zetje had ik 
nodig om er ook echt voor te gaan. Ik hou van jouw laagdrempelige manier van leidinggeven. 
Heerlijk ook de discussies aan de koffietafel op maandagochtend waarin de vorderingen van 
Ajax ruim aan bod kwamen. Bedankt voor je steun.  
 
Lieve Egbert, naast mijn lief ben je ook mijn copromotor. Samen hebben we G250 “ontdekt” 
en in New York naar de kliniek gebracht. Nu ben jij copromotor op mijn promotie waarin 
G250 opnieuw centraal staat. Hoe bijzonder! Ik bewonder je enorme kennis, 
relativeringsvermogen en je veerkracht. Zonder jouw kritische blik op mijn manuscripten en 
jouw schrijftalent was dit boekje er niet gekomen. Ik ben enorm trots dat jij copromotor bij 
mijn promotie bent.  
 
Mirjam en Dorien, wat leuk dat jullie op 9 december aan mijn zijde staan als paranimf. 
Beste Mirjam, wij zijn bijna tegelijkertijd op het lab experimentele urologie gestart (toen nog 
URL). Samen hebben we vanaf 1993 aan diverse promotieonderzoeken meegewerkt. Ik 
bewonder jouw expertise, betrokkenheid en je enorme creativiteit. Je bent een gezellige  
collega die ik zelden hoor zeuren. Ik hoop nog lang met je samen te werken.  
Beste Dorien, hoewel de laatste jaren niet direct betrokken bij mijn onderzoek door jouw 
overstap naar tissue-engineering hebben wij een aantal jaar geleden veel samengewerkt o.a. 
aan de klinische studie met DC-vaccin waarin we uren hebben doorgebracht in de cleanroom 
of op de OK om vaccins te bereiden en patiënten materiaal te verzamelen. Met jou is het 
altijd lachen geblazen, je vrolijkheid werkt heel aanstekelijk. Jouw inzet en betrokkenheid 
maken jou tot een zeer gewaardeerde collega.  
Bedankt voor jullie gezelligheid, hulp bij de experimenten en steun bij de laatste loodjes van 
het manuscript. 
 
Analisten van het van het lab experimentele urologie: Tilly, Kees, Onno, Cindy, Marion en 
Elze. Jullie zijn eigenlijk mijn labfamilie. Het feit dat jullie al heel lang op dit lab werken zegt 
wel iets over de goede werksfeer op het “URL”. Bedankt voor de samenwerking en de 
gezelligheid, door jullie voelt werk meer als een hobby. Dank ook voor jullie interesse in de 
voortgang van mijn promotie. Beste Kees, jou wil ik in het bijzonder bedanken voor je hulp bij 
de dierexperimenten. Jij bent nooit te beroerd om bij te springen. 
 
Alle promovendi, postdocs en studenten van het lab experimentele urologie, bedankt voor de 
goede samenwerking, gezellige koffiemomenten, de congressen, borrels en leuke etentjes. 
Op het lab is het nooit saai. Super dat we zo’n internationaal gezelschap zijn, dat maakt het 
werken op het lab nog leuker. 
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Maureen, jij was mijn “U-genootje” tot je vertrek van het lab. Bedankt voor de goede 
gesprekken en gezellige bioscoopavondjes. Ik hoop snel weer af te spreken om te kunnen 
bijkletsen. Heel veel succes in je nieuwe baan! 
 
Medewerkers van PRIME, in het bijzonder, Bianca, Kitty, Henk en Iris. Jullie vaardigheid, 
kennis en inzet was ontzettend belangrijk voor de uitvoering van de dierexperimenten die 
een essentieel onderdeel vormen van dit boekje. Hartelijk dank voor al jullie hulp. 
 
Ik wil ook een aantal mensen bedanken van de afdeling Radiologie en Nucleaire 
geneeskunde en afdeling Pathologie waar ik een deel van het werk heb uitgevoerd. Prof. Dr. 
Boerman, beste Otto, je kritisch commentaar op mijn manuscripten en je hulp bij het 
ontwerpen van de dierexperimenten waren heel waardevol en verhoogden de kwaliteit. 
Gerben, bedankt voor je hulp met de In-111 en Lu-177 labelingen. Ondanks de lastige 
logistiek zag je altijd kans op de afgesproken tijd materiaal klaar te hebben. Janneke, 
bedankt voor je hulp met het zetten van de NU12 tumoren. Jij was degene die hierin het 
meeste geïnvesteerd heeft en deze tumor jaren voor ons in stand hebt gehouden. We zien 
elkaar nog regelmatig na je overstap van Urologie naar Nucleaire geneeskunde. Dit model 
blijft belangrijk. Cathelijne en Lieke, bedankt voor de hulp die jullie mij hebben geboden bij 
o.a. labelingen en autoradiografie op jullie lab. William, jouw kennis en enthousiasme over 
angiogenese remmers zijn ongekend. Onze samenwerking is zeer vruchtbaar en ik hoop dat 
er nog vele artikelen zullen volgen waarin jij een aandeel hebt.  
 
Lieve vrienden, 
De “kampeerclub”: Mathieu, Annelies, Klaas, Nel, Marco, Sietske, Renee en Fieke. Bedankt 
voor jullie jarenlange vriendschap die dateert van vóór ons New York avontuur en voor de 
mooie kampeerweekenden de afgelopen jaren met onze gezinnen. We doen niet veel meer 
dan bbq’en, wijn drinken en bijkletsen en oké af en toe een fietstochtje maar de sfeer is altijd 
super en relaxed. Volgend jaar nemen we de beroemde “Egbert’s BBQ’ weer mee! 
 
Het pufclubje: Ina, Henk, Andy en Hank, we kennen elkaar nu al meer dan 20 jaar. De vele 
gezellige etentjes en avondjes met jullie hebben gezorgd voor de nodige ontspanning. Bij 
jullie voel ik me enorm op mijn gemak. Bedankt voor jullie vriendschap. 
 
Marijke en Peter, ondanks onze volle agenda’s blijven vinden we toch altijd weer een gaatje 
om elkaar te zien. Naar Sauna of restaurant of op vakantie, met jullie is het altijd goed 
toeven. Bedankt voor jullie vriendschap. 
 
Gerald en Heidi, Ik hou enorm van jullie nuchtere kijk en directheid. Spelletjes avonden en 
etentjes, er wordt altijd veel gelachen. Met onze gezinnen hebben we mooie vakanties 
gemaakt naar Thailand en Marokko. Ik heb er ontzettend van genoten en hoop dat er nog 
leuke reisjes zullen volgen (met of zonder kids). Bedankt voor de gezelligheid en jullie 
vriendschap. 
 
“Sisters” en “(Ex-)Kleidonkers”, Theo, Petra, Arnold, Jeanet, Leo en Lucia, Marianne, Frank, 
Renée, Marloes en Jeanne, bedankt voor alle gezellige musical-, spelletjes-, 4-daagse-, 
dansavonden en wat al niet meer waarin ook heel veel gelachen werd. Dat er nog veel leuke 
momenten mogen volgen!  
 
Dear Paco, Chetan, Martina,  Nuria, Michelle and Tom, we may not see each other often but 
when we do it’s like old times. I cherish the time we had together in New York at 81st Street, 
where our friendship started when we were at Memorial Sloan Kettering Cancer Center. I 
hope we can see each other more often in the future despite all our commitments. Thanx for 
your comradeship. 
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Lieve familie, 
Ik hoop dat jullie na het lezen van de Nederlandse samenvatting enigszins begrijpen wat ik 
de afgelopen jaren heb gedaan.  
Lieve zus Lotte, onze band is heel sterk. Je interesse en steun in de voortgang van mijn 
promotie waren voor mij heel belangrijk. Jij staat altijd voor mij klaar en dat is heel bijzonder. 
Als deze promotie achter de rug is heb ik weer tijd om samen leuke dingen te doen. Ben, 
Susanne, Rian, Sebastiaan, Mariko, Jasmijn en Joel. Wij zijn een hechte familie en missen 
doorgaans niets van elkaar. Bedankt voor jullie gezelligheid tijdens feesten, verjaardagen, en 
familie-uitjes.  
Lieve mama, zonder papa en jou had ik hier niet gestaan. Dankzij jullie ben ik geworden wie 
ik ben. Jammer dat papa dit niet meer kan meemaken, ik weet dat hij enorm trots op me zou 
zijn geweest. Gelukkig kun jij deze bijzondere dag wel met ons allen in goede gezondheid 
meemaken. Mam, bedankt voor je liefde, goede zorgen en nooit aflatende steun. Bedankt 
voor alles. 
Roos, Roderick en Jesse, wat ben ik trots op jullie. Lieve Roos, jouw lef, gedrevenheid en 
ambitie hebben er toe geleid dat je na afgestudeerd te zijn als bewegingswetenschapper nu 
als trainee bij het ministerie van VWS in dienst bent. Een prestigieuze baan, supergoed 
gedaan! Je bent daarnaast ook heerlijk spontaan en zeer sociaal. Heel veel succes in Den 
Haag en veel geluk met Tom. 
Lieve Roderick, dit jaar ben je zonder vertraging aan je master Biomedical Engineering in 
Eindhoven begonnen, een knappe prestatie. Je bent toegewijd, gedreven, sociaal en 
betrokken en ik ben overtuigd dat deze eigenschappen je een goede toekomst zullen bieden. 
Geloof in jezelf!  
Lieve Jesse, jouw studentenleven is dit jaar echt begonnen. Ik hoop dat dit voor jou een 
super jaar wordt, waarin alles op zijn plaats valt en dat je snel je draai in Eindhoven kunt 
vinden bij de studie MWT. Met jouw slimheid, sociale karakter en het snel kunnen schakelen 
denk ik dat het zeker gaat lukken. Gezellig dat je nog even thuis blijft wonen. Heel veel geluk 
met je liefde Jessica. 
Lieve kinderen, bedankt voor jullie onvoorwaardelijke liefde.  
Lieve Egbert, de steun die je als promovendus van je partner ondervindt is het 
allerbelangrijkste. Al bijna 30 jaar ben jij mijn rots in de branding. Jij hebt me geholpen om dit 
promotietraject door te zetten, jij wist mij te motiveren en helpen. Het schrijven van dit 
proefschrift was alleen mogelijk dankzij jouw onvoorwaardelijke steun en liefde en je geloof 
in mij. Dank voor alles.  
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